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Abstract 
Overexpression of RBBP6 in cancers of the colon, lung and oesophagus makes it a potential 
target in anticancer therapy. This is especially important because it associates with the tumour 
suppressor gene p53, inactivation of which has been linked to over 50% of all cancer types. 
Cancer is an enormous burden of a disease globally. Today, more people die from cancer than 
HIV/AIDS, tuberculosis and malaria combined. And in females, breast and cervical malignancies 
remain the most common types. Currently, cervical cancer is the most diagnosed gynaecological 
cancer type, whose mortality rate is the highest in developing countries due to the asymptomatic 
nature of the disease coupled with inadequate cancer control tools and facilities.  Breast cancer 
incidence rate has increased beyond that of lung cancer, making it the most common malignancy 
among women.  
 
Breast and cervical tumour progression is partly as a result of p53 inactivation by overexpressed 
ubiquitous regulatory proteins that possess an E3 ligase activity. MDM2 and E6 viral 
oncoprotein have been shown to negatively regulate p53 in breast and cervical cancer, 
respectively. RBBP6 forms a member of such proteins since it has an E3 ligase activity and a 
RING finger-like domain. And therefore its overexpression in several malignancies makes it a 
potential target in cancer management. However, it is not clearly defined whether or not RBBP6 
interaction with p53 promotes cancer progression and therefore serves as a potential biomarker. 
In this study we manipulated RBBP6 expression levels and treated cells with either camptothecin 
or GABA treatment in breast and cervical cancer cells to induce apoptosis or cell cycle arrest. 
Initially, the human cervical cancer tissue sections were stained with anti-RBBP6 mAb to 
evaluate its extent of expression in patients’ specimens. We then followed on with silencing or 
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overexpression of RBBP6 and treatment with anticancer agents to evaluate how cells respond to 
combinational therapy. Furthermore, we evaluated the apoptotic response of breast cancer cell 
lines that display different p53 expression levels, to RBBP6 targeting and co-treatment with 
anticancer agents.  Apoptosis induction was evaluated using confocal microscopy, flow 
cytometry with Annexin V staining as well as assessing the mitochondrial and caspase 3/7 
activities. The cell cycle arrest was evaluated using flow cytometry through staining with 
propidium iodide.  
 
RBBP6 was highly expressed in cervical cancer tissue sections that were in stage II and III of 
development. Overexpression of RBBP6 seemed to promote S-phase in cell cycle and cell 
proliferation whereas silencing triggered apoptosis. This observation predicts a proliferative role 
for RBBP6 in cancer progression rather than a cancer causing gene. The wt. p53-expressing cell 
lines (MCF-7, HeLa and SiHa) were more susceptible to apoptosis induction as opposed to the 
mt. p53-expressing MDA-MB-231. RBBP6 silencing led to a significant accumulation of p53 
expression in MCF-7, HeLa and SiHa as compared to MDA-MB-231. These results implicate the 
distinctive p53 genotypic status of the cancer cell lines to play a major role in their 
responsiveness to RBBP6 targeting. Furthermore, co-treatment with camptothecin seemed to 
sensitize the cells to apoptosis induction rather than cell cycle arrest; whereas GABA co-
treatments failed to substantially exhibit this phenotype.  Sensitization of cells to camptothecin-
induced apoptosis by RBBP6 silencing therefore suggests a promising tool for halting breast and 
cervical cancer progression.  
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CHAPTER ONE - Introduction and Literature Review 
1.1. Introduction 
Second to cardiovascular diseases, cancer claims more lives globally than (Human 
Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), Tuberculosis 
(TB) and Malaria combined (Iyoke and Ugwu, 2013). Previously, gynaecological cancers 
including breast cancer have been reported to account for only 11% of all female-related cancer 
cases (Ma and Yu, 2006). However, in a recent report by the Cancer Research UK (2013), breast 
cancer incidence is the highest of all cancers overtaking lung cancer. Cervical cancer remains the 
only gynaecological cancer that can be detected at an early stage using the Pap test while similar 
cancers are still reliant on symptoms. This results in poor statistical reporting of the diseases 
especially in developing and poor countries due to lack of adequate cancer control tools (Cancer 
Research UK, 2013; Iyoke and Ugwu, 2013).   
 
The cause of these cancers is not thoroughly understood; however deregulation of tumour 
suppressor genes has been adequately shown to play a central role in cancer development where 
mutation and inactivation of p53 tumour suppressor accounts for over 50% of all human cancers 
(Haupt et al., 2016). For example, in cervical cancer wt. p53 is negatively regulated by the E6 
oncoprotein which has been shown to mediate its degradation via the ubiquitin proteasome 
pathway, whereas in breast cancer MDM2 is responsible for the negative regulation of p53 
(Yuan et al., 2016; Haupt et al., 2016). Recently, RBBP6 has been shown to negatively regulate 
p53 (Li et al., 2007, Mbita et al., 2012; Chen et al., 2013; Moela et al., 2014). These recent 
reports have drawn our attention as to whether RBBP6 can be used as early detection marker for 
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gynaecological cancers. Therefore the present study focuses on investigating the involvement of 
RBBP6 in breast and cervical cancer as a potential cancer biomarker.  
1.2. Cervical Cancer 
ervical cancer is the most common cancer type amongst women second to breast cancer 
,worldwide, with over 80% of cases arising from women in developing countries (Siegel et al., 
2014; Richter, 2013; Snyman, 2013). Ninety-nine percent of cervical cancers arise from 
persistent infection of the cervix by the sexually transmissible human papilloma viruses (HPVs), 
making HPV infection a prerequisite in the pathogenesis of cervical cancer (Hu et al., 2015; 
Fernandes and Araujo, 2013; Crosbie et al., 2013; Denny, 2010; Bosch et al, 2002; Schiffman 
and Brinton, 1995 and Munoz et al., 1992). Therefore, cervical cancer is preventable through 
targeting the HPV virus (Botha and Richter, 2015; Richter, 2013; Snyman, 2013; Sherris et al., 
2001). Two groups of HPV have been classified, those that infect keratin-rich skin surfaces 
resulting in common warts and those that infect the mucosa of the mouth, trachea, respiratory 
and mostly the anogenital tract (Fernandes and Araujo, 2013). Certain strains of mucosal HPVs 
may cause common genital warts whereas other types are implicated in the development of 
premalignant intraepithelial lesions, a major risk factor of invasive cervical cancer development 
(Fernandes and Araujo, 2013).   
1.2.1. Current Status of Cervical Cancer in Southern Africa 
On a worldwide scale, cervical cancer is highest in Eastern, Western and Middle Africa, 
followed by central America, south-central Asia and Melanesia (Arbyn et al., 2011).  Moreover, 
sub-Saharan Africa has been reported to have an estimated 667 000 cervical cancer diagnoses in 
2008 and a 78% mortality rate mostly due to poor socio-economic conditions, competing health 
needs and incomplete infrastructure (Denny, 2010). This makes cervical cancer prevention and 
P. Moela: PhD Thesis 
3 
 
treatment more important in South Africa and other developing countries (Denny, 2010). About 
38.7 incidence rates have been reported in southern Africa as a whole, where an incidence rate of 
61.6 was reported in Lesotho, 58.9 in Swaziland, 30.4 in Botswana and 22.2 in Namibia (Denny, 
2010). 
Data on cervical cancer for South Africa has been unavailable since 1999 due to poor 
maintenance of pathology-based cancer registry until recently where it was estimated that 1 in 41 
South African women screen positive for cervical cancer and approximately 8 deaths are 
reported daily (Botha and Richter, 2015; Snyman, 2013; Denny, 2010). In terms of race, cervical 
cancer is more prevalent in black women over the age of forty (Snyman, 2013). The lifetime risk 
of cervical cancer is higher in black women from developing countries (1 in 43) when compared 
to that in white women (1 in 94) and this discrepancy may be as a result of the reflected better 
socio-economic status and more frequent screening practices among the white community 
(Botha and Richter, 2015; Crosbie et al., 2013; Moodely, 2009). These alarming statistics 
potentiate the need to implement new and efficient cervical cancer management strategies.  
1.2.2. Cervical Cancer in the Context of HIV 
It is highly important to understand the incidence of cervical cancer in the context of Human 
Immunodeficiency Virus (HIV) since it remains a serious pandemic more especially in South 
Africa. A South African statistical release of 2013 reported that an estimated 5.6 million 
population size of adults and children are living with HIV, 68% of which is women (Adler et al., 
2014; Tshifularo et al., 2013). Research shows that even though HIV positive women have a 
reduced AIDS mortality due to access to antiretroviral therapy, the incidence rate of cervical 
cancer is most likely to be increased as a result of the HIV pandemic (Reddy and Frantz, 2011). 
This is because it has been noted that the longer an HIV positive woman lives, the higher the 
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chances of her developing cervical cancer due to a compromised immune system (Tshifularo et 
al., 2013; Chirenje, 2005; Denny, 2010). And as a result, large numbers of women living with 
HIV have been diagnosed with cervical cancer (Tshifularo et al., 2013; Chirenje, 2005; Denny, 
2010). Both HPV and HIV are sexually transmitted diseases that present without any immediate 
visible symptoms (Tshifularo et al., 2013). However, the difference between a woman who has 
oncogenic HPV infection and one who has HIV infection is that the HIV infected woman 
commonly shows invasive cancer ten years earlier than the woman who has early stage cervical 
lesions and that is due to excessive immunosuppression by HIV (Bomela and Stevens, 2009).   
1.2.3. Biological Mechanism of HPV Infection 
Oncogenic viral infections such as hepatitis viruses (B/C) and human HPV are responsible for up 
to 20% cancer deaths in low and middle-income countries (deMartel, 2012). HPV, which 
accounts for 99% of cervical cancer cases, is a minute viral particle of approximately 50-60 nm in 
diameter that lacks an envelope and contains a closed circular genome protected by a network of 
capsid proteins named L1 and L2 (Fernandes et al., 2013). HPV is classified as mucosal and non-
mucosal. Of the mucosal types, high-risk types and the probable high-risk types may cause 
cancer whilst the low-risk types cause genital warts. The high-risk types include HPV 16, 18, 45, 
31, 33, 52, 58 and 35 among others (Munoz et al., 1992; Munoz et al., 2003).  
 
Cervical infection by HPV takes advantage of the exposed basement membrane of the cervix 
following chemical or mechanical trauma of the epithelium as a result of sexual intercourse or 
direct contact of infected mucosal surfaces of the genitalia (Bosch et al., 2002; Munoz et al., 
1992). The viral particle is therefore able to secrete viral proteins that are capable of executing 
internalisation of the virus into the host cells (Munoz et al., 1992). L1 is a major capsid protein 
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responsible for first interaction of viral particle to the extracellular matrix of the epithelial cell 
surface receptors known as heparin sulphate proteoglycans, which are located on the regions of 
the exposed basement membrane (Bosch et al., 2002).  
 
The host’s repair mechanism induces migration of basal keratinocytes over the basement 
membrane in order to cover the wound (Munoz et al., 1992). However this triggers 
conformational changes in the L1 capsid protein which exposes a previously hidden region of the 
L1 that interacts with basal keratinocytes that have migrated over the wounded basement 
membrane, thus kick-starting the infection process (Munoz et al., 1992). This is followed by 
internalisation of the viral particle via the keratinocyte surface receptor with a subsequent entry 
of the viral genome into the nucleus (Fernandes et al., 2013). 
 
The life cycle of HPV inside the host cell is divided into two infection stages, namely the 
maintenance phase and the proliferation-dependant phase. The purpose of the maintenance phase 
is to delay viral antigen expression and replication inside the basal undifferentiated cells to 
locations that are less likely to have a high host immune response (Munoz et al., 1992). The virus 
does this by maintaining a low copy number of the viral genome which is kept in tight regulation 
by viral expression of the E1 and E2 proteins which are responsible for recruiting cellular DNA 
polymerases necessary for DNA replication and the E6 and E7 proteins for modulation of cell 
cycle regulators in order to maintain a long-term infection (Bosch et al., 2002; Fernandes et al., 
2013). 
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During the differentiation-dependant phase, the E6 and E7 viral proteins regulate the viral 
replication ability in differentiated cells by supressing transcription of the p53 and retinoblastoma 
protein (pRB) cellular proteins thus abrogating the host cells’ potential to initiate cell cycle arrest, 
prompting uncontrolled cell proliferation (Bosch et al., 2002; Fernandes et al., 2013). This type 
of HPV interference with p53 and Rb functioning is similar to that of RBBP6 functioning which 
has been shown to bind p53 and Rb thus leading to cell cycle inactivation and subsequently 
increased cell proliferation. Possibly this may suggests a mechanism by RBBP6 and HPV in the 
development cervical cancer. Human papilloma viruses use this infection tactic of reducing viral 
protein expression in undifferentiated cells and intensifying it in differentiated cells in order to 
escape the host immune response (Fernandes et al., 2013). The clearance of high-risk HPV (HR 
HPV) by the immune system occurs one to two years after infection. However some women 
(~10%) fail to clear HPV infection and this results in a persistent infection that leads to the 
development of lesions that favour the progression to malignancy, the most important risk factor 
for cervical cancer (Fernandes et al., 2013).    
1.2.4. Other Risk Factors of Cervical Cancer 
Besides HPV infection, cervical cancer aetiological factors include long-term use of oral or 
hormonal contraceptives, parity and other sexually transmitted diseases such as herpes simplex 
virus subtype 2 (Holmes et al., 2009). A minimum of five years is sufficient to place users at risk 
of developing cervical cancer and the risk increases far more after ten years of oral contraceptive 
usage. This relationship between long-term usage of oral or hormonal contraceptives and 
cervical cancer development is however not extensively assessed, leaving room for confirmation 
of these findings in a more diverse population.  
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The risk of cervical cancer development has also been shown to increase in HPV-positive 
women with high parity, i.e. women with more than seven full-term pregnancies have a four-fold 
higher risk than nulliparous women. Tobacco use has also been associated with increasing risk of 
cervical cancer as seen in HPV-positive current smokers presenting with a three-fold higher risk 
than HPV-positive non-smokers (Holmes et al., 2009). However the biological mechanism 
behind smoking and cervical cancer development is not fully understood.  
 
Human immunodeficiency virus (HIV) is another sexually transmitted disease that is believed to 
be a potential causal factor of cervical cancer (Keller, 2015; De Flora and La Maestra, 2015; 
Ebrahim et al., 2016; Konopnicki et al., 2016). This current research suggests that suppression of 
the immune system by the HIV makes patients highly susceptible to persistent HPV infection 
which might increase the prevalence of cervical intraepithelial neoplastic lesions and a rapid 
progression to invasive cervical cancer. HPV/HIV co-infection results in dysfunction of cellular 
and hormonal arms of the local and systemic immune system and a subsequent disease 
progression (Keller, 2015). HIV-infected women with decreased CD4 counts show a two-fold 
increase in the prevalence of squamous intraepithelial lesions (SIL) when compared to women 
with higher counts meaning higher immunosuppression results in high HPV viral load (Keller, 
2015; Konopnicki et al., 2016). Highly active antiretroviral therapy (HAART) is a combination 
of multiple drugs that act on different targets of HIV in an attempt to control HIV infection (De 
Flora and La Maestra, 2015; Ebrahim et al., 2016). These drugs have proven to be so successful 
that in many parts of the world HIV has become a chronic condition in which progression to 
AIDS has become increasingly rare.   
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1.2.5. Prevention, Screening and Treatment of Cervical Cancer 
Primary prevention of cervical cancer previously relied on conventional strategies such as 
abstinence, mutual monogamy of virgins and use of condoms which proved insufficient as seen 
by alarming figures of cervical cancer incidence in developing countries (Sawaya and Smith-
McCune, 2016; Mariani et al., 2015). Recently, a breakthrough in the development of two 
commercially available vaccines against high-risk HPV type 16 and 18 gave new promise for 
primary prevention strategies (Smith et al., 2015). Cervarix® is a bivalent injection suspension 
that prevents infection of HPV 16 and 18 types and Gardasil® is a quadrivalent injection 
suspension against HPV type 6, 11, 16 and 18 (Panatto et al., 2015).  
 
The mechanism of action by these two vaccines relies on the use of L1 proteins of HPV which 
form bodies of virus-like particles (VLPs) that function by inducing neutralising serum 
antibodies. These are meant to pass through the membrane across the cervical epithelium in 
concentrations that are high enough to interact with virus particles and prevent infection (Panatto 
et al., 2015). The vaccines are safe, highly immunogenic and vaccination lasts for up to 6.5 years 
and therefore highly efficient; however at a cost of three hundred and sixty US dollars per three 
injection doses these are the most expensive vaccines available (Isidean et al., 2015). 
 
Even though it is too late for women already infected with HR-HPV strains, these vaccinations 
suggest that future generation women might enter their sexually active years protected from 
infection by HPV 16 and 18 if administered in young girls (Handler et al., 2015; Kash et al., 
2015). Modelling research predicts that 70% vaccine coverage in young girls between ages 9-12 
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might reduce cervical cancer life-time risk by up to 45%. Consequently in March 2014, a 
vaccination program was launched in South Africa, targeting about 550 000 young girls entering 
grade 4 of their primary level of school (Palmer et al., 2014). In a study performed by Moodely 
et al. (2013) it has been shown that the overall uptake of the Gardasil vaccine among 9-12 year 
old school girls in Kwa-Zulu Natal, South Africa, was as high as 99.7%, 97.9% and 97.8% for all 
first, second and third doses, respectively, demonstrating a highly successful implementation of 
HPV vaccination among young school girls (Moodely et al., 2013).     
 
Cervical cancer screening is a strategy used to detect the cervical cancer-causing precursors, 
namely pre-invasive lesions and early-stage invasive lesions in order to inhibit progression of the 
disease into invasive cervical cancer (Richter, 2013).  A traditional method referred to as cervical 
cytology which involves collection of cells from the cervical canal onto a glass microscope slide 
or into a liquid medium for screening is the first technique that has led to a marked reduction in 
the incidence rate of cervical cancer in the early 1980’s (ACOG Practice Bulletin 45, 2003). Also 
known as Papanicolaou technique, Pap smear screening has proven successful however 
discrepancies such as human errors in sampling and data interpretation as well as the requirement 
for high level of medical infrastructure each year of screening have contributed to low sensitivity 
of the technique. 
 
HPV-based screening offers more advantages over cervical cytology such as high clinical 
sensitivity and excellent negative predictive value (Richter, 2013). This screening procedure 
focuses on detecting HPV DNA in squamous epithelial cells of the cervix and sample collected 
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is similar to that in conventional screening. Recently a few techniques have been developed to 
detect mRNA of the E6 and E7 proteins that form part of HPV genome profile.  
 
Screening guidelines for South Africa are that every woman should take three pap smears in a 
lifetime at 10 year intervals from the age of 30 and internationally, guidelines allow 30 year old 
women and above to combine HPV screening with cervical cytology (Kitchener et al., 2013). 
Affordable screening methods in resource-restricted environments have been implemented, such 
as the visual inspection using 3-5% acetic acid (VIA) which uses naked eye examination aided 
by a bright light source (Nalliah et al., 2015; Sankaranarayanan et al., 2009; Denny 2010; Louie 
et al., 2009). The VIA works by detecting aceto-white or yellow areas in the cervical 
transformation zone, which serve to indicate cervical abnormalities and possible pre-cancerous 
lesions (Nalliah et al., 2015; Sankaranarayanan et al., 2009). This method has been advocated as 
the most inexpensive screening technique that provides immediate results and therefore offers a 
good alternative screening method for women in developing countries (Nalliah et al., 2015; 
Sankaranarayanan et al., 2009).  
 
Screen-positive women normally undergo a pre-therapy procedure known as colposcopy which 
is a method used to diagnose and evaluate the extent of lesion on the cervix (Richter, 2012). This 
is followed by a treatment method, either cryotherapy or loop electrosurgical excision procedure 
(LEEP) (Louie et al., 2009). In cryotherapy, abnormal tissue on the cervix is subjected to 
extreme cold that freezes the tissue until it gradually disappears allowing the cervix tissue to 
P. Moela: PhD Thesis 
11 
 
heal. Unlike cryotherapy, LEEP functions to remove the abnormal cervical tissue using a low-
voltage electrified wire loop (Louie et al., 2009). 
 
Although very effective in reducing cervical cancer as evidenced by high successful rates, most 
of the current methods are highly expensive thus making cervical cancer management in 
developing areas very restricted. This therefore calls for a need to implement more diagnostic 
and treatment strategies that are cost-effective and therefore easily accessible in developing 
countries like South Africa. Recent research indicates that RBBP6 is highly expressed in several 
malignancies and it is responsible for promoting cell proliferation, making it a potential marker 
of cancer and thus a promising target for gene therapy against cancer (Moela et al., 2014; Li et 
al., 2007; Chen et al., 2013; Mbita et al., 2012)..  
1.3. Breast Cancer  
Breast cancer is classified into three subtypes based on the presence or absence of certain cancer 
cell receptors (Tinoco et al., 2013). These include the hormone receptor (HR) subtype (estrogen 
and/or progesterone receptors) which accounts for nearly 60% of all breast cancer incidences, the 
oncogene human epidermal growth factor receptor 2 (HER2/neu) subtype of which 20% is 
observed in all breast cancer cases and the triple negative breast cancer (negative for the 
expression of estrogen, progesterone and HER2/neu receptors) which also constitute about 20% 
of all breast cancer cases (Tinoco et al., 2013). The estrogen receptor positive breast cancers are 
the most common type of breast cancer because the estrogen and progesterone hormones are 
playing a primary role as transcription factors that mediate breast tumorigenesis, thus enabling 
recurrence of the disease even after an effective targeting of the estrogen receptor (ER) signalling 
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(Lim et al., 2012).  In addition to the receptor-associated subtypes of breast cancer, researchers 
have documented intrinsic molecular subtypes: Luminal A and B, and HER2-like subsets 
(Tinoco et al., 2013); (Lim et al., 2012). This heterogeneous nature of breast cancer implicates a 
need for patient-specific treatment, making breast cancer management a major challenge. 
1.3.1. Breast Cancer Statistics 
Breast cancer remains a female-related health problem on a global scale, accounting for over a 
million newly estimated cases that are still on the rise (Tao et al., 2015; Jemal et al., 2012). 
Breast cancer incidence rate differs much across the world and this remarkable variance is 
attributed to substantial regional differences in the prevalence and distribution of socio-economic 
factors (Jemal et al., 2012). For example, a highest incidence rate of 99.4 per 100 000 people in 
North America alone was reported (WHO, 2013). Furthermore, moderately increasing incidence 
rates are reported in Europe, other parts of America as well as in Southern Africa (WHO, 2013).  
 
Mortality rates amongst women were estimated at 69% worldwide (~519 000 deaths) in 2012 
(Tao et al., 2015; Jemal et al., 2012). Breast cancer survival rate (number of people per 100 000 
who die of breast cancer during a given time period) is lower in black women (75%) than in 
white women (89%) as a result of poor prognosis in black women (Tao et al., 2015; Jemal et al., 
2012). This is because black women often present with late stage breast cancers with large and 
more aggressive tumours (Jemal et al., 2012). The World Health Organisation statistics for the 
year 2012 indicate a steady increase of breast cancer cases worldwide where about 380 000 
deaths are observed each year (WHO, 2013). In Africa, 92 600 breast cancer cases and 50 000 
deaths were reported in 2008 statistics, with Southern African women showing highest breast 
cancer incidence rates when compared to women from all African countries (Jemal et al., 2012).  
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1.3.2. Breast Cancer Risk Factors 
In a study published by (Steiner, Klubert and Knutson, 2008), breast cancer risk factors are 
divided into non-modifiable and modifiable factors. Advanced age and female gender are the 
major non-modifiable risk factors associated with breast cancer. This is due to the fact that the 
patient’s lifetime exposure to female hormones (progesterone and estrogen) associated with 
breast cancer would have increased significantly (Steiner et al., 2008). Other important non-
modifiable breast cancer risk factors are menarche before the age of 12, menopause after the age 
of 45, genetic mutations and family history (Steiner et al., 2008). 
 
In addition, women with first degree relatives demonstrate higher risk of developing breast 
cancer. Furthermore, the risk is much higher in women with first degree relatives who are 
diagnosed at a younger age compared to older aged first degree relatives (Nelson et al., 2012). 
However, breast cancer cases arising from genetic mutations account for only about 5% and 60% 
of inherited breast cancers are as a result of mutations in tumour suppressor genes, BRCA1 and 
BRCA2 (breast cancer 1 and 2) (Steiner et al., 2008). P53 is another tumour suppressor gene 
known to contribute not only to breast cancer development but most human cancers as well (Bai 
and Zhu, 2006; Dumitrescu and Cotarla, 2005). Functional p53 helps prevent cancer 
development through activation in response to a stress signal. This is usually followed by 
induction of cell cycle arrest in order to allow for DNA repair (Bai and Zhu, 2006). However the 
presence of p53 negative regulators compromises the cells’ ability to correct for such alterations, 
thus leading to cancer development. Besides MDM2 and E6 oncoprotein, RBBP6 is also 
suspected to play a role in the negative regulation of p53 since it has been show to interact with 
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RBBP6 prior to degradation by the proteasome pathway (Li et al., 2007). The restoration of 
active p53 by targeting RBBP6 is therefore important in the present study.   
1.4. The Cell Cycle 
Cancer develops from mutations in tumour suppressor genes which lead to alterations in 
signalling pathways (Bai and Zhu, 2006). The cell cycle is the most vulnerable signalling 
pathway during tumorigenesis since it is responsible for cell proliferation. The most important 
function of the cell cycle is to make sure that DNA is faithfully replicated in the S-phase and that 
identical chromosomes are equally distributed to two daughter cells during the mitotic phase 
(DiPaola, 2002). However, during cancer development cells have the ability to progress through 
the cell cycle without being monitored due to deregulated cell cycle checkpoints. RBBP6 plays a 
role during cell division in which it has been shown to stabilize chromosomal fragile sites (CFSs) 
in order to accelerate cell cycle progression (Miotto et al., 2014). Overexpression of RBBP6 in 
tumorigenesis might therefore be responsible for the uncontrolled cell proliferation. This makes 
functional studies of RBBP6 in relation to the cell cycle necessary.  
 
There are four coordinated processes involved in eukaryotic cell cycle, namely cell growth, DNA 
replication process (or the interphase), the segregation of replicated chromosomes into two 
separate cells (or mitotic phase), and cell division (cytokinesis) (Figure 1)  (Vermeulen et al., 
2003; Cooper, 2000). A typical human cell divides approximately every 24 hours and even 
though mitosis is the most dramatic stage of the cell cycle, it only lasts about an hour, while the 
interphase takes up about 95% of the cell cycle duration in which cell growth and DNA 
replication occur in preparation for cell division (Cooper, 2000).  
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Figure 1: The stages of the cell cycle and the sites of regulatory cyclin/CDK complexes (Vermeulen et al., 
2003). 
 
The interphase is made up of G1, S and the G2 phase and DNA replication takes place in the S-
phase. The S-phase is preceded by the G1 phase where preparation of DNA synthesis takes place 
followed by G2 phase where preparation of cell division or mitosis occurs as shown in Figure 1 
(Khodjakov and Rieder, 2009; Collins et al., 1997; DiPaola, 2002). Depending on the type of 
extracellular stimuli, cells in G1 respond by either progressing to the S-phase or by entering a 
quiescent or resting phase called G0 where they do not undergo any form of cellular growth 
though they are metabolically active (Sherr, 1996; Vermeulen et al., 2003).  
1.4.1. Regulation of the cell cycle 
Uncontrolled cell proliferation is the hallmark of cancer development mostly due to damage in 
genes that are responsible for the regulation of the cell cycle (Sherr, 1996). Serine/threonine 
protein kinase family members known as the cyclin-dependent kinases (CDKs) are the key 
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regulators of the transition from one cell cycle phase to another (Vermeulen et al., 2003). Five 
CDKs are known to be activated during different stages of the cell cycle, i.e. CDK 4, 6 and 2 
during G1, CDK 2 during the S-phase and CDK 1 during G2 and M-phase (Khodjakov and 
Rieder, 2009; Collins et al, 1997; DiPaola, 2002). The activated CDKs phosphorylate target 
proteins in order to induce downstream processes. CDKs are activated by cyclins which are 
required at different stages of the cell cycle. The type D cyclins (cyclin D1, D2, and D3) bind 
and activate CDK 4 and 6, and cyclin E and A bind to CDK 2. In addition to cyclin binding, 
CDKs are activated by phosphorylation at conserved serine/threonine regions and are 
counteracted by CDK inhibitors which bind to either CDKs alone or to CDK/cyclin complexes 
(Khodjakov and Rieder, 2009; Vermeulen et al., 2003). These protein complexes ensure a tight 
regulation of cell cycle progression.  
1.5. Apoptosis 
Apoptosis is a programmed cell death strategy that plays a central role in controlling the cell fate 
if DNA damage is not repaired. DNA can be damaged by stress signals such irradiation, reactive 
oxygen species (ROS) as well as other potential carcinogens, thus leading to cancer development 
(Ouyang et al., 2012; Liu et al., 2011). The cell responds to these signals by activating p53 
tumour suppressor gene. The activated p53 in turn activates genes responsible for cell cycle 
arrest so as to allow for DNA repair, failure of which prompts the cell to undergo apoptosis 
(Debatin, 2004). Apoptosis, as first described by Kerr et al. (1972), is a form of programmed cell 
death characterized by cell morphological changes that include blebbing, cell shrinkage, nuclear 
fragmentation, chromatin condensation and chromosomal DNA fragmentation and a subsequent 
cell death (Ouyang et al., 2012). Other forms of programmed cell death include autophagy and 
necrosis which are both distinguished from apoptosis by their morphological differences (Bialik 
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et al., 2010). The understanding of apoptosis has provided the basis for novel targeted therapies 
that can induce death in cancer cells or sensitize them to established cytotoxic agents and 
radiation therapy (Ghobrial et al., 2005). 
1.5.1. The Apoptotic Pathway 
Apoptosis is comprised of two signalling pathways, namely the death receptor pathway 
(extrinsic) and the mitochondrial pathway (intrinsic) (Wen et al., 2012). Activation of the 
extrinsic pathway is initiated by binding of the Fas Ligand to the cell surface death receptor, Fas, 
a member of the TNF (tumour necrosis factor) receptor superfamily. Other members include the 
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor, Apo-2 and TNF-1 
death receptors (Ghobrial et al., 2005). The Fas-L-Fas (Fas ligand) complex forms a death 
inducing signalling complex (DISC) by aggregating with the Fas-associated death domain 
(FADD) adaptor protein and pro-caspase-8. This therefore leads to an active caspase-8 enzyme 
which subsequently activates pro-caspase-3, an effector caspase required for the execution of 
apoptosis (Ouyang et al., 2012). In other cells, caspase-8 interacts with death modulators (e.g. 
Bid) of the intrinsic pathway which lead to the release of cytochrome c, a crosstalk between the 
extrinsic and the intrinsic pathways (Ghobrial et al., 2005). 
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Figure 2: A simplified schematic diagram of both the intrinsic and extrinsic apoptotic pathways 
 
The intrinsic pathway is regulated by the Bcl-2 family proteins which become activated by 
posttranslational modifications followed by translocation to the mitochondria in response to 
either extracellular or intracellular stimuli. This triggers the release of cytochrome c from the 
outer mitochondrial membrane into the cytoplasm. The cytoplasmic cytochrome c interacts with 
pro-caspase-9 and Apaf-1 molecule to form an apoptosome body which leads to an active 
caspase-9 responsible for cleaving pro-caspase-3 into an active caspase-3 necessary for the 
induction of apoptosis (Ouyang et al., 2012; Ghobrial et al., 2005). 
1.5.2. Regulation of Apoptosis: Bcl-2 Family Proteins 
The Bcl-2 family proteins, first identified in follicular non-Hodgkin lymphoma (NHL), are 
known to control apoptosis at the intrinsic pathway level and are highly expressed in many other 
cancers, therefore numerous anti-tumour drugs exerts their effect on the Bcl-2 proteins (Ghobrial 
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et al., 2005). This family of proteins is made up of the proapoptotic Bcl-2 proteins which 
promote apoptosis (Bax, Bak, Bad, Bcl-Xs, Bid and Bik) and the anti-apoptotic Bcl-2 proteins 
which suppress apoptosis (Bcl-2, Bcl-XL, Bcl-W, Bfl-1 and Mcl-1) (Ghobrial et al., 2005). 
 
The proapoptotic members promote apoptosis by mediating the release of cytochrome c from 
mitochrondria and the anti-apoptotic members block apoptosis by inactivating the pro-apoptotic 
members (Ouyang et al., 2012). Bax and Bak are termed BH3-only proteins which exert their 
pro-apoptotic effects using the BH3 molecule (Ghobrial et al., 2005; Ouyang et al., 2012). In 
response to cellular stress, these proapoptotic proteins undergo activation processes such as 
dephosphorylation and cleavage followed by movement to the mitochondria where they initiate 
cytochrome c release by permeabilizing the outer mitochondrial membrane (Ghobrial et al., 
2005; Ouyang et al., 2012).  
1.6. Targeting Apoptosis in Cancer 
The attached manuscript “Apoptotic Molecular Advances in Breast Cancer Management” 
below is a recently (2015) published chapter with a literature review on the importance of 
targeting apoptosis in breast cancer and tumorigenesis in general. 
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Abstract
Breast cancer is the most common cancer type amongst women, accounting for most fe‐
male cancer deaths second to cervical cancer worldwide. It is, therefore, highly crucial to
understand the molecular biology and explore other pathways involved in carcinogenesis
in order to select appropriate treatment not only for breast cancer but for other cancers as
well. Cancer progression is favoured by DNA damage and in most cases a consequent
disruption of the apoptotic pathway, thus leading to uncontrolled cell proliferation.
Therefore, current therapeutic strategies aim at targeting the apoptotic pathways in order
to combat cancer. In this manuscript, we discuss the ways in which evasion of apoptosis
during carcinogenesis occurs and the types of current therapeutic strategies as well as
promising future approaches against breast cancer.
Keywords: Breast cancer, apoptosis, small molecules, p53, RBBP6
1. Introduction
The human body is composed of trillions of cells that behave and function to provide structure
of the body, convert nutrients into energy and carry out specialised functions [1, 3]. Growing,
dividing, differentiating and dying are the cells’ behavioural mechanisms to maintain tissue
homeostasis [3]. However, molecular disturbances that disrupt this balance may potentially
lead to disease. Such molecular disturbances include mutations, among others, during which
any change to the DNA sequence might result in abnormality in the cell or tissue [4]. With a
population of more than a trillion cells, the human body is prone to mutations that may give
one cell a selective advantage of growing and dividing more vigorously to become a growing
mutant clone [4, 5]. Such mutations, in which a mutant clone of cells grows and divides out of
control at an expense of neighbouring wild-type cell populations, serve as a prerequisite for
the development of cancer [3].
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Cancer is defined as uncontrolled cell proliferation that leads to the formation of abnormal
cells and invasion of other adjacent tissues [1, 3-5]. The migration of cells from the origin of
tumour to another part of the body is referred to as metastasis. Tumours can either be
malignant or benign. While malignant tumours have the ability to invade surrounding tissue,
benign tumours cannot invade other tissues and are therefore not as life-threatening [3].
Efficient treatment against malignant tumours is therefore necessary in cancer management.
In this chapter, we discuss current anticancer strategies that are targeted on the apoptosis
pathway in breast cancer management.
In order to understand breast cancer, it is necessary to understand the normal anatomy of the
female breast [3, 20]. The female breast is made up of milk-producing glands called lobules
which are connected to ducts that transport milk from the glands to the nipples. The ducts and
lobules are surrounded by connective tissue, fatty tissue, blood vessels and lymphatic vessels.
In most cases, breast cancer starts in cells surrounding the ducts or the lobules [23]. Metastatic
breast cancer is as a result of migration of cancerous cells from ducts and/or lobules via
lymphatic vessels to the lymph nodes of the lymphatic system [3, 20, 23].
Breast cancer is the most common cancer type amongst women accounting for many cancer
deaths, second to cervical cancer. Risk factors of breast cancer are divided into non-modifiable
and modifiable factors [39]. Advanced age, female gender, menarche before the age of 12,
menopause after the age of 45, genetic mutations and family history are the major non-
modifiable risk factors associated with breast cancer [6, 11, 26, 46, 56, 57]. Breast cancer risk
factors that can be controlled include hormone replacement therapy, oral contraceptives,
pregnancy, breast feeding and high breast density [31]. Behavioural and life-style risk factors
associated with the development of breast cancer include poor diet, i.e. high fat, low vegetable/
fruit, low fibre and high in simple carbohydrates; overweight and obesity; and decreasing
physical activity [29, 39].
Nearly 80% of human breast cancers are hormone-positive (estrogen and progesterone),
followed by human epidermal growth factor receptor 2 (HER2)-positive, then vascular
endothelial growth factor (VEGF)-positive breast tumours [8, 9]. Targeting estrogen receptor
(ER) pathway, VEGF and HER2 are the long-established breast cancer therapeutic approaches
responsible for the improvements of breast cancer prevention and treatment. However,
resistance to these endocrine and cell-growth-inhibiting treatments is the main drawback that
reduces the benefits of these novel treatment approaches [8, 9, 20, 23]. It is therefore highly
crucial to understand the molecular biology and explore other pathways involved in carcino‐
genesis in order to select appropriate treatment not only for breast cancer but for other cancers
as well. In this chapter we discuss different ways of targeting apoptosis in breast cancer
management.
2. Targeting apoptosis in breast cancer treatment
During the process of breast cancer progression, normal cells transform into malignant types
as a result of genetic alterations [12]. This leads to dysregulation of cellular processes such as
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angiogenesis, cell cycle and apoptosis [17]. Therefore, current therapeutic strategies aim at
targeting these pathways, more especially apoptosis, in order to combat cancer [18]. Apoptosis
is a form of programmed cell death in which cells are programmed to die if found to be cellular
damaged [21, 25]. Apoptosis is made up of two major pathways called the death receptor
pathway and the mitochondrial pathway, which are both propagated by a caspase cascade
that ultimately leads to apoptosis induction [27, 34]. Evasion of apoptosis during carcinogen‐
esis occurs by three distinct mechanisms: disrupted signalling of death receptors, loss of
caspase activity as well as impaired balance between anti-apoptotic and pro-apoptotic proteins
[14, 42, 50, 59]. Targeting the caspase cascade, Bcl-2 family proteins as well as other factors
associated with apoptosis signalling have thus become the major strategy in anticancer
therapeutics (table 1).
Reagent Target Technology Function Status
Apoptin Caspases in the
extrinsic pathway
Vector-based
(adenoviral and virus
vectors)
Caspase 3 and 8
activation
Preclinical
Flavipirodol, gossypol,
depsipeptide, ABT-737,
ABT-264, fenretinide, HA
14-1, GX15-070
Anti-Bcl-2 family
proteins
Small molecule Inhibit BCl-2 family
proteins by reducing their
expression
Phase I/II
ABT 737 Anti-apoptotic
proteins
Small molecule Inhibit expression of anti-
apoptotic proteins such as
Bcl-xL, Bcl-2 and Bcl-W
Phase I
Oblimersen Sodium Anti-Bcl-2 targeted
drug
Antisense Bcl-2 antisense increases
survival rates in chronic
myeloid leukaemia
patients when combined
with chemotherapy
Phase II
ONYX-015 drug p53-based gene
therapy
Adenoviral Genetically engineered
adenovirus that has been
modified to infect and
lyse p53-deficient cells
Phase III
CD8+ cytotoxic T-
lymphocytes (CTLs)
Tumour associated
antigens (mutant
p53)
Vaccine Recognize TAA-derived
peptides that are
processed and presented
on the tumours cell
surface in association
with MHC class I
molecules, leading to
killing of tumour cells
Phase I
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Reagent Target Technology Function Status
Phikan083,
CP-31398
p53-targeted Small molecule Restores p53 function by
intercalating with p53-
bound DNA and
destabilising the p53-
DNA interaction
Phase I/II
Tenovins, Nutlins, MI-219 p53-MDM2
interaction
Small Molecule Interrupt the p53-MDM2
interaction to prevent
inactivation of p53 by
MDM2
Phase I/II
siMDM2, siE6/7, siBBP6 p53-MDM2, p53-E6,
p53-RBBP6
interaction
Liposomal
encapsulated synthetic
siRNA
Interrupt p53 interaction
with its negative
regulators
Research
Table 1. Apoptosis-based anticancer drugs in development
2.1. Caspase-targeted therapy
Pathogenic as they are, disruptions in the apoptotic pathway provide compelling possible
strategies for the treatment of breast cancer and other related types of cancers [59]. Therapeutic
agents designed to re-establish the normal functioning of the apoptotic signalling pathways
have the potential to get rid of over 50% of human cancers including breast cancer [34]. Novel
drug discoveries in recent years have led to promising advances in the treatment of breast
cancer as well as other cancers. For example, the caspase-targeting therapies that use small
molecules to act as caspase activators have been identified [24, 32]. These small molecule
caspase activators are pro-apoptotic due to their characteristic arginine-glycine-aspartate motif
that enables them to directly convert non-active procaspase-3 into active caspase-3 thus leading
to apoptosis induction.
Apoptotin is a caspase-based drug therapy that has the ability to induce caspase activity thus
increasing apoptosis induction [32]. MCF-7 breast cancer cells completely lack the expression
of caspase-3 due to frame-shift mutation in exon 3 of the caspase-3 gene [13]. As a result,
caspase-based gene therapy that relies on caspase-3 gene delivery techniques in order to up-
regulate caspase-3 expression in caspase 3-deficient breast cancers has been invented. In
human liver tumorigenesis, caspase-3 gene therapy led to a significant increase in apoptosis
and shrinkage in tumour size when combined with other chemotherapeutic drugs [13, 32].
Caspase-8 expression has also been found to be impaired due to hypermethylation in several
cancer cells. In small cell lung carcinomas, demethylation treatments have been shown to
sensitise these cancer cells to drug-induced apoptosis [32, 53].
2.2. Anti-Bcl-2 therapy
The mitochondrial pathway is down-regulated by the anti-apoptotic Bcl-2 family proteins [19,
22, 40, 43, 60]. Drug-based therapy using anti-Bcl-2 small molecules has led to a significant
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induction of apoptosis in several cancers. Flavipirodol, gossypol, depsipeptide, ABT-737,
ABT-264, fenretinide, HA 14-1 and GX15-070 are some of the small molecules that inhibit BCl-2
by reducing their expression [41, 45, 59]. Small molecules with the ability to mimic pro-
apoptotic or anti-apoptotic BH3-only Bcl-2 family proteins in order to induce apoptosis have
also been designed [2, 41]. This class of drugs that imitate BH3-only pro-apoptotic and anti-
apoptotic Bcl-2 family proteins is referred to as BH3-only mimetic drugs [2, 35]. ABT 737 is one
example of the BH3-only mimetics that has been shown to inhibit expression of anti-apoptotic
proteins such as Bcl-xL, Bcl-2 and Bcl-W; and is showing promising results in clinical trials [2,
59]. The first anti-Bcl-2 targeted drug to enter clinical trials in leukemic patients is known as
oblimersen sodium [41, 59]. This Bcl-2 antisense has been shown to increase survival rates in
chronic myeloid leukaemia patients when combined with chemotherapy [41, 59].
2.3. p53-based gene therapy
The loss of p53 function is a common feature in almost all human cancer including breast cancer
[37, 43, 47]. Because of this, there is a lot of interest in targeting p53 for anticancer therapeutic
drugs [7, 10, 16, 55]. The first biological approach which is now widely used in targeting p53
is gene delivery of wild-type p53 into tumour cells using adenoviral or retroviral techniques
[28, 48]. p53-based gene therapy is however not effective on its own in killing cancer cells and
for this reason combinational therapies involving other modes of treatments in the presence
of p53 therapy are being investigated [10, 55, 59].
For example, it was discovered that concurrent treatment using adenoviral-mediated wild-
type p53 injection with ionising therapy significantly reduces tumour size in cancers of
prostate, brain and spine as well as head and neck [28, 59]. Elimination of p53-defective cells
using synthetic viruses designed to infect and kill cancer cells is another breakthrough in p53-
based gene therapy [28, 48, 59]. One example is the ONYX-015 drug, which is a genetically
engineered adenovirus that has been modified to infect and lyse p53-deficient cells [28].
Genetic alterations that take place in p53 during tumorigenesis can trigger the immune
responses in both T- and B-cells [10]. This provides yet another interesting platform for p53-
based anticancer therapy, and a number of p53-based vaccines are currently undergoing
clinical trials [10, 59].
2.4. Small molecule approach in p53-based drug therapy
In comparison to large biological drugs that are present with complex structures, small
molecular drugs are organic compounds designed to be extremely low in molecular weight
and are made up of well-defined chemical structures that enable them to pass through the cell
membrane when taken orally. A further advantage of small molecule drugs over biologics is
that they are stable, mostly non-immunogenic and it is easy to characterise their molecular
composition and heterogeneity. The mode of action for small molecules relies on their binding
to specific biopolymers such as proteins and nucleic acids and act as effectors to alter function
or activity of the specific biopolymer.
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In cancer, small molecules are used to restore mutated proteins back to their wild-type forms
and induce activity of proteins responsible for elimination of tumorigenic cells [30]. In p53-
based drug therapy, several small molecules that can restore the function of mutated p53 have
been investigated. One example of a small molecule drug known is CP-31398; which has been
shown to restore p53 function by intercalating with p53-bound DNA and destabilising the p53-
DNA interaction [30]. Another small molecule called Phikan083, which is a derivative of
carbazole, has been identified as one of the small molecules that has the ability to restore
mutant p53 too. The most advanced of these small molecules are those that act by interrupting
the p53-MDM2 interaction which is responsible for the inactivation of wild-type p53 [51, 52,
54]. These include the nutlins, tenovins and the MI-219 [52]. MDM2 acts as a negative regulator
of p53 by binding to and inactivating the function of p53. This activity results in the loss of
p53-mediated apoptosis in cancer cells, thus promoting carcinogenesis. While the MI-219 small
molecular drugs are responsible for the destabilisation of the MDM2-p53 interactions in order
to selectively induce apoptosis and inhibit apoptosis, nutlins disrupt the MSM2-p53 complex
and selectively induce senescence [51, 52, 54].
2.5. siRNA-based p53 therapy
There are certain cancers with no mutations in p53 but in which non-mutated p53 might be
down-regulated by certain p53 negative regulators [30]. In these cancers, development of
specific siRNAs for silencing of the negative regulatory genes is often used to activate p53 [10,
30, 55]. MDM2 E3 ligase and the viral E6 protein are two extensively studied negative regu‐
lators of p53 that are associated with cancer progression [51, 52, 54].
Under normal cellular conditions, p53 tumour suppressor gene is kept under tight regulation
by the MDM2-p53 auto-regulatory feedback loop [36, 51, 52]. In response to stress stimuli such
as DNA damage or radiation, activated p53 interacts with genes responsible for the induction
of cell cycle arrest or apoptosis (figure 1) [36]. During cancer development, the interaction
between p53 and MDM2 mediates p53 interaction with the ring finger domain of the MDM2
ubiquitin ligase for degradation of the p53 tumour suppressor protein [54]. This event
compromises the occurrence of cell cycle arrest and p53-mediated apoptosis and facilitates
abnormal cell proliferation52. The use of MDM2-specific siRNA to disrupt the p53-MDM2
interaction in breast cancer cells has been shown to induce apoptosis, inhibit cell proliferation
and lead to decreased tumour size [36, 51, 52, 54].
The E6 viral  protein  is  another  thoroughly studied p53 negative  regulator  in  HPV (hu‐
man papillomavirus)-related cancers such as anogenital,  cervical,  head and neck cancers.
During HPV infection, E6 protein expression increases in order to facilitate HPV replica‐
tion and viral integration into the host cell. The E6 protein achieves this outcome by using
its E3 ligase Hect domain to bind to and degrade the cellular tumour suppressor proteins
p53  and  pRB,  thus  abrogating  the  host  cells’  potential  to  initiate  cell  cycle  arrest  and
apoptosis. Therapeutic strategies to disrupt E6-p53 interactions in the form of antisense and
siRNA application specific to E6 viral  protein have received the most attention in HPV-
related cancer therapeutics [10, 30, 55].
A third ubiquitous protein suspected to be yet another negative regulator of active p53
especially in breast cancer progression is known as retinoblastoma binding protein 6 (RBBP6)
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[36]. RBBP6 is a 250kDa protein that has been shown to interact with and possibly lead to the
degradation of p53 tumour suppressor gene since it possesses an E3 ligase activity [44, 49]. Its
mRNA codes for a p53-binding domain as well as other domains known as DWNN domain,
zinc finger domain and a ring finger domain, which are responsible for the ubiquitous nature
of RBBP6 [44]. Besides the p53 domain, which is only present in human RBBP6, the above-
mentioned domains are conserved in about all eukaryotic organisms such as humans, plants,
protozoa, fungi, microsporidia and the single-celled parasite Encephalitozoon cuniculi [44].
RBBP6 is a spliced-associated protein and therefore exists in different other homologues
known as PACT and P2P-R [44, 58].
A critical insight into the role played by RBBP6 in certain cancers via p53 has been elucidated
[15]. Transfection of lung cancer cells with siRBBP6 led to a decrease in RBBP6 expression
whereas sip53 transfection led to an increase in RBBP6 expression and, according to this study,
RBBP6 may be involved in the degradation of p53 thereby enhancing abnormal cell prolifer‐
Figure 1. A simplified diagrammatic representation of the apoptotic signalling pathway and p53 negative regulation
by MDM2 and another ubiquitous protein (RBBP6) suspected to be involved in p53 degradation. Current drugs that
target different points of the apoptotic pathways are highlighted in light-green
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ation [38]. In one study, it was demonstrated that down-regulation of the PACT homologue
of RBBP6 in mice induces embryonic lethality with a consequent accumulation of p53 and a
widespread apoptosis [33]. In addition to identifying PACT as a negative regulator of p53,
further discoveries suggest that PACT knockdown enhances p53-Hdm2 interaction thus
reducing p53 poly-ubiquitination by RBBP6 [33].
In recent studies, it was found that silencing RBBP6 gene in MCF-7 and CAMA-1 cells led to
p53 up-regulation and sensitised the breast cancer cells to apoptosis induction [36]. Concurrent
treatment of these cells with apoptosis-inducing agents, camptothecin or staurosporine,
further increased apoptosis induction [36]. Furthermore, up-regulation of bax as a result of the
co-treatment provided early insights into the possible mechanism behind the observed
apoptosis [36]. Taken together, it is suspected that RBBP6 silencing may be responsible for the
identified p53 up-regulation in breast cancer and other cancers and that the observed apoptosis
is more likely p53-dependent; however, further in vivo investigations would validate these
observations.
3. Conclusions
Taken all together, it is evident that anticancer therapeutics primarily depend on apoptosis
pathway activation in breast cancer and several other cancers. However, a few milestones still
need to be reached with regard to this novel anti-tumour molecular approach. For example,
most of the experimentally studied apoptosis-inducing regimens in breast cancer cells have
not reached the clinical stages. Another important factor that needs to be addressed in
apoptosis-targeted therapy is to determine whether the observed cytotoxicity of breast cancer
cells in experimental settings is comparable in clinical settings. Moreover, understanding
tumour biology of individual cancer patients can help select therapeutic interventions that are
highly specific to a presented tumour. Nonetheless, the link between apoptosis and tumori‐
genesis has been thoroughly investigated in breast cancer and has led to lots of promising
strategies that attempt to eradicate cancer cells by targeting the apoptosis signalling pathway.
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1.7. Retinoblastoma Binding Protein 6 (RBBP6) 
RBBP6 is a 250kDa protein that has been shown to interact with p53 and pRB tumour suppressor 
genes (Pugh et al., 2006; Simons et al., 1997; Gao et al., 2002; Sakai et al, 1995). Also known as 
RBQ-1 (RB-binding Q-protein), PACT (p53-Associated Cellular protein Testis-derived) or P2P-
R (Proliferation Potential protein-Related), the RBBP6 mRNA consists of three main types of 
domains known as DWNN domain, zinc finger domain and RING finger domain, which are 
conserved in all eukaryotic organisms including humans, plants, protozoa, fungi, microsporidia 
and the single-celled parasite Encephalitozoon cuniculi as shown in Figure 3 (Pugh et al., 2006). 
In higher eukaryotes (human and mouse) and insects (D. melanogaster and C. elegans) RBBP6 
has been found to be larger in size due to the presence of two additional domains known as p53-
binding domain and pRB-binding domain located towards the C-terminus of the 1792 amino 
acid-long peptide (Pugh et al., 2006). 
 
Figure 3: Domain structure of RBBP6 in eukaryotic organisms. DWNN, Zinc knuckle and RING finger  
domains are found in the complete genome of all eukaryotes whereas the SR domain, p53 domain and the 
pRB domain are only found in human genome (Pugh et al., 2006). 
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The DWNN (Domain With No Name) is a highly conserved domain located from residue 1-81 
on the N-terminus of the RBBP6 protein. It is present in all three RBBP6 isoforms, with isoform 
3 consisting entirely of the DWNN domain. The region from 1-81 amino acid residues on 
RBBP6 was confirmed by recombinant expression studies in E. coli, and the heteronuclear NMR 
technique was used to determine the structure of DWNN domain. Comparison of the DWNN 
structure to a protein database using a tool called Dali Server confirmed high similarity between 
DWNN and human ubiquitin domains, a finding that confers DWNN as a domain that has an 
ubiquitin-like function. A double glycine region at the C-terminus of ubiquitin-like proteins 
serves as a recognition motif for proteolysis and the presence of this GG-motif (glycine-glycine 
motif) at the same location in both human and mouse DWNN domain further implicated DWNN 
as an ubiquitin-like protein (Pugh et al., 2006). 
   
RING finger-like domains (or zinc knuckles) are small independently-folded cysteine/histidine-
rich motifs of widely diverse structure and function that fold into a secondary structure made up 
of antiparallel β-sheets and an α-helix joined together by long peptide loops (Pugh et al., 2006; 
Liew et al., 2000; Mulaudzi et al., 2007; Laity, Lee and Wright, 2001). Independent folding of 
the RING finger motif is made possible by its ability to interact with two Zn2+ ions via cysteine 
and histidine residues, forming a stabilized zinc finger structure as shown in Figure 4 (Liew et 
al., 2000; Laity et al., 2001). The diverse functions of zinc finger domains as a result of their 
structural diversity ranges from cell growth, differentiation and ubiquitination (Liew et al., 2000; 
Mulaudzi, 2007).  
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Figure 4: Solution structure of zinc finger-like domain, FOG family protein U-shaped mediate interaction.  
The structure is made up of antiparallel β-sheets (orange) and α-helices (green and grey), one histidine 
and three cysteine residues (blue) joined together by long peptide loops (green) (Liew et al., 2000). 
1.7.1. RBBP6 Homologues 
Retinoblastoma binding protein 6 (RBBP6) was isolated by direct screening of human cDNA 
clones using pRB as a probe (Saijo et al., 1995). The 140 kDa RBQ-1 protein lacks 34 amino 
acids which correspond to a region on exon 11 of the full length RBBP6 gene and this is as a 
result of alternative splicing.  Alternative splicing is a process in which gene expression results in 
a single gene coding for multiple proteins that will contain differences in their biological 
functions. RBBP6 has been shown to be a splicing-associated protein and another truncation of 
the RBBP6 protein was isolated using p53 as a probe by screening a mouse testis expression 
library, which encodes a 250 kDa protein named PACT (Simons et al., 1997). PACT has been 
shown to interact with p53 using a C’ terminal lysine-rich domain and introduction of two 
mutations in this region led to a loss of this function (Simons et al., 1997). Using precipitation 
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experiments it was also shown that PACT can interact with both cellular p53 and pRB.  Another 
PACT homologue was discovered from a cDNA encoding a P2P-R protein that had 1 exon 
responsible for encoding 34 amino acids demolished. This 250 kDa protein was isolated using 
antibodies against P2P-R protein and RB1 precipitation using glutathione-s-transferase. This 
provided evidence that the P2P-R cDNA encodes a protein domain that binds Rb1 (Witte and 
Scott, 1997).  
 
The RBBP6 name was approved for the full length gene. Characterisation of the 16p12.2 gene 
locus on human cDNA suggests that RBBP6 has three major transcripts of 6.1, 6.0, and 1.0 kb in 
size named isoform 1, 2, and 3, respectively, as a result of alternative splicing. They appear in 
the GeneBank under the accession numbers NP_008841, NP_061173 and NP_116015, 
respectively.  RBBP6 has since been known as a 250 kDa protein that interacts with both pRB 
and p53 tumour suppressor genes in human and mouse (Pugh et al., 2006).  
1.7.2. RBBP6 Expression in Cancer 
Complementary DNA microarray analysis showed that RBBP6 is highly expressed in 
oesophageal cancer cells than in normal cells where it has a role in promoting cell proliferation 
of oesophageal cancer cells (Yoshitake et al., 2004). A critical insight into the level of expression 
of RBBP6 in colon cancer has been elucidated by Chen et al. (2013). The study found that 
RBBP6 was highly expressed in colon tumorous tissues coupled with accumulation of mutant 
TP53. Chen et al. (2013) further demonstrated that RBBP6 overexpression alone or in 
combination with mutant TP53 accumulation leads to recurrent cancer and poor survival rate. 
Similarly, in a study performed by Dlamini et al. (2005) it has been shown that RBBP6 
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expression is high in squamous tumours that are well-differentiated and that RBBP6 expression 
is directly proportional to proliferation. They also demonstrated the occurrence of apoptosis 
around islands of such tumours, stipulating it to be involved in fighting invading tumours as 
there was no visible apoptosis in tissues with little or no RBBP6 expression (Dlamini et al., 
2005). Similarly, expressional experiments performed by Motadi et al. (2011) showed that 
RBBP6 mRNA and its protein products were significantly expressed in subtypes of lung cancer.  
 
Transfection of lung cancer cells with siRBBP6 led to a decrease in RBBP6 expression whereas 
sip53 transfection led to an increase in RBBP6 expression. This suggests that RBBP6 may be 
involved in the degradation of p53 thereby enhancing cell proliferation (Motadi et al., 2011). In a 
study performed by Li et al. (2007) it was demonstrated that down-regulation of the PACT 
homologue of RBBP6 in mice induces embryonic lethality with a consequent accumulation of 
p53 and a widespread apoptosis. In addition to showing that PACT might be a negative regulator 
of p53, findings by Li et al. (2007) further suggest that PACT-knockdown enhances p53-Hdm2 
interaction thus reducing p53 poly-ubiquitination by RBBP6. In a recent study we further 
demonstrated using breast cancer cell line models (MCF-7 and CAMA-1) that indeed down-
regulation of RBBP6 using RNA interference leads to p53 accumulation and a notable 
enhancement of apoptosis (Moela et al., 2014). We also demonstrated that further down-
regulation of RBBP6 was observed following co-treatment with camptothecin; however the 
study still warrants further investigation into the mechanism responsible for the further down-
regulation of RBBP6 as a result of camptothecin. Furthermore, up-regulation of bax as a result of 
the co-treatment provided early insights into the possible mechanism of the observed apoptosis, 
(Moela et al., 2014). Conversely, data presented by Gao and Scott (2003) indicates that 
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overexpression of P2P-R, another homologue of RBBP6, promotes camptothecin-induced cell 
death as well as cell cycle arrest in MCF-7 cell line. These findings (Li et al., 2007; Moela et al., 
2014; Gao and Scott, 2003) may appear contradictory. However taken altogether they suggest 
that RBBP6 is involved in p53 regulation and apoptosis, and may therefore serve as an important 
marker in cancer therapy development.    
1.7.3. RBBP6 Role in p53 Regulation 
Ubiquitin-like DWNN domain and RING finger-like domain presence give RBBP6 the ability to 
function through some ubiquitin-like modification. It is thus associated with the execution of p53 
degradation via its p53-binding domain following inhibition of the tumour suppressor gene by 
MDM2, thus facilitating cell proliferation.  Little is known however, about the mechanism by 
which RBBP6 degrade the p53 tumour suppressor protein (Li et al., 2007; Ntwasa, 2008; 
Pretorius et al., 2013). The first human cDNA clones of the p53 tumour suppressor gene which 
codes for a protein of 393 amino acid were first isolated in the early 1980’s and it was named so 
because it elicits a band size of 53kDa in agarose gel electrophoresis (Nag et al., 2013). P53 is a 
tumour suppressor gene responsible for the regulation of cell cycle arrest, DNA repair and 
apoptosis and it is highly mutated in several cancers thus leading to deregulation of the cell cycle 
and apoptosis impairment (Ghobrial et al., 2005).  
 
Following nuclear stress such as radiation, p53 activates p21 gene which is responsible for the 
induction of cell cycle arrest during which damaged DNA is allowed to undergo repair. 
However, if damage is irreversible, p53 activates pro-apoptotic Bcl-2 protein members in order 
to induce apoptosis although the mechanism by which p53 induces apoptosis is not well 
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understood. Oncogenes and tumour suppressor genes maintain the balance between cell growth 
and cell death and p53 is one of the well-studied tumour suppressor genes that plays a role in the 
development and homeostasis of cells and tissues (Jiang et al, 2013). In addition to its 
downstream effectors such as cyclin dependent kinase inhibitor p21, pro-apoptotic bax and 
tumour necrosis factor receptors (Fas and/or Apo1), p53 transcriptionally activates its negative 
regulator, MDM2, in an auto-regulatory feedback loop (Jiang et al., 2013; deRoziere et al., 
2000).   
   
MDM2 was established as an oncogene in a study which demonstrated that overexpression of the 
MDM2 gene rendered rodent fibroblasts tumorigenic in nude mice (Mendez et al, 2009). The 
MDM2 gene codes for a 491 amino acid protein and it contains two transcriptional promoter 
elements, one of which is p53-dependent (Mendez et al, 2009). Also known as a family member 
of the E3 ubiquitin ligases, MDM2 directly interacts with p53 to mediate its ubiquitination (Jiang 
et al, 2013). Following its expression, MDM2 translocates from the nucleus to the cytoplasm 
where it mediates the degradation of p53 and other targets (Mendez et al, 2009). In most cancers, 
the mutated p53 or the function of wild-type p53 is inhibited by the MDM2 oncogene resulting 
in the impairment of tumour suppressive p53-pathways such as apoptosis and cell cycle arrest 
(Nag et al, 2013). 
1.8. Rationale/Hypothesis 
Previous RBBP6 expressional studies have shown that RBBP6 localization is widespread in a 
number of squamous cell carcinomas including those of the lung, colon and oesophagus; 
suggesting that the protein may serve as an important diagnostic marker and a promising target 
P. Moela: PhD Thesis 
27 
 
for treatment of squamous cell carcinomas. Limited evidence however exists on the involvement 
of RBBP6 in the progression of breast and cervical cancer. Cancer is an enormous burden of a 
disease globally and today more people die from cancer than HIV/AIDS, tuberculosis and 
malaria combined. Currently, cervical cancer is the most common cancer; accounting for over 
60% of the gynaecological cancer burden in developing countries (Sankaranarayanan et al., 
2009) and breast cancer remains the leading cause of cancer related deaths in women. RBBP6 
has been shown to be highly expressed in several cancers, and its ability to interact with p53 
tumour suppressor has drawn attention in evaluating its potential as a cancer biomarker. P53 is a 
crucial regulatory protein that triggers cellular responses such as DNA repair, cell cycle arrest, 
senescence and apoptosis in response to cellular stress. In most human cancers, however, the 
TP53 pathway is often found to be defective, either by mutations or through deregulation by its 
negative regulators. In cervical cancer and certain breast cancer subtypes, p53 is found to be 
inactivated rather than mutated and RBBP6 is suspected to be one of such negative regulators of 
p53.  
 
In terms of cervical cancer, extensive research of the main causative agent of cervical cancer has 
evidently singled out HPV as the main cause (Fernandes et al., 2013; Denny, 2010; Bosch et al., 
2002). During the differentiation-dependant phase, the E6 viral protein regulates the viral 
replication in differentiated cells by supressing transcription of active p53 cellular protein thus 
abrogating the host cells’ ability to initiate cell cycle arrest, prompting uncontrolled cell 
proliferation. It is suspected that the viral protein achieves this p53 suppression via the 
proteasomal pathway in which it acts as an E3 ligase that functions to ubiquitinate protein 
molecules for proteasomal degradation (Fernandes et al., 2013; Denny, 2010; Bosch et al., 
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2002). This mechanism is similar to the one involving RBBP6 in which it interacts with TP53 
via its p53-binding domain. Research has shown that RBBP6 plays a role as a scaffold protein to 
promote the assembly of the p53/TP53-MDM2 complex, resulting in increased MDM2-mediated 
ubiquitination and degradation of p53/TP53. Therefore, this suggests that RBBP6 may function 
as a negative regulator of p53/TP3, thus leading to both apoptosis and cell growth (Pugh et al., 
2006; Motadi et al., 2011).  
Therefore in this study we propose that RBBP6 mediates TP53 inactivation in the same manner 
as MDM2 in breast cancer and HPV E6 protein in cervical cancer since these proteins possess 
the activity of E3 ligases and have also been shown to interact with TP53. Our hypothesis is that 
RBBP6 expression may be high in cervical cancer as is in breast cancer. In addition, that further 
up-regulation of this gene in both cancers would lead to poor prognosis whereas down-regulation 
might slow down breast and cervical cancer progression. We have therefore asked the following 
question: what is the expression profile of RBBP6 in cervical cancer and how would 
manipulation of this gene affect cervical as well as breast cancer progression? We therefore aim 
to manipulate the expression of RBBP6 in breast and cervical cancer cell lines and co-treat with 
chemotherapeutic agents in order to sensitise apoptosis induction. 
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CHAPTER TWO - Research Aim and Objectives 
2.1. Aim 
The main aim of this study was to manipulate RBBP6 gene expression and evaluate its effects in 
cervical and breast cancer progression. Targeted therapy works best in combination with 
chemotherapy which is why we further aim to analyse the effect of RBBP6 targeting in 
combination with anticancer agents camptothecin and γ-Aminobutyric acid (GABA) on cancer 
progression. We also aim to understand the relationship between RBBP6, p53 and p53-mediated 
apoptotic genes and possibly outline their mechanism of action relative to apoptosis at a 
transcriptional level. Understanding these relationships may confer RBBP6 as an important 
diagnostic marker of cervical and breast cancer. 
2.2. Objectives 
 To localize RBBP6 in cervical cancer tissue microarray slides using 
immunohistochemistry in order to understand RBBP6 distribution in cervical cancer in 
the context of intact tissue. 
 To overexpress and silence RBBP6 gene in adherent breast and cervical cancer cell lines 
(HeLa, SiHa, MCF-7 and MDA-MB-231) using an expression vector and siRNA 
technology, respectively, and quantify the level of RBBP6 expression using qPCR, 
immunoprecipitation/western blotting, FACS analysis and confocal microscopy  
  To analyse the effect of RBBP6 targeting  (overexpression and silencing) on cell 
proliferation using xCELLigence real time cell analyser (RTCA)  
 To analyse the effect of RBBP6 targeting  (overexpression and silencing) and co-
treatment on apoptosis by measuring  plasma membrane integrity, mitochondrial ATP 
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content and caspase activity and on cell cycle by quantifying DNA content in the cell 
cycle checkpoints (G0/G1 and G2/M) and the S-phase  
 To quantify the expression of p53, bax, bak1, bad, bcl-2, caspase-3 and caspase-8 
apoptotic genes in response to RBBP6 gene manipulation and co-treatment using 
quantitative PCR.  
 To analyse the effect of RBBP6 overexpression and silencing on the expression of p53 at 
a protein level using western blotting 
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CHAPTER THREE - Materials and Methods 
3.1. Materials 
3.1.1. Tissue Sections 
Formalin-fixed paraffin-embedded human cervical cancer tissue microarray slides (TMAs) were 
purchased from Cybrdi (USA) with ethics clearance number M140801. The TMAs consisted of 
20 cases of both squamous cell carcinoma and adenocarcinoma that were diagnosed between 
stages I to III in Caucasian and African-American women aged between 25 and 51. 
3.1.2. Cell lines 
Breast and cervical cancer cell lines as well as a non-tumorigenic cell line were used in this study 
as a source of mRNA and protein, and for studying growth and morphological changes after co-
treatment.  The MCF-7 breast cancer cell line was used as a wild-type p53-expressing cell line 
and the highly metastatic MDA-MB-231 as a mutant p53-expressing cell line. The 
adenocarcinoma-derived HeLa and the squamous cell carcinoma-derived SiHa cervical cancer 
cell lines, both of which express wild-type p53 were used as cell line models for cervical cancer 
studies. MRC-5 lung fibroblasts were treated as normal cells and all cell lines were obtained 
from ATCC (USA).     
3.1.3. Primers and Antibodies 
Pre-designed and validated IDT PrimeTime® qPCR primers for rbbp6, TP53, bax, bak1, bad, 
bcl-2, caspase-3 and caspase-8 were purchased from Whitehead Scientific (Pty) Ltd. GFP (green 
fluorescent protein) tagged mouse (IgG2a) monoclonal primary antibody and goat anti-mouse 
IgG (H+L) secondary antibody with alexa fluor® 488 conjugate were obtained from Life 
Technologies™. Mouse monoclonal primary antibody against the full length RBBP6 was 
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purchased from Cell Signalling Technology®. Anti-mouse secondary antibody with HRP-
conjugate and p53 mouse monoclonal primary antibody were from Santa Cruz Biotechnology®, 
Inc.   
3.1.4. RNAi Oligos  
Silencing was achieved by the use of Ambion’s Silencer® Select Pre-designed siRNAs supplied 
by Life Technologies™, which target the full length RBBP6. Delivery of the Ambion’s 
Silencer® Select Pre-designed short interfering RNAs into the mammalian adherent cells was 
achieved by the use of the lipid-based siPORT™ NeoFX™ transfection agent also manufactured 
by Ambion®. 
3.1.5. Expression Vector  
TrueORF™ pCMV6-AC-GFP (cytomegalovirus 6) cDNA clone containing open reading frame 
of RBBP6 transcript variant 3 (NM_032626.5) sequence was purchased from Origene Co. for 
transient transfection of cell lines. The pCMV6 expression vector contained ampicillin as an 
antibiotic selection marker and was tagged to green fluorescent protein (GFP) tag at the carboxy-
terminus which allowed positive identification of RBBP6-overexpressing cells (Figure 5). 
Transfection of cells with the RBBP6 construct was obtained using Lipofectamine® 3000 
transfection reagent purchased from Life Technologies™. 
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Figure 5: An example of a typical vector map for pCMV6-AC-GFP with antibiotic selection markers  
Ampr (confers selection in E. coli) and Neor (confers selection in mammalian cells), origins of replication 
SV40 ori (mammalian), ColE1 (bacterial) and f1 ori (filamentous phage), CMV promoter region, ORF 
insert region, restriction enzyme sites (Sgf I, Asc I, Rsr II, and Mlu I) and the GFP (green fluorescent 
protein) tag region. 
3.1.6. γ-Aminobutyric acid (GABA) 
Chosen as one of the anticancer agents in this study, GABA (Sigma®) is known as a major 
inhibitory neurotransmitter in adult central nervous system (CNS) which acts on GABAA/C 
ionotropic and GABAB metabotropic receptors. Binding to GABAA/C receptors leads to an 
increase in chloride ion conductance thus restoring the cell resting membrane potential. As an 
inhibitory neurotransmitter GABA is therefore used clinically as a dietary supplement to reduce 
anxiety and enhance sleep. As an anticancer agent, it is suspected to be involved in modulation 
of proliferation, differentiation and migration of cancer cells as shown by a recent study (Chen et 
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al., 2013) where migration of human liver cancer cells was reduced in the presence of GABA 
even though its mechanism of action is not yet fully discovered.  
3.1.7. Camptothecin 
Camptothecin (Calbiochem®) is a plant extract isolated from Camptotheca acuminata tree which 
is originally cultivated in most regions of China where it is used for anticancer treatment in 
Chinese traditional medicine. It is classified as a quinoline alkaloid that exerts its cytotoxic 
effects by the induction of apoptosis. Camptothecin binds to DNA topoisomerase I complex to 
form a ternary structure that stabilizes the complex to block religation of DNA thus causing 
DNA strand breaks that result in apoptosis (Nieves-Neira and Pommier 1999). Clinical trials on 
this apoptosis-inducing agent revealed low solubility and adverse drug reactions which led to the 
synthesis of more soluble and beneficial camptothecin derivatives which demonstrate good 
activity against tumours of the lung, breast, colorectal and ovary (Nieves-Neira and Pommier 
1999). Examples are irinotecan hydrochloride and topotecan which have been clinically 
approved by the FDA and are clinically used in anticancer therapy (Arakawa et al., 2009).    
3.2. Methods 
3.2.1. Immunohistochemistry (IHC) 
Principle 
Immunohistochemistry is a technique used to demonstrate distribution and location of proteins in 
tissue sections and although less sensitive quantitatively compared to western blot and ELISA it 
enables observation of processes in the context of intact tissue (Taylor, 2014; Ramos-Vara, 
2011). Protein of interest is detected by the use of specific antibodies that recognize the target 
protein inside the tissue section and visualisation is accomplished by the use of chromogenic 
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enzymes conjugated on the secondary antibody to cleave the substrate and create a coloured 
precipitation at the location of the protein (Taylor, 2014; Ramos-Vara, 2011). Alternatively, 
fluorescent dyes are used to enable detection of target protein in which a fluorophore conjugated 
to a secondary antibody can be visualised using fluorescent microscopy (Valli et al., 2009).  
 
Sample preparation for IHC is very important for the maintenance of cell morphology, tissue 
architecture and the antigenicity of target epitope. To obtain this one needs proper tissue 
collection, fixation and sectioning. Fixation helps prevent the excised tissue from autolysis, 
necrosis, protects antigenicity and helps increase resistance of cellular components from tissue 
processing. Paraformaldehyde is a commonly used fixative however different antigens prefer 
different fixation methods and for this reason a wide variety of fixatives exists for a particular 
type of antigen. A robust and optimized fixation protocol is therefore a critical step in IHC. This 
is then followed by tissue imbedding in paraffin medium or by freezing in order to preserve 
morphology and give the tissue support during microtomy, a process used to section tissues 
(Ramos-Vara, 2011).   
 
This is then followed by tissue sectioning using microtome or cryostat instrument, mounting of 
tissue slices onto a slide, dehydration using alcohol washes of increasing concentrations, 
followed by clearing of dehydrating agents using xylene. Fixation can lead to cross-linking 
which masks epitopes and can lead to restricted antigen-antibody binding and this makes it 
necessary to include additional step called antigen retrieval that involves pre-treating the sections 
with heat or protease. The proteolytic-induced epitope retrieval (PIER) method makes use of 
enzymes such as pepsin, trypsin, or proteinase k to restore binding of the antibody to its epitope 
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and the heat-induced epitope retrieval (HIER) method uses heat from a variety of sources such as 
water bath, microwave, autoclave, pressure cooker or steamer to unmask epitopes.  
 
For cytoplasmic target of epitopes, permeabilization will be necessary following antigen retrieval 
and solvents like methanol and acetone or detergents like NP-40, triton or tween-20 are 
commonly used. Before immunostaining, blocking with sera is essential to block unspecific 
absorbance to tissue. Factors commonly blocked include protein-protein unspecific binding, 
biotin unspecific binding (if using biotinylated secondary antibody), peroxidase if using HRP-
linked secondary antibody, alkaline phosphatase blocking if using AP chromogenic substrate, or 
autofluorescence blocking if using fluorescent label for detection. 
 
Technique 
Paraffin-embedded formalin-fixed cervical cancer TMAs were firstly heated in an oven at 65˚C 
for 1 hour followed by deparaffinization and rehydration steps in which slides underwent a series 
of washes with xylene twice for 5 minutes each. This was then followed by ethanol rinses of 
decreasing concentrations for 5 minutes each, twice per concentration of 100%, 95%, 70%, 50%, 
30%, then 5 minutes washes with H2O and wash buffer on a shaker. Antigen retrieval was done 
at 80˚C for 5 minutes at low microwave setting in 0.1M sodium citrate, pH 6.0. The sections 
were then allowed to cool to room temperature for about 20 minutes followed by a 2 minutes 
wash with wash buffer containing 1% BSA (bovine serum albumin). Hydrogen peroxidase was 
then inactivated using 3% hydrogen peroxide at room temperature followed by 2 minutes 
washing with TBST containing 1% BSA. Primary antibody was diluted in 1% BSA per 
recommendation on data sheet followed by application of diluted primary antibody to the tissue 
P. Moela: PhD Thesis 
37 
 
sections and an overnight incubation in a humidified chamber at 4˚C. This was then followed by 
3 minute washes with TBST three times on a shaker, then incubation with secondary antibody 
for 1 hour at room temperature. The tissue sections were then incubated with freshly prepared 
substrate according to manufacturer’s protocol (ABC Staining System®, Santa Cruz 
Biotechnology) followed by coverslip mounting of slides with xylene-based medium and 
allowed to completely dry before visualization and imaging with light microscope.          
3.2.2. Cell culture routine 
Human monolayer normal and cancer cell lines were grown in HyClone® DMEM/High Glucose 
growth medium supplemented with 10% FBS (fetal bovine serum) and 1% antibiotic 
(penicillin/streptomycin) and routinely maintained at 37°C in a 5% CO2 incubator. The cells 
were fed every second day of the week by replacing old growth medium with equal amount of 
fresh growth medium after rinsing twice with 2ml PBS. The cells were sub-cultured when at 
near-confluency by trypsinization at least once per week and excess sub-cultures were preserved 
at ≥ -80°C in DMEM/High Glucose growth medium supplemented with 10% FBS and 20% 
DMSO (dimethyl sulfoxide).   
3.2.3. RBBP6 Protein Overexpression 
Principle 
Most biopharmaceutical drugs, vaccines and clinical reagents are based on recombinant protein 
overexpression for use in diagnoses, prevention and therapeutics. The first recombinant protein, 
insulin, was approved by the FDA in the early 1980s and ever since then hundreds of 
recombinant therapeutics has been FDA-approved (Kamionka, 2011). The process of 
recombinant protein production in mammalian cells depends on the delivery of a cDNA clone 
into the host cell nucleus using a liposomal transfection reagent, where it becomes transcribed 
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and translocated into the cytoplasm for translation into r-protein of interest (Aricescu et al., 
2006; Condreay et al., 1999). In the present section we overexpressed RBBP6 protein by 
transient transfection (Tom et al., 2008) using the expression vector described in section 3.1.5 
above. 
 
Technique 
Briefly, fifty thousand (5X104) cells were plated in a 6-well plate 18-24 hours before transfection 
to obtain 50-70% confluency. A mixture of cDNA clone/transfection reagent in a 1:3ratio was 
then prepared and incubated at room temperature for 10 minutes to allow DNA uptake by the 
transfection reagent.  The cDNA clone/transfection reagent mixture was then added drop-wise 
into each well that already contained 500 µl of culture medium followed by gentle back-and-
forth side-to-side rocking of the 6-well plate in order to achieve an even distribution of the 
transfection mixture before incubating for 18-24 hours at 37˚C.  
3.2.4. RNA interference (RNAi) 
Principle 
RNA interference (RNAi), also called post-transcriptional gene silencing (PTGS), is a eukaryotic 
regulatory mechanism that plays an important role in directing development and suppressing 
parasitic gene expression. It uses small interfering RNA (siRNA) molecules to degrade specific 
mRNA and silence gene activity (Aagaard and Rossi, 2007). The RNAi pathway is initiated by 
cleavage of long double-stranded RNA by DICER enzyme into short interfering double-stranded 
RNA molecules of about 20 nucleotides in length. 
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These short interfering RNA molecules have a characteristic 5’phosphate and a two nucleotide 
3’overhang which allows them to be recognised by the RNAi machinery that eventually leads to 
degradation of target mRNA (Meister and Tuschl, 2004). The short double-stranded siRNA 
separates into two single-stranded RNA (ssRNA) named the guide strand and the passenger 
strand. The passenger strand becomes degraded and the guide strand associates with the RNA-
induced silencing complex (RISC) where it specifically base pairs with complementary target 
mRNA. This induces catalytic cleavage of the target gene by a component of the RISC complex 
known as Argonaute enzyme (Aagaard and Rossi, 2007 and Meister and Tuschl, 2004).  
 
Introduction of artificial siRNAs has been adopted as a tool to target and inactivate gene 
expression both in-vitro and in-vivo. Most human diseases such as cancer, viral infections, 
autoimmune diseases, and genetic disorders are associated with alterations in one or more genes 
and therefore this makes the RNAi intervention an attractive strategy for gene-related 
therapeutics (Aagaard and Rossi, 2007). In this study we used RNAi to silence RBBP6 in breast 
and cervical cancer cell lines. 
 
Technique 
Briefly, 70-80% confluent cells were transfected with 30nM siRNAs targeting RBBP6 over a 24 
hour period and the adherent cells were trypsinized and resuspended in an antibiotic-free media. 
The cell suspension was then mixed with siRNA/transfection agent complex in a 24-well plate 
and incubated at 37°C for 24 hours. Post-transfection cells were exposed to 100μΜ GABA and 
0.25μΜ camptothecin for additional 24 and 48 hours and then harvested for subsequent analysis. 
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3.2.5. RNA Extraction 
Principle 
RNA is used as a starting point for downstream processes such as reverse transcription real-time 
PCR (polymerase chain reaction), conventional PCR, array analysis and cDNA library 
constructions (Valasek and Repa, 2005; Ginzinger, 2002). However this single-stranded RNA is 
highly unstable with a very short half-life once extracted from cells or tissues. It is the ubiquitous 
presence of RNAses on all tissues (especially on skin, in blood, and in most bacteria and fungi in 
the environment) that make RNA easily degradable. High quality total RNA is therefore an 
absolute prerequisite in the performance of molecular techniques (Huggett et al., 2013; Tan and 
Yiap, 2009). Most RNA isolation procedures make use of RNAse inhibitory agents such as 
chaotropic ions (e.g. guanidine salt), sodium dodecylsulfate (SDS) denaturant or phenol-based 
compounds. The commercial RNA isolation kit used in this study relies on guanidine chaotropic 
salt.  
 
Technique 
Cells were transfected with siRBBP6 (short interfering RBBP6) and pRBBP6 (RBBP6 cDNA 
construct) construct for 48 hours and co-treated with camptothecin and GABA for additional 24 
hours before RNA isolation. The general purification steps which were used in this study 
following co-treatments of nearly confluent cultured cells with Nucleospin® RNA II total RNA 
isolation kit (Separations Scientific) include: effective disruption of cells → denaturation of 
nucleoprotein complexes → inactivation of DNAses → washing steps for the removal of salts, 
metabolites and macromolecular cellular components → elution of pure RNA. The resulting 
RNA was quantified using the nanodrop technique and RNA purity was confirmed by ensuring 
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that A260/A280 ratio was >1.7 and the RNA integrity was confirmed by examination of the 18S 
and 28S RNA bands on agarose gel stained with ethidium bromide. 
3.2.6. Reverse Transcription 
Principle 
In order to perform RT-PCR, the obtained RNA template must first be converted into a cDNA by 
the use of reverse transcriptase enzyme. In this study we performed reverse transcription using 
the ImProm-II™ Reverse Transcription System commercial kit manufactured by Promega.  
 
Technique 
Cells were transfected with siRNAs and pRBBP6 construct for 48 hours and co-treated with 
camptothecin and GABA for additional 24 hours before RNA isolation. Sequence specific 
primers together with the obtained total RNA template formed major components of the PCR 
cocktail used in the synthesis of cDNA. The RNA reverse transcription was performed according 
to the manufacture’s detailed protocol using the Multigene Gradient Thermal Cycler.  
3.2.7. Real Time RT-PCR 
Principle 
Quantitative PCR was performed to check whether the transfection of cells was successful and to 
study gene expression changes following co-treatment of cells (Huggett et al., 2013; Tan and 
Yiap, 2009). The total mRNA transcribed into complementary cDNA was amplified and 
quantified a thermal light cycler (Roche® Light Cycler 480). Quantitative PCR differs from 
conventional PCR in that instead of detecting and quantifying amplified DNA at the end of the 
reaction, the amount of PCR product is measured at each cycle in real time (Valasek and Repa, 
2005; Ginzinger, 2002).  Measurement of the amount of DNA at each cycle is accomplished by 
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the use of fluorescent dyes capable of intercalating each of the newly synthesized double-
stranded DNA to produce a signal that’s directly proportional to the amount of PCR product. 
Commonly used fluorescent dye or probes include SYBR Green, TaqMan, Molecular Beacons, 
Scorpions, etc. and in our study we chose to use SYBR Green fluorescent dye due to its 
advantages, i.e. it is inexpensive, easy to use and highly sensitive (Valasek and Repa, 2005; 
Ginzinger, 2002).   
 
Technique 
SYBR® Green JumpStart Taq ReadyMix (SIGMA®) dye was used to quantify the amount of 
gene expression from cDNA synthesized from total RNA that was isolated from cultured cells 
exposed to 48 hour transfection with 30nM siRBBP6 and 1μg pRBBP6 and co-treatment with 
GABA and camptothecin. The qPCR was performed in a 20μl reaction mixture containing 
2100ng/ul cDNA, SYBR Green, forward and reverse primers under the following conditions: 36 
cycles of 94°C for 35s, 59°C for 45s, and 72°C for 45s.  
3.2.8. Western Blot and Immunoprecipitation 
 
Western Blotting 
 
Principle 
Western blot analysis continues to be a routine technique in most laboratories to determine the 
level of expression of proteins. This protein analysis technique was introduced by Towbin et al. 
(1979). The term blotting refers to the transfer of biological samples from a gel to a membrane 
and their subsequent detection on the surface of the membrane (Harper et al., 1990). The first 
step in a western blotting procedure is to separate the macromolecules using gel electrophoresis. 
Following electrophoresis, the separated molecules are transferred or blotted onto a second 
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matrix, generally a nitrocellulose or polyvinylidene fluoride (PVDF) membrane (Osborne and 
Brooks, 2006; Kurien and Scofield, 2006). Next, the membrane is blocked to prevent any 
nonspecific binding of antibodies to the surface of the membrane. The transferred protein is 
complexed with an enzyme-labeled antibody as a probe. An appropriate substrate is then added 
to the enzyme and together they produce a detectable product such as a chromogenic or 
fluorogenic precipitate on the membrane for colorimetric or fluorometric detection, respectively.  
 
The most sensitive detection methods use a chemiluminescent substrate that, when combined 
with the enzyme, produces light as a by-product (Alegria-Schaffer et al., 2009). The light output 
can be captured using film, a CCD camera or a phosphor-imager that is designed for 
chemiluminescent detection (Haan and Behrmann, 2007). Whatever substrate is used, the 
intensity of the signal should correlate with the abundance of the antigen on the blotting 
membrane. Detailed procedures of a western blot vary widely.  One common variation involves 
direct vs. indirect detection. With the direct detection method, the primary antibody that is used 
to detect an antigen on the blot is also labeled with an enzyme or a fluorescent dye. This 
detection method is not widely used as most researchers prefer the indirect detection method. In 
the indirect method, a primary antibody is added first to bind to the antigen. This is followed by a 
labeled secondary antibody that is directed against the primary antibody (Osborne and Brooks, 
2006; Kurien and Scofield, 2006). Labels include biotin, fluorescent probes such as fluorescein 
or rhodamine, and enzyme conjugates such as horseradish peroxidase (HRP) or alkaline 
phosphatase (AP) (Scofield, 2006). In this study, the indirect method was used since it offers 
more advantages over the direct method, i.e. it has increased sensitivity, a wide variety of labeled 
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secondary antibodies are available commercially and immunoreactivity of the primary antibody 
is not affected by labeling.   
Technique 
Whole cell protein was extracted using RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 
10% sodium SDS, and 3 μl/ml aprotinin and 5μg/ml leupeptin in PBS, pH 7.4). Seventy two 
hours post-transfection and co-treatment with either GABA or camptothecin, cells were washed 
twice with cold PBS then resuspended in 500μl RIPA buffer and collected by scraping. The total 
protein was then separated from cell debris by centrifugation at 14000 rpm for 15 minutes 
followed by quantification with Pierce® BCA Protein Assay Kit.  The protein was heated at 
95°C for 5 minutes and 30μg was loaded per well for electrophoretic separation in 30% 
acrylamide/bis (37.5:1) gel preparation at 100V for 1hour. The protein was transferred onto a 
nitrocellulose membrane using wet electro-transfer method overnight at 30V followed by 
incubation with primary antibody after 1 hour of blocking with 5% non-fat milk buffer. The 
weak light signal produced by HRP-linked secondary antibody was detected and enhanced using 
the Pierce® ECL Western Blotting Chemiluminescence Substrate and the blots were imaged by 
the CCD-based ChemiDoc™ MP system.  
 
Immunoprecipitation 
Principle 
Immunoprecipitation is a procedure that results in the enrichment of a specific protein from a 
heterogeneous mixture, cell lysate or culture supernatant (Chan et al., 2015). This enrichment is 
accomplished by binding the protein of interest with a specific antibody, followed by 
precipitation of the immune complexes with Protein G or Protein A immobilized onto beads such 
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as agarose (Moser et al, 2009; Lal et al, 2005). The precipitated immune complexes are then 
denatured and resolved by SDS-PAGE (polyacrylamide gel electrophoresis) for further analysis. 
Immunoprecipitation can be used to confirm the identity of a protein, to quantify expression 
levels, to study the biochemical characteristics such as protein:protein interactions, or to evaluate 
posttranslational modifications (Chan et al., 2015; Moser et al., 2009; Lal et al., 2005). In this 
study immunoprecipitation was used to purify our protein of interest which was overexpressed in 
the cells by the use of RBBP6-containing construct labelled with GFP reporter gene. Cells 
transfected with the pRBBP6 construct were lysed and the cell lysates were precipitated with 
anti-GFP monoclonal antibody and the antibody-antigen complex was extracted from the sample 
using protein G-coupled agarose beads before western blot analysis as described above. 
 
Technique 
Following 48 hour transfection of cells with the pRBBP6 construct, culture medium was 
removed and cells were washed with ice-cold PBS followed by harvesting of approximately 
5x106 cells by scrapping; which were then centrifuged at 400xg for 10 minutes at 4°C. After the 
second wash, the supernatant was completely removed and pellet resuspend in 1mL of ice-cold 
RIPA buffer containing protease and phosphatase inhibitors. The cell lysate was then gently 
vortexed and then transferred to a fresh 1.5 mL tube and placed the tube on ice for 30 minutes 
with occasional mixing. Another centrifugation of the cell lysate followed at 10,000xg for 15 to 
30 minutes at 4°C then supernatant was carefully collected without disturbing the pellet and 
transferred to a clean tube. The protein concentration was determined by BCA assay. To pre-
clear the lysate, immobilized protein G bead slurry was resuspended by gentle vortexing and 10 
μl of the prepared protein G slurry was added to 100 μL of cell lysate (~1x106 cells or ~100 µg 
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protein) then incubated on a rotator for 30 to 60 minutes at 4oC. The mixture was centrifuged at 
2,500xg for 2 to 3 minutes at 4°C and the supernatant was transferred to a fresh 1.5 mL tube. An 
amount of 1μg GFP antibody was added to the pre-cleared cell lysate then incubated at 4°C 
overnight on a rotator followed by addition of at least 10 μL of protein G slurry pre-equilibrated 
in the corresponding IP (immunoprecipitation) buffer/Lysis buffer then incubated overnight at 
4°C on a rotator to capture the immune complexes. The tubes were then centrifuged at 2,500xg 
for 30 seconds at 4°C followed by careful removal of the supernatant. The beads were then 
washed three to five times with 500 μl of ice-cold lysis buffer then centrifuged to pellet the beads 
in between each wash. After the last wash, supernatant was carefully aspirated and 1X Laemmli 
sample buffer was added to the bead pellet followed by vortexing for 10 minutes and 
centrifugation at 10,000xg for 5 minutes to pellet the beads. Supernatant was then collected 
carefully for subsequent loading onto an SDS-PAGE gel which preceded western blot analysis.  
3.2.9. xCELLigence System 
Principle 
Conventional methods used to assess cytotoxicity of certain compounds administered in cultured 
cells include the use of tetrazolium salts such as MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide), which reduces into insoluble purple formazan crystals by NAD(P)H-
dependent enzymes present in viable cells (Jurisic and Bumbasirevic, 2008; Larson and 
Worzella, 2005).  Other related tetrazolium salts include XTT, MTS and the WSTs (water-
soluble tetrazolium salts). To date, tetrazolium salts have since been the most widely used assays 
in cell biology for measuring cell viability, proliferation and cytotoxicity, and for this reason they 
serve as the gold standard for comparing modern techniques that provide similar outputs (Jurisic 
and Bumbasirevic, 2008; Larson and Worzella, 2005). However, these end-point qualitative 
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methods are labor-intensive as they present with multiple-step protocols that might greatly lead 
to inconsistencies among the end-points (Limame et al., 2012). Furthermore, results obtained 
from these conventional assays are in the form of fluorescent intensity, absorbance spectra or 
luminescence, markers which are often prone to interferences that might cause them to deform 
thus leading to unreliable data. Implementation of new technologies capable of non-invasively 
monitoring physiological parameters of the cell in real time without compromising the quality of 
results is therefore necessary (Larson and Worzella, 2005). 
  
Real time cell analyzer (RTCA) named xCELLigence system™ is a recent technique launched by 
Roche Applied Sciences in collaboration with ACEA Biosciences (Ke et al., 2011; Scrace et al., 
2013). This label-free assay allows the possibility for real time measurement of cellular 
responses and potentially eliminates most of the aforementioned short-comings of end-point 
assays. The xCELLigence system™ uses specially designed microtiter 16-well E-plates that 
contain interdigitated gold microelectrodes at the base of each well (Ke et al., 2011; Scrace et al., 
2013). This technique non-invasively monitors the adhesion, spreading and/or proliferation of 
adherent cells using electrical impedance as a read out in the form of cell index (CI). An electric 
field is created between the electrodes at the bottom of the wells by the application of a low 
voltage in the presence of a buffer or cell culture medium. Introduction of adherent cells into the 
medium can impede the existing current flow and this impedance is displayed as the previously 
mentioned CI algorithm which is defined as  CI = 𝑅𝑛 −
𝑅𝑏
𝑅𝑏
 where Rn is impedance of the well 
with cells and Rb is background impedance of the well with cell culture medium only (Scrace et 
al., 2013). 
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In addition to being able to assess responses of cells in their physiological state, the 
xCELLigence system™ can reveal changes in cell morphology and growth (Scrace et al., 2013). 
The assay also provides IC50 (inhibitory concentration) values that are time-dependent thus being 
more informative compared to single IC50 end-points in conventional assays. Another advantage 
of xCELLigence system™ is that it is cost-effective since it does not require additional reagents 
as in end-point methods. 
 
Technique 
Before cells were seeded, 16-well E-plates containing antibiotic-free medium were imposed to 
current flow on the xCELLigence instrument to record background readings. 1 x 105 cells were 
then seeded in each well of the E-plates simultaneously with transfection agents siRBBP6 and 
pRBBP6. The E-plates were connected back on current flow supplied by the xCELLigence 
instrument that was placed in a 37°C incubator and the experiment was allowed to run for 24 
hours before further treatment with GABA and camptothecin. The experiment was continued for 
an additional 48 hours. Cell Index values were recorded at 15 minute interval sweeps until the 
end of the experiment under the following xCELLigence parameters: [1st step: 1 sweep, 1 
minute interval, 00:00:39 total time; 2nd step: 100 sweeps, 15 minute interval, 24:45:39 total 
time; 3rd step: 100 sweeps, 15 minute interval, 49:30:39 total time].  
3.2.10. Flow Cytometry 
Flow cytometry enables measurement of optical and fluorescence characteristics of single cells 
(or any other particle, including nuclei, microorganisms, chromosome preparations, and latex 
beads) (Adan et al., 2016; Wlodkowic et al., 2009; Williams, 2004). Physical properties, such as 
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size (represented by forward angle light scatter) and internal complexity (represented by right-
angle scatter) can resolve certain cell populations. Fluorescent dyes may bind or intercalate with 
different cellular components such as DNA or RNA. Additionally, antibodies conjugated to 
fluorescent dyes can bind specific proteins on cell membranes or inside cells (Adan et al., 2016). 
When labelled cells are passed by a light source, the fluorescent molecules are excited to a 
higher energy state. Upon returning to their resting states, the fluorochromes emit light energy at 
higher wavelengths (Wlodkowic et al., 2009). The use of multiple fluorochromes, each with 
similar excitation wavelengths and different emission wavelengths (or “colors”), allows several 
cell properties to be measured simultaneously (Williams, 2004). Commonly used dyes include 
propidium iodide, phycoerythrin, and fluorescein, although many other dyes are available 
(Wlodkowic et al., 2009). The present study employed the use of flow cytometry in order to 1) 
detect and measure apoptosis, 2) to analyse cell cycle and 3) to quantify the expression of an 
intracellular protein of interest. 
 
AnnexinV FITC/PI Staining 
Principle 
Apoptosis is a physiological process which occurs normally during embryonic development as 
well as in maintenance of tissue homeostasis, and is turned off during abnormal growth of cells 
or in cancer (Liu et al., 2011; Ouyang et al., 2012; Wen et al., 2012). The apoptotic process is 
characterized by certain morphological features, including loss of plasma membrane asymmetry 
and attachment, condensation of the cytoplasm and nucleus and internucleosomal cleavage of 
DNA. Loss of plasma membrane asymmetry and attachment are the earliest features of 
apoptosis. In early apoptotic cells, the membrane phospholipid phosphatidyl serine (PS) is 
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translocated from the inner to the outer leaflet of the plasma membrane, thereby exposing PS to 
the external cellular environment.  
 
Annexin V, a 35-36 kDa Ca2+ dependent phospholipid-binding protein that has a high affinity for 
PS, binds to the exposed PS (Adan et al., 2016; Wlodkowic et al., 2009; Williams, 2004). 
Annexin V may be conjugated to fluorochromes including FITC. This format retains its high 
affinity for PS and thus acts as a sensitive probe for flow cytometric analysis of cells that are 
undergoing apoptosis. Since externalization of PS occurs in the earlier stages of apoptosis, 
AnnexinV FITC staining can identify apoptosis at an earlier stage than assays based on nuclear 
changes such as DNA fragmentation. 
 
AnnexinV FITC staining precedes the loss of membrane integrity which accompanies the latest 
stages of cell death resulting from either apoptotic or necrotic processes. Therefore staining with 
AnnexinV FITC is typically used in conjugation with vital dyes such as propidium iodide (PI) to 
allow identification of early apoptotic cells (PI negative, AnnexinV FITC positive). Viable cells 
with intact membrane exclude PI, whereas the membranes of the dead and damaged cells are 
permeable to PI (Newbold et al., 2014). Viable cells are considered AnnexinV FITC and PI 
negative, cells that are in early apoptosis are considered AnnexinV FITC positive and PI 
negative, and cells that are in late apoptosis are considered both AnnexinV FITC and PI positive. 
 
Technique 
Cultured cells were transfected with siRBBP6 and pRBBP6 construct for 48 hours and co-treated 
with camptothecin and GABA for additional 24 hours. The co-treated cells were then 
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trypsinized, transferred to 15 ml tubes, pelleted for 2 minutes at 1500 rpm and resuspended in 
100µl 1X binding buffer (annexin V-FITC Apoptosis Detection Kit, Abcam®) at a concentration 
of 1x104 cells/ml. The cell solution was then transferred into 1ml tubes and 5µl of FITC Annexin 
V and 5µl of PI were added. This was followed by gentle vortexing and incubation for 15 
minutes at room temperature in the dark. 400µl 1X binding buffer was then added to each tube 
and the cell solutions were analysed by flow cytometry within 1 hour. 
 
Cell Cycle Analysis 
Principle 
Cell cycle analysis is a well-established method that enables the identification of cell distribution 
during the various phases of the cell cycle by quantitatively measuring nuclear DNA content of a 
cell using flow cytometry (Huang et al., 2013). Four distinct phases can be recognized in a 
proliferating cell population: the G1, S- (DNA synthesis phase), G2- and M-phase (mitosis) 
(Khodjakov and Rieder, 2009; Collins et al., 1997; DiPaola, 2002). At different stages of the cell 
cycle, cell nuclei contain different amounts of DNA. For example, after receiving signals for 
proliferation, diploid cells exit the resting state Gap 0 (G0) phase and enter the Gap 1 (G1) 
phase. At this stage, the diploid cells maintain their ploidy by retaining two complete sets of 
chromosomes (2N). As the cells enter the synthesis (S) phase, DNA replication starts, and in this 
phase, cells contain varying amounts of DNA. The DNA replication continues until the DNA 
content reaches a tetraploid state (4N) with twice the DNA content of the diploid state. 
Tetraploid cells in the G2 phase start preparing for division and enter the mitosis (M) phase when 
the cells divide into two identical diploid (2N) daughter cells. The daughter cells continue on to 
another division cycle or enter the resting stage (G0 phase) (DiPaola, 2002).   
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Based on DNA content alone, the M phase is indistinguishable from the G2 phase, and G0 is 
indistinguishable from G1. Therefore, when based on DNA content, cell cycle is commonly 
described by the G0/G1, S, and G2/M phases (Khodjakov and Rieder, 2009). Damage to DNA 
often triggers the cell to interrupt the cell cycle at G0/G1 and G2/M checkpoints in order to 
prevent progression to the next phase; however during cancer development the cell machinery 
fails to arrest cells at these checkpoints thus leading to uncontrolled cell proliferation. 
Experimentally, a fluorescent dye that binds stoichiometrically to the DNA is added to a 
suspension of permeabilized single cells or nuclei (Khodjakov and Rieder, 2009). The principle 
is that the stained material has incorporated an amount of dye proportional to the amount of 
DNA (Khodjakov and Rieder, 2009). The stained material is then measured in the flow 
cytometer and the emitted fluorescent signal yields an electronic pulse with a height (amplitude) 
proportional to the total fluorescence emission from the cell. Propidium iodide (PI) was used as a 
DNA-binding fluorescent dye in this study in order to analyse the effect of RBBP6 expression 
and co-treatment with camptothecin or GABA on cell cycle in cancer cells. 
 
Technique 
Following 48 transfection with either siRBBP6 or pRBBP6 and 24-hour co-treatment with 
camptothecin or GABA, old medium was discarded and cells were washed twice with 2 ml cold 
PBS, followed by trypsinization for 2-3 minutes in order to detach cells from the 6-well plates. 
Trypsin was deactivated by the addition of 2 ml fresh DMEM followed by transfer of cells into 
1.5 ml tubes and centrifugation at 2000 rpm in order to collect the pellet, which was further 
rinsed twice with cold PBS. This was then followed by fixation and permeabilization of the cell’s 
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plasma membrane using 500 μl ice cold methanol for 1 hour at -20 °C. The cells were then 
collected by centrifugation at 2000 rpm and then rinsed twice with ice cold 1 ml PBS before 
adding 300µl of PI containing RNase (Life Technologies®) and vortexed for 30seconds followed 
by 30 minutes incubation in the dark. The cell suspension was then analysed using the Acuri C6 
flow cytometer (BD Biosciences, USA). 
 
FACS Analysis 
Principle 
The availability of fluorescent proteins now allows real-time monitoring of gene expression and 
protein localization. Many applications for these proteins require the ability to analyze and sort 
expressing cells accurately and quantitatively using a fluorescence-activated cell sorter (FACS).  
In particular we demonstrate the utilization of FACS to isolate populations of cells that express 
the GFP from those that do not express the protein of interest. 
  
Technique 
Cells were seeded in the presence of pRBBP6 for 72 hours in 6-well plates followed by 
harvesting using 1 ml trypsin for 2-3 minutes after rinsing cells twice with PBS. After the last 
wash, supernatant was discarded and pulse vortexed the sample to completely dissociate the 
pellet. Typically about 100 μL residual volume remained. Cells were then fixed by adding 100 
μL of BD Fixation Buffer then pulse vortexed again. Followed by incubation of  tubes in the 
dark at room temperature for 20-60 minutes. Without washing, 2 mL of 1X BD permeabilization 
buffer was added to each tube. Samples were then centrifuged at 300-400 rpm at room 
temperature for 5 minutes, then supernatant was discarded. The cell pellet was then resuspended 
P. Moela: PhD Thesis 
54 
 
in 2 mL of 1X permeabilization buffer then centrifuged at 300-400 rpm at room temperature for 
5 minutes. Pellet was then resuspended in 100 μL of 1X BD permeabilization buffer. Anti-GFP 
primary antibody for detection of intracellular RBBP6 antigen was added to cells and incubated 
in the dark at room temperature for 20-60 minutes. 2 mL of 1X BD permeabilization buffer was 
added to each tube followed by centrifugation of samples at 300-400xg at room temperature for 
5 minutes. Alexa Fluor-488-conjugated secondary antibody was added to cells and further 
incubated in the dark for 20-60 minutes followed by addition of 2 mL flow cytometry staining 
buffer to each tube. Samples were then centrifuged at 300-400rpm at room temperature for 5 
minutes, then supernatant was discarded. Stained cells were then resuspended in an appropriate 
volume of flow cytometry staining buffer and samples were analysed on a flow cytometer.  
3.2.11. Confocal Microscopy 
Principle 
Confocal microscopy is an imaging technique in which a beam of incoming light (the excitation 
beam) is focused through the microscope objective on a small spot inside the specimen where the 
same objective gathers the reflected or fluorescent light coming back from the same specimen 
(Que et al., 2015; Sanderson et al., 2015; Coling and Kachar, 2001). In contrast to conventional 
light microscopy, this light is projected (like a slide projector) and not directly viewed. The 
advantages of confocal microscopy over conventional one is that it captures images of high 
resolution and contrast and it does not bring about artifacts induced by conventional microscopy 
such as cell shrinkage, loss of fat, etc (Que et al., 2015; Sanderson et al., 2015; Coling and 
Kachar, 2001). Immunocytochemistry is one of the most powerful ways of asking where in an 
organism a particular protein/molecule is expressed (Ramos-Vara, 2011). It is used to 
anatomically localize the presence of a specific protein antigen in cells by use of fluorescent dyes 
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or a specific primary antibody that binds to it. In terms of immunostaining, the primary antibody 
is bound to a secondary antibody conjugated to a fluorophore in order to allow visualisation of 
the protein under a fluorescence microscope. Fluorescent dyes are usually added to cells at an 
optimum dilution followed by incubation in the dark prior to imaging (Sanderson et al., 2015). In 
this study, the Olympus BX 63 OM/FM confocal microscopy was used to visualise the 
overexpression of RBBP6 following transfection with an expression vector and to detect 
apoptosis induction using annexinV/FITC/DAPI in cell lines (Hollville and Martin, 2016).  
Technique 
Cells were grown on coverslips inserted in 6 well plates to attach overnight in the presence of 
siRBBP6 and pRBBP6 and then treated with the desired concentration of camptothecin 
(0.25μM) or GABA (100μM). The cells were then allowed for further 24 hour incubation. For 
apoptosis detection, the cells were washed with cold PBS, stained with annexin V-FITC/DAPI 
for 30 minutes in the dark followed by fixation for 30 minutes with 4% formaldehyde.  For 
protein expression analysis, fixed cells were permeabilized using 0.01% triton-X100 and then 
immunostained with anti-GFP primary antibody for one hour in the dark after blocking for non-
specific binding with 1% BSA blocking buffer. The cells were then rinsed 4X with cold PBS 
followed by incubation for another one hour with secondary antibody conjugated to alexa fluor-
488 fluorescent dye in order to enable visualization of GFP-positive cells. The cells were imaged 
at 10X magnification using Olympus BX63 confocal fluorescence microscope.  
3.2.12. Caspase 3/7 Activity 
Principle 
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Caspases are a group of cysteine protease enzymes which play an essential role in apoptosis 
(Parrish et al., 2015). Caspases were first identified in C. elegans when the CED-3 was found in 
close homology with the mammalian interleukin-1-converting enzyme and that overexpression 
of the enzyme induced apoptosis (Parrish et al., 2015; Nicholson and Thornberry, 1997). 
Caspases are divided into two types, namely the initiator caspases (caspase 1,2,8,9 and 10) and 
the effector caspases (caspases 3, 6, 7 and 14). During apoptosis, the initiator caspases cleave the 
inactive pro-forms of effector caspases, thereby activating them (Parrish et al., 2015; Preaudat, 
2002). Effector caspases in turn cleave other protein substrates within the cytoplasm and the 
nucleus thus executing apoptosis. During cancer development however, transforming cells have 
the ability to avoid apoptosis and therefore continue to proliferate (Preaudat, 2002). Anticancer 
therapeutic strategies therefor focus on restoring the apoptotic pathway and caspases are some of 
the potential targets in anticancer therapeutics (Parrish et al., 2015). Endpoint assays that detect 
activity of effector caspases allow for the confirmation of whether or not apoptosis has occurred 
and in this case apoptosis was measured by analysing the activity of effector caspases 3 and 7. 
The following protocol was adopted from Promega’s Caspase-Glo® 3/7 Assay kit which relies 
on the cleavage of luminogenic caspase-3/7 substrate by active caspases 3 and 7 present in the 
cell sample. Addition of the luminogenic caspase-3/7 substrate results in cell lysis followed by 
caspase cleavage of the substrate and generation of a glow-type luminescent signal which is 
proportional to caspase activity. 
 
Technique 
Before starting the assay, caspase-Glo® 3/7 reagent was prepared by transferring the contents of 
the caspase-Glo® 3/7 buffer bottle into the amber bottle containing caspase-Glo® 3/7 substrate 
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followed by swirling and inverting the contents until the substrate was thoroughly dissolved to 
form the reagent. The reagent was then allowed to equilibrate to room temperature for 30 
minutes. Briefly, cells (5x104 cells/well) were seeded in the presence of either siRBBP6 or 
pRBBP6 (expression vector) on a white-walled 96-well microplate and treated with 
camptothecin or GABA for 24 hours. The well plates containing cells were then removed from 
the incubator and allowed to equilibrate to room temperature followed by the addition of 100µl 
Caspase-Glo® 3/7 reagent to each well containing 100µl of blank, negative control cells or 
treated cells in culture medium. The contents of the wells were then gently mixed using a plate 
shaker at 300–500rpm for 30 seconds followed by incubation at room temperature for 1 hour. 
Luminescence was then measured using a plate-reading Glomax®-96 microplate luminometer. 
The assay was performed in triplicates and the results were presented as mean of Relative Light 
Units (RLU). 
3.2.13. Mitochondrial ATP Depletion Assay 
Principle 
Total levels of cellular ATP can be used to assess cell viability, cell proliferation and cytotoxicity 
of a wide range of compounds and biological response modifiers (Hansen et al., 2015; Gergely et 
al., 2002). While the levels of cellular ATP serve as a hallmark of cell viability, proliferation, 
cytotoxicity and cell death under standard culture conditions, they are not representative of the 
mitochondrial bioenergetic state of the cell (Tokarz and Blasiak, 2014; Lu et al., 2000; Goldin et 
al., 2007). Cultured cells can survive in the absence of an active electron transport chain by 
supplying all their ATP demands through glycolysis. However, when cells are cultured with non-
fermentable carbon substrates such as galactose, they require an active electron transport chain 
(ETC) to supply all their ATP demand. Under these conditions, damage to the mitochondrial 
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bioenergetic state of the cell will lead to depletion of cellular ATP, which can be easily measured 
by luminescence as a decrease in total levels of ATP measured. The assay is based on the 
production of light caused by the reaction of ATP with added luciferase and D-luciferin. The 
emitted light is proportional to the ATP concentration inside the cell. The reaction can be 
summarized as follows: 
ATP + D-Luciferin + O2                        Oxyluciferin + AMP + PPi + CO2 + Light 
This luminescence assay allows irreversible inactivation of ATP degrading enzymes (ATPases) 
during the lysis step, ensuring that the luminescent signal obtained truly corresponds to the 
endogenous levels of ATP. The major advantages of the luminescence assay include long 
luminescence signal since half-life of the luminescent signal is greater than 5 hours and therefore 
a special luminometer with injectors is not required; results are obtained in less than 30 minutes, 
the assay is simple to perform, i.e. there are no separation steps and there are only 2 reagent 
additions, no cell harvesting or centrifugation are required, it is highly sensitive with a wide 
linear dynamic range of approximately from 1pM to 1µM of ATP (Tokarz and Blasiak, 2014; Lu 
et al., 2000; Goldin et al., 2007). 
 
Technique 
Twenty five microlitres of 1x104 cells per well were plated in wells of white luminometer plate 
containing glucose-free, galactose enriched growth medium in the presence of transfection 
agents (siRBBP6 or pRBBP6) for 48 hours. Cells were then treated with equal amount of 
0.25μM camptothecin or 100μM GABA diluted in a glucose free media supplemented with 
10mM galactose. Before starting with the assay, the ATP detection reagent was prepared by 
Mg2+ 
Luciferase 
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thawing the ATP detection buffer in a 37°C water bath and the ATP detection substrate at room 
temperature. 10ml of ATP detection buffer was then transferred to the amber bottle containing 
the ATP detection substrate to reconstitute the lyophilized enzyme/substrate mixture in order to 
make up a 2X ATP detection reagent. The reagent was then mixed by vortexing and swirling the 
contents to obtain a homogeneous solution and equilibrated to room temperature for 5-10 
minutes prior to use. ATP detection reagent was added at a 1:1 ratio to each well at 2, 4, 6, 8, and 
18 hour intervals following a 24 hour treatment with camptothecin and GABA. The plate was 
mixed by orbital shaker (500–700rpm) for 1–5 minutes and then incubated for 30 min at room 
temperature before luminescence was measured using GLOMAX (Promega, USA). The assay 
was conducted in triplicates and ATP levels were reported as a mean of relative light units 
(RLU) normalized to percentage of control at each time point.  
3.3. Statistical analysis 
The results of each series of experiments (performed in triplicates unless otherwise stated) are 
expressed as the mean values ± standard deviation of the mean (SD). Levels of the statistical 
significance were calculated using the paired student t-test when comparing two groups. 
Statistical significance was considered according to the following p-values: ***P < 0.001, **P < 
0.01, *P < 0.05.  
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The attached email below serves as proof that the manuscript “Retinoblastoma binding protein 
6 (RBBP6): a potential biomarker for apoptosis induction in human cervical cancer cell 
lines” as detailed in the following chapter (4), has been accepted for publication and is currently 
in press. 
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CHAPTER FOUR - Retinoblastoma binding protein 6 (RBBP6): a potential 
biomarker for apoptosis induction in human cervical cancer cell lines 
4.1.  Introduction 
Cancer is an enormous burden of a disease globally (Ma and Yu, 2006). Today, more people die 
from cancer than HIV/AIDS, tuberculosis and malaria combined. Currently, cervical cancer is 
the most common, accounting for over 60% of the gynaecological cancer burden in developing 
countries (Sankaranarayanan et al., 2009). RBBP6 has been shown to be highly expressed in 
several cancers, and its ability to interact with p53 tumour suppressor has drawn attention in 
evaluating its potential as a cancer biomarker. P53 is a crucial regulatory protein that triggers 
cellular responses such as DNA repair, cell cycle arrest, senescence and apoptosis in response to 
cellular stress. In most human cancers, however, the TP53 pathway is often found to be 
defective, either by mutations or through deregulation by its negative regulators. In cervical 
cancer, p53 is found to be inactivated rather than mutated and RBBP6 is suspected to be one of 
such negative regulators of p53.  
 
Extensive research on the cause of cervical cancer has evidently singled out human 
papillomaviruses (HPVs) as the main causative agent (Fernandes, 2013; Denny, 2010; Bosch et 
al., 2002; Schiffman, 1995; Munoz et al., 1992). During the differentiation-dependant phase, the 
E6 viral protein regulates the viral replication in differentiated cells by supressing transcription 
of active p53 cellular protein thus abrogating the host cells’ ability to initiate cell cycle arrest, 
prompting uncontrolled cell proliferation (Fernandes, 2013; Bosch et al., 2002). It is suspected 
that the viral protein achieves this p53 suppression via the proteasomal pathway in which it acts 
as an E3 ligase that functions to ubiquitinate protein molecules for proteasomal degradation. This 
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mechanism is similar to the one involving RBBP6 in which it interacts with TP53 via its p53-
binding domain. Research has shown that RBBP6 plays a role as a scaffold protein to promote 
the assembly of the p53/TP53-MDM2 complex, resulting in increased MDM2-mediated 
ubiquitination and degradation of p53/TP53. Therefore, this suggests that RBBP6 may function 
as a negative regulator of p53/TP3, thus leading to both apoptosis and cell growth (Pugh et al., 
2006; Motadi et al., 2011). So in this study we propose that RBBP6 mediates TP53 inactivation 
in the same manner as HPV viral proteins since both proteins possess the activity of E3 ligases 
and have also been shown to interact with TP53. We therefore aim to manipulate the expression 
of RBBP6 in cervical cancer cell lines and co-treat with chemotherapeutic agents in order to 
sensitise apoptosis induction. 
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4.2.  Results 
This section describes results obtained from both human cervical cancer tissue specimens and 
cell lines HeLa, SiHa and MRC-5. TMA slides were immunostained with full length RBBP6 
mAb for analysis of localization and spread of the protein in cervical cancer tissues. This was 
followed by manipulation at gene level by both silencing and up-regulation. Successful 
transfections prompted further analysis of any possible effect RBBP6 might have on growth of 
the cell lines in question. Annexin V staining, mitochondrial ATP levels and activity of caspase 
3/7 were used to detect and confirm apoptosis induction following RBBP6 targeting alone or in 
combination with anticancer agents camptothecin and GABA. mRNA quantification of key 
apoptotic genes including p53 were quantified for further investigation and western blot was 
used for analysis at protein level.  
 
4.2.1. Immunohistochemical staining in human cervical cancer tissues sections 
Before altering the expression of RBBP6 in cell lines, it is important to understand its expression 
profile in cervical cancer patients. We employed the use of immunohistochemical staining of 
human cervical cancer tissue sections where haematoxylin and eosin (H&E) staining procedure 
was first used to examine histopathology of the tissue in order to understand the manifestations 
of the disease before immunostaining with monoclonal anti-mouse primary antibody raised 
against RBBP6. Haematoxylin stains the nuclear components including nucleoli and chromatin 
material whereas eosin stains the cytoplasmic components such as muscle fibres, red blood cells, 
collagen, etc. (Fischer et al., 2008). Tissue microarray (TMA) slides consisting of 20 cases of 
both squamous cell carcinoma (SCC) and adenocarcinomas were diagnosed relative to adjacent 
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normal cervix tissue in a mix of Caucasian and African American females aged between 25 and 
51.  
 
In terms of histopathology, H&E staining revealed early invasive phenotypes of cancer in some 
patients where neoplastic cells appeared to have penetrated through the basement membrane 
separating the epithelium from connective tissue, into the underlying stroma (Figure 6, panel A).  
Panel A shows non-keratinizing invasive squamous cell carcinoma which appears as infiltrating 
network of neoplastic lymphocytes and plasma cells with intervening stroma. Well-differentiated 
keratinizing SCCs are shown (Figure 6 A) as characteristic whorls of polygonal epithelial cells 
containing central nests of keratin pearls. In the less prevalent adenocarcinoma as shown in 
Figure 6 (panel G), well-differentiated columnar cells form abnormal glandular elements that 
seem to project into the endocervix.  
 
Immunostaining of RBBP6 in paraffin-embedded formalin-fixed TMAs followed by treatment 
with the chromogenic DAB (3,3'-diaminobenzidine) substrate, which enabled visualization of 
our protein of interest revealed localization mostly in the cytoplasm of early invasive squamous 
cells as shown by the brown precipitates indicated by the arrow (Figure 6, panel B). Colorization 
of the DAB product was even higher in both the cytoplasm and the nucleus of non-keratinizing 
SCC (Figure 6, panel B). However, expression was only confined to the keratinizing areas in the 
well-differentiated squamous cell carcinoma (Figure 6, panel B). Out of the 20 cases analyzed, 
only two diagnoses were categorized as adenocarcinomas and similar to SCC, they also stained 
positive for RBBP6 as shown by the intensely chromogenic columnar cells in the well-
differentiated phenotype (Figure 6, panel B).    
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Figure 6: Expression of RBBP6 protein in subtypes of cervical cancer. 
(A) Early invasive stromal squamous cell carcinoma (SCC), (C) Keratinizing well-differentiated SCC, (E) 
well-differentiated adenocarcinoma and (G) Non-keratinizing invasive squamous carcinoma (B) 
Expression of RBBP6 in the stromal region of the cancer. (D) RBBP6 expression in well-differentiated 
RBBP6 expression in non-keratinized tissue of the cervical cancer showing over expression of RBBP6 in 
the cytoplasm of the cells. The sections were taken at 40X squamous cell carcinoma with poor expression 
in most cell but higher expression around the keratin regions (k). (F) Expression of RBBP6 in squamous 
well-differentiated cancer cell 100X magnification (H). 
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4.2.2. Confirmation of gene silencing and up-regulation  
In order to continue with our analysis of the role played by RBBP6 in cervical cancer 
progression, we had to verify if our silencing and overexpression was successful.  RBBP6 
overexpression was confirmed using immunoprecipitation of GFP reporter gene. In HeLa cell 
line, transfection efficiency was significantly high (P < 0.001) with GFP expression of ~98% 
band intensity (Figure 7 A). A second distinct yet smaller band is detected in pCMV6-AC-GFP+ 
cell lysate of HeLa cells which might be indicative of one of the RBBP6 spliced variants. 
Similarly, GFP expression was significant (P < 0.05) in SiHa cell lysates, with a band intensity 
of 87% (Figure 7 B). Western blotting and qPCR were used to confirm gene silencing at both 
mRNA and protein levels. RBBP6 mRNA was successfully silenced in both HeLa and SiHa cell 
lines, with nearly 90% and 80% knockdown, respectively (Figure 7 C). Quantification at protein 
level further confirmed the observed gene knockdown (Figure 7 C).  Approximately 72.9% and 
53.4 % up-regulation was recorded in HeLa and SiHa cells, respectively, compared to non-
transfected controls where only 0.4% auto-fluorescence was observed in both cell lines 
according to FACS analysis which was further confirmed by fluorescence microscopy (Figure 8; 
Figure 9).  
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Figure 7: Confirmation of successful gene silencing and up-regulation of RBBP6-GFP tagged cDNA. 
(A) Shows successful overexpression of RBBP6 tagged with GFP in HeLa cell line, (B) shows successful 
overexpression of RBBP6-GFP tagged in SiHa cells and (C) showing successful silencing of RBBP6 in 
both HeLa and SiHa cell lines. 
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Figure 8: FACS analysis and immunocytochemistry of HeLa cells. 
Stained with 0.2 μg/ml mouse monoclonal anti-GFP antibody and labelled with Alexa Fluor-488 goat 
anti-mouse secondary antibody 48-hours post-transfection. Cells were fixed using 4% formaldehyde and 
permeabilized using 0.01% triton X-100 before immunostaining. Counterstaining was obtained using 
DAPI. Histograms represent FACS profiles of RBBP6 expression, i.e. top left: control cells that were not 
transfected and bottom left: cells transfected with the plasmid (pCMV6-AC-GFP). Fluorescence 
microscopy images (top and bottom right) show cytoplasmic/nuclear localisation of RBBP6. 
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Figure 9: FACS analysis and immunocytochemistry of SiHa cells. 
Stained with 0.2 μg/ml mouse monoclonal anti-GFP antibody and labelled with Alexa Fluor-488 goat 
anti-mouse secondary antibody 48-hours post-transfection. Cells were fixed using 4% formaldehyde and 
permeabilized using 0.01% triton X-100 before immunostaining. Counterstaining was obtained using 
DAPI. Histograms represent FACS profiles of RBBP6 expression, i.e. top left: control cells that were not 
transfected and bottom left: cells transfected with the plasmid (pCMV6-AC-GFP). Fluorescence 
microscopy images (top and bottom right) show cytoplasmic/nuclear localisation of RBBP6. 
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4.2.3. The effect of RBBP6 overexpression and silencing on cell proliferation 
The objective of this section was to monitor the effect of RBBP6 overexpression and silencing 
on cell proliferation in both the normal and the tumorigenic cell lines using xCELLigence 
system.  The xCELLigence system uses specially designed microtiter 16-well plates that contain 
interdigitated gold microelectrodes at the bottom of each well to non-invasively monitor the 
viability of cultured cells using electrical impedance as a read out in the form of cell index (CI) 
(Ke et al., 2011). The cells were monitored over a period of about 3 days in the presence of 
transfection agents, i.e. the RBBP6 expression vector (pRBBP6) and siRBBP6 oligonucleotide. 
Growth curves were normalised to the cell index (CI) at 24 hours just before the effects of either 
gene silencing or overexpression on cell proliferation was monitored.  
 
HeLa growth curve, which is presented in Figure 10, showed a significant reduction in cellular 
growth 24 hours post siRBBP6 transfection. RBBP6 (red curve) overexpression promoted 
growth of HeLa cells, as shown by the continued proliferation of cells transfected with pRBBP6 
(Figure 10). In SiHa cells, RBBP6 silencing steadily reduced growth rate to 1.0 cell index, 
whereas RBBP6 overexpressing cells maintain higher cell index throughout the remaining 32 
hours of the entire experiment (Figure 11). In siRBBP6 and siRBBP6+Camptothecin, there was 
significant reduction in HeLa and SiHa cell indices while GABA and siRBBP6+GABA could 
not reduce cell index (Figure 12). MRC-5 cell line did not show any change in cell index. In 
MRC-5, pRBBP6 significantly increased cell index or cell proliferation (Figure 13).  
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Figure 10: Cell growth of HeLa cells was analyzed using the xCELLigence system 
It relies on the generation of electrical impedance as cell growth by 16-well plates coated with a gold 
microelectron covering at the base of each well. The y-axis shows normalised cell index or cell adhesion 
over a period of about 72 hours (x-axis). The growth patterns highlighted in green show cells that are not 
treated. Those highlighted in coral show control cells populations treated with transfection reagent only 
whereas red and magenta growth curves show cells that are overexpressing RBBP6 (transfected with 
pRBBP6) and cells that were silenced, respectively. 
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Figure 11: Cell growth of SiHa cells was analyzed using the xCELLigence system 
It relies on the generation of electrical impedance as cell growth by 16-well plates coated with a gold 
microelectron covering at the base of each well. The y-axis shows normalised cell index or cell adhesion 
over a period of about 72 hours (x-axis). The growth patterns highlighted in green show cells that are not 
treated. Those highlighted in coral show control cells populations treated with transfection reagent only 
whereas red and magenta growth curves show cells that are overexpressing RBBP6 (transfected with 
pRBBP6) and cells that were silenced, respectively. 
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Figure 12: Cell growth of MRC-5 cells was analyzed using the xCELLigence system 
It relies on the generation of electrical impedance as cell growth by 16-well plates coated with a gold 
microelectron covering at the base of each well. The y-axis shows normalised cell index or cell adhesion 
over a period of about 72 hours (x-axis). The growth patterns highlighted in green show cells that are not 
treated. Those highlighted in coral show control cells populations treated with transfection reagent only 
whereas red and magenta growth curves show cells that are overexpressing RBBP6 (transfected with 
pRBBP6) and cells that were silenced, respectively. 
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Figure 13: Growth of SiHa (B), HeLa (A) and MRC-5 (C) cells analysed using xCELLigence system.  
Camptothecin and siRBBP6 treatment shows significant cell growth inhibition. 
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4.2.4. Apoptosis Detection 
Apoptosis is an energy-dependent form of programmed cell death commonly characterised by 
distinct morphological changes and condensation of the chromatin network (Liu et al., 2011; 
Ouyang et al., 2012; Wen et al., 2012). Under normal physiological conditions, a cell maintains 
an asymmetric distribution of phospholipids in the outer and inner membrane leaflets with 
phosphatidylserine (PS) facing the cytoplasmic leaflet.  During early apoptosis induction this 
membrane asymmetry is lost resulting in the exposure of PS on the outer membrane leaflet 
which enables recognition and a subsequent removal of the dying cell by phagocytes. This 
phenomenon provides platform for the novel annexin V apoptosis detection assay described by 
Andree et al. (1990) which is based on the measurement of PS exposure on the outer membrane 
leaflet using the high affinity binding of annexin V peptide to the phospholipid. AnnexinV-FITC 
staining combined with the DNA intercalating PI (propidium iodide) agent make flow cytometry 
an effective technique to distinguish between necrosis, early and late apoptosis in cultured cells. 
In this section, we measured apoptosis following transfection of HeLa, SiHa, and MRC-5 cell 
lines with siRBBP6 or pRBBP6 and co-treatment with either camptothecin or GABA using flow 
cytometry.  
 
Flow cytometry detection of apoptosis 
Analysis by flow cytometry revealed that the percentage of apoptotic cells following transfection 
with siRBBP6 was significantly increased in most cell lines, with 48% apoptosis in HeLa and 
46% in SiHa (p˂0.05) (Figure 14). Treatment with only camptothecin and GABA led to a 
significantly increased apoptosis induction in HeLa (52% and 29%, respectively) and SiHa cells 
(44% and 32%, respectively). Co-treatment of siRBBP6 and camptothecin significantly 
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increased apoptosis in HeLa and SiHa cells to 62% and 49% respectively with a change of 18% 
and 17% increments, respectively due to combination (Figure 14).  However, no increase in 
apoptosis was observed in HeLa and SiHa cells that were co-treated with siRBBP6 and GABA 
(Figure 14).  
 
 Transfection with pRBBP6 induced minimum amount of apoptosis in both cell lines, with 18% 
and 14% apoptosis in HeLa and SiHa, respectively (Figure 14). Co-treatment of pRBBP6 and 
camptothecin or GABA reduced apoptosis by 30% or 16% in HeLa cells and by 12% or 19% in 
SiHa (Figure 14). Apoptosis induction in MRC-5 fibroblast was fairly low following treatment 
with camptothecin or GABA (16% and 12%, respectively) as compared to the one observed in 
tumorigenic cell lines (Figure 15). Only 0.2% apoptosis was observed in untreated MRC-5 cells. 
Silencing MRC-5 with siRBBP6 induced 13% apoptosis whereas up-regulation of RBBP6 
induced 0.1% apoptosis (Figure 15). Combination with camptothecin led to 19% and 13% 
apoptosis induction following silencing and up-regulation, respectively (Figure 15). There was 
no significant change in apoptosis following combination of siRBBP6 and GABA (11%) or 
pRBBP6 with GABA (18%) when compared to GABA treatment only (12%) (Figure 15). No 
significant necrosis was observed in response to all treatments across all cell lines as shown in 
Figure 16, Figure 17 and Figure 18. 
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Figure 14: Statistical analysis of flow cytometry-obtained apoptosis (%) in HeLa and SiHa cell lines. 
T-test was used to generate p-values in order to compute the difference between treated and untreated 
scores. * indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** indicates p ≤ 0.001 and ns indicates p ≥ 0.05. 
 
 
Figure 15: Statistical analysis of flow cytometry-obtained apoptosis (%) in MRC-5 cell line. 
T-test was used to generate p-values in order to compute the difference between treated and untreated 
scores. * indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** indicates p ≤ 0.001 and ns indicates p ≥ 0.05. 
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Figure 16: Apoptosis of HeLa cells was analyzed using flow cytometer with annexin V and PI staining. 
Upper left quadrants show necrotic cells which stain positive for PI and negative for annexin V, upper 
right quadrants show cells undergoing late apoptosis with positive staining for both PI and annexin V. 
Lower right quadrants show cells undergoing early apoptosis and are staining positive for annexin V and 
negative for PI; and lastly the lower left quadrants show viable cells. (a) Untreated. (b)  Camptothecin, (c) 
GABA, (d) siRBBP6, (e) siRBBP6+camptothecin, (f) siRBBP6+GABA, (g) pRBBP6, (h) 
pRBBP6+camptothecin and (i) pRBBP6+GABA. 
P. Moela: PhD Thesis 
79 
 
 
Figure 17: Apoptosis of SiHa cells was analyzed using flow cytometer with annexin V and PI staining. 
(a) Untreated. (b)  Camptothecin, (c) GABA, (d) siRBBP6, (e) siRBBP6+camptothecin, (f) 
siRBBP6+GABA, (g) pRBBP6, (h) pRBBP6+camptothecin and (i) pRBBP6+GABA. 
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Figure 18: Apoptosis of MRC-5 cells was analyzed using flow cytometer with annexin V/PI staining. 
(a) Untreated. (b)  Camptothecin, (c) GABA, (d) siRBBP6, (e) siRBBP6+camptothecin, (f) 
siRBBP6+GABA, (g) pRBBP6, (h) pRBBP6+camptothecin and (i) pRBBP6+GABA. 
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Microscopic detection of apoptosis 
As mentioned in the previous section, externalization of PS, which is a marker of early apoptosis, 
as well as changes in nuclear morphology, were used to analyse the observed apoptosis. These 
events were imaged using confocal fluorescence microscopy in the presence of DAPI and 
annexin V-FITC staining to confirm the event of apoptosis in intact attached cells. In HeLa cells, 
green fluorescence signal which is indicative of apoptosis induction was observed in both 
siRBBP6 and camptothecin treatment, whereas combinational treatment further indicated 
increased apoptosis induction (Figure 19). GABA treatment alone produced a weaker 
fluorescence signal; however combination with siRBBP6 led to higher fluorescence intensity 
(Figure 19).  
 
pRBBP6, alone or in combination with camptothecin or GABA, produced weaker fluorescence 
signal compared to siRBBP6 combination (Figure 19). Changes in cell morphology were 
observed in treated cells compared to untreated cells, where nuclei appeared to remain intact and 
round in shape in untreated cell (blue stain) whereas cells undergoing apoptosis had adopted 
irregular shapes (Figure 19).  RBBP6 silencing led to a subtle apoptosis induction in SiHa cells 
as shown by the weak fluorescence signal; however combination with camptothecin led to a 
much higher PS externalization and loss in cell morphology (Figure 20). Unlike GABA 
treatment alone, combination with siRBBP6 produced a visibly strong fluorescence signal 
coupled with loss of cell shape in SiHa cells (Figure 20). Co-treatment of pRBBP6 with either 
camptothecin or GABA failed to produce any visible green fluorescence signal in SiHa cells, 
however cell shrinkage is especially observed in pRBBP6+GABA co-treatment (Figure 20).   
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Figure 19: Microscopic analysis of Annexin V stained HeLa cells. 
The Annexin V positive cells are indicated by the green dye as a representation of apoptotic cells. It is 
visible from the staining above that siRBBP6 (panel D), siRBBP6+camptothecin (panel E) and 
siRBBP6+GABA (panel F) were able to induce apoptosis in HeLa at 10X magnification. 
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Figure 20: Microscopic analysis of Annexin V stained SiHa cells. 
The Annexin V positive cells are indicated by the green dye as a representation of apoptotic cells. It is 
visible from the staining above that siRBBP6+camptothecin (panel E) and siRBBP6+GABA (panel F) 
were able to induce apoptosis in SiHa cells at 10X magnification. 
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4.2.5. Analysis of Caspase activity and mitochondrial ATP 
Flow cytometry and fluorescence microscopy confirmed that the observed reduction in cell viability 
was as a result of apoptosis. In this section, caspase activity and mitochondrial ATP measurement were 
performed to further confirm the observed apoptosis induction and to determine whether or not the 
observed apoptosis was as a result of the activation of mitochondrial pathway. Caspase 3/7 activity was 
significantly increased in both HeLa (4100 RLU) and SiHa (3800 RLU) cells transfected with siRBBP6 
in comparison to untreated cells (~400 RLU) (Figure 21). Camptothecin alone or combined with 
siRBBP6 further increases caspase activity relative to either untreated or siRBBP6 transfected in both 
HeLa and SiHa cells (Figure 21). 
 
 In HeLa cells, co-treatment of siRBBP6 and camptothecin significantly sensitizes the activity of caspase 
3/7 to 8200 RLU in comparison to siRBBP6-only (4100 RLU) or camptothecin only (5900 RLU). 
Caspase activity is sensitized from 3800 RLU in siRBBP6-only to 7200 RLU in siRBBP6+camptothecin 
in SiHa cells however no significant increase is observed between camptothecin-only and 
siRBBP6+camptothecin (Figure 21). No significant activation of caspase 3/7 was observed in pRBBP6-
only or pRBBP6 combination with either camptothecin or GABA in both HeLa and SiHa cell lines 
(Figure 21). No significant caspase activity was observed in normal fibroblasts (MRC-5) except 
in cells transfected with siRBBP6 where a statistically significant caspase activity (308 RLU) 
was induced (Figure 22). 
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Figure 21: Caspase 3/7 activity analysis of Hela and SiHa cells. 
Caspase activity was increased in siRBBP6 treated only and in co-treatment with Camptothecin.  
 
 
Figure 22: Caspase 3/7 activity analysis of MRC-5 cells. 
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Mitochondrial ATP depletion is a good indicator of outer membrane permeabilization due to 
activated pro-apoptotic proteins responsible for the activation of the intrinsic pathway. Following 
transfection with either siRBBP6 or pRBBP6 for 24 hours, mitochondrial ATP depletion was 
measured at two hours intervals post co-treatment with either camptothecin or GABA. In both 
HeLa and SiHa cell lines, six hours after treatment with siRBBP6-only or co-treated with 
siRBBP6+camptothecin ATP production decreased to below 50 RLU (Figure 23). No ATP 
depletion was observed in cells co-treated with siRBBP6+GABA in both HeLa and SiHa cells. 
HeLa and SiHa cells treated with either pRBBP6+camptothecin or pRBBP6+GABA continued 
to show increase in ATP generation throughout the entire experiment (Figure 23). No ATP 
depletion was observed in MRC-5 fibroblasts except in camptothecin and siRBBP6+GABA 
treatments where it decreased for 2 hours before continuing to increase for the remainder of the 
experiment (Figure 24). 
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Figure 23: Mitochondrial ATP analysis in HeLa and SiHa cells at different time interval in hours. 
The assay was conducted in triplicate and ATP levels were reported at two hour intervals as a mean of 
relative light units (RLU) normalized to percentage of control at each time point. 
 
Figure 24: Mitochondrial ATP analysis in MRC-5 cells at different time intervals in hours. 
The assay was conducted in triplicates and ATP levels were reported as a mean of relative light units 
(RLU) normalized to percentage of control at each time point. 
  
P. Moela: PhD Thesis 
88 
 
4.2.6. Analysis of cell cycle arrest 
The cell cycle is a set of organized and monitored events responsible for proper cell division and 
proliferation. It is divided into three sequential phases that go from quiescence (G0 phase) to 
DNA replication (S phase) and then cell division (M phase); with G0/G1 and G2/M sensor 
mechanisms serving as checkpoints that function to prevent transition to the next phase until the 
previous one is complete (Khodjakov and Rieder, 2009; Collins et al., 1997). Cell proliferation is 
an essential mechanism for cell growth and development; however disturbances in regulatory 
proteins responsible for keeping the cell cycle in check often lead to cancer development 
(Khodjakov and Rieder, 2009; Collins et al., 1997). During cancer progression cells evade the 
cell cycle checkpoints and continue to proliferate uncontrollably (Khodjakov and Rieder, 2009; 
Collins et al., 1997). In this section we analyze the induction of cell cycle arrest following 
treatment with siRBBP6+camptothecin, siRBBP6+GABA, pRBBP6+camptothecin and 
pRBBP6+GABA by measuring DNA content at G0/G1, G2/M checkpoints and the S-phase 
using flow cytometry. 
 
Camptothecin and GABA significantly induced G0/G1 cell cycle arrest in HeLa cells by 68.65% 
and 61.65%, respectively (Figure 25). Percentage of cells in the S-phase decreases in 
camptothecin (9.75%) and GABA (9.5%) relative to untreated (14.8%). G2/M arrest in untreated 
cells was at 17.9%, however following treatment with camptothecin it decreased slightly to 
13.5% while in GABA remained the same at 16.55%. RBBP6 gene silencing alone or in 
combination with either camptothecin or GABA led to a significant induction of cell cycle arrest 
at the G0/G1 checkpoint in both HeLa and SiHa cells (Figure 25). In HeLa cells, siRBBP6 
induced 67.25% G0/G1 arrest whereas pRBBP6 induced about 48.65%. In HeLa cells treated 
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with siRBBP6+camptothecin and siRBBP6+GABA, G0/G1 populations remained unchanged at 
67.9% and 59.55% respectively. The opposite was true in pRBBP6+camptothecin and 
pRBBP6+GABA were populations in G0/G1 arrest were reduced to 37.25% and 38.1% in HeLa. 
The percentage of HeLa cells undergoing DNA replication in the S-phase was slightly reduced in 
siRBBP6 at 10.85%, 8.25% in siRBBP6+camptothecin and 6.7% in siRBBP6+GABA relative to 
untreated cells which recorded 14.8% (Figure 25). The cells in the S-phase were increased from 
14.8% in untreated to 30.9% in pRBBP6, 21.25% in pRBBP6+camptothecin and 27.6% in 
pRBBP6+GABA treatments (Figure 25). For G2/M, there was no significant change in cell 
populations following treatment will all anticancer agents and transfections.  However, there was 
a slight reduction of cells in G2/M arrest from 20.15% in siRBBP6-only to 16.2% in 
siRBBP6+camptothecin and to 15.75% in siRBBP6+GABA (Figure 25). Similar trend was also 
recorded in pRBBP6 treatments where cells in G2/M arrest were reduced from 18.75% in 
pRBBP6-only to 13.15% in pRBBP6+camptothecin. However there was an increase in cell 
percentage to 22.9% in pRBBP6+GABA (Figure 25). 
 
In SiHa cell line, camptothecin and GABA induced a significant amount of populations in 
G0/G1 cell cycle arrest by 66.3% and 58.5%, respectively (Figure 25). Percentage of cells in the 
S-phase remained unchanged in camptothecin (3.55%) and slightly increased in GABA (9.45%) 
treatment relative to untreated (4.4%). Cells in G2/M arrest in camptothecin treated cells 
increased slightly from 26.45% in untreated to 30.35% and no significant change in GABA 
(27.1%). G0/G1 arrest of SiHa cells showed no significant change in siRBBP6+camptothecin at 
69% and siRBBP6+GABA at 66.8% relative to siRBBP6-only which was 70.25% (Figure 25). 
Treatment with pRBBP6, pRBBP6+camptothecin and pRBBP6+GABA induced G0/G1 arrest of 
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48.65%, 37.25% and 38.1%, respectively of SiHa cells (Figure 25). Populations in the S-phase 
remained lower at 4.4% in untreated, 3.55% in camptothecin, 9.44% in GABA, 4.55% in  
siRBBP6, 3.75% in siRBBP6+camptothecin and 7.2%  in siRBBP6+GABA, however a 
significant increase was observed in pRBBP6 at 17.4%,  16.5% in pRBBP6+camptothecin and 
14.6% in pRBBP6+GABA (Figure 25). Cells in G2/M arrest remained almost unchanged across 
all treatments, i.e. untreated (26.45%), camptothecin (30.35%), GABA (27.1%), siRBBP6 
(24.6%), siRBBP6+camptothecin (25.8%), siRBBP6+GABA (18.9%), pRBBP6 (18.75%), 
pRBBP6+camptothecin (13.15%) and pRBBP6+GABA (22.9%) (Figure 25).  
 
Figure 25: Cell cycle analysis in HeLa, SiHa cell lines. Note increase in S-phase in pRBBP6 cells. 
 
In normal lung fibroblasts (MRC5) induction of G0/G1 arrest was observed however there was 
no significant change following different treatments (Figure 26). Cells in G0/G1 arrest was 
recorded as  53.85% in untreated, 59.55% in camptothecin, 50.2% in GABA, 50.55% in 
siRBBP6, 55.35% in siRBBP6+camptothecin, 50.95% in siRBBP6+GABA, 55.5% in pRBBP6, 
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57.75% in pRBBP6+camptothecin and 57.6% in pRBBP6+GABA. Slight changes were 
observed in cell populations in the S-phase with camptothecin treatment at 19.55% in 
comparison to untreated at 13.85%. There was a decrease of cell populations, however to 10.2% 
in GABA, 10.55% in siRBBP6 and 10.95% in siRBBP6+GABA. The cells in S-phase were 
increased to 15.4% in pRBBP6, 17.75% in pRBBP6+camptothecin and 16% in 
pRBBP6+GABA. G2/M arrest populations remained around 30% across all treatments, with 
32.75% in untreated, 33.55% in camptothecin, 25.75% in GABA, 37.8% in siRBBP6, 38.75% in 
siRBBP6+camptothecin, 38.7% in siRBBP6+GABA, 38.65% in pRBBP6, 27.25% in 
pRBBP6+camptothecin and 28.1% in pRBBP6+GABA (Figure 26). 
 
 
Figure 26: Cell cycle analysis in MRC-5 cell line. 
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4.2.7. Quantification of genes involved in apoptosis 
The apoptotic phenotypes observed by microscopic detection in treated cells prompted us to 
evaluate if there were any possible changes in the gene expression at mRNA level that might be 
involved in inducing apoptosis that was observed in our study. qPCR was used to analyse mRNA 
expression levels of both pro- and anti-apoptotic genes in response to RBBP6 gene silencing and 
overexpression. Key regulatory genes that were quantified include the transcription factor TP53, 
which is involved in cell cycle and apoptosis, pro-apoptotic bax, bak1, bad, caspase-3 and 
caspase-8 and the anti-apoptotic Bcl-2. Relative gene expression  was calculated using REST 
2009 software (version 2.0.13) which computes expression ratios based on real time PCR 
efficiency and delta crossing points (∆CP) of unknown samples versus a untreated control. 
 
As expected, RBBP6 was down-regulated by a mean factor of 0.095 following silencing of HeLa 
cells with 30nM siRNA. Whereas transfection with 1μg pRBBP6 led to the up-regulation of 
RBBP6 by a mean factor of 16.000 (Figure 27). TP53 expression was significantly increased by 
a mean factor of 42.518 in response to RBBP6 silencing while the expression of pro-apoptotic 
genes was observed to be increased following silencing of RBBP6. That is, bax was up-regulated 
by a mean factor of 6.727, bad by 2.099 and caspase-3 by 7.037; however change in the 
expression of bak1 was not significant. The death receptor pathway-associated caspase-8 was 
down-regulated by a mean factor of 0.428 following RBBP6 silencing as well as the pro-survival 
Bcl-2 at 0.402. Overexpression of RBBP6 (16.000) had no significant impact on TP53 
expression including bax, bak1, bad and bcl-2. It was however interesting to notice change in the 
expression of caspases in response to RBBP6 overexpression where caspase-3 was up-regulated 
by a mean factor of 1.414 whereas caspase-8 was down-regulated by 0.250. Treatment with 
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camptothecin led to the up-regulation of bak1, bad and caspase-3 by mean factors of 3.482, 
4.691 and 6.916, respectively, whereas other genes were not significantly changed. GABA 
resulted in no significant change in the expression of RBBP6 including the apoptosis regulatory 
genes TP53, bax, bak1, bad, caspase-3, caspase-8 and bcl-2. Regulation of apoptotic genes in 
cells treated with GABA remained unchanged, with the exception being the death receptor 
associated caspase 8 (1.5-fold increase) and the effector caspase-3 (3-fold increase). 
 
Combination of siRBBP6 with camptothecin increased the overexpression of TP53 
synergistically by a mean factor of 75.061 (Figure 28). Bax expression increased from a ratio of 
6 in silencing-only to a 20-fold expression in camptothecin+siRBBP6 combination. The 
mitochondria-associated bad mRNA level was increased by a 4-fold change with a mean factor 
of 5.296; however bak1 did not change relative to its control group (Figure 27). Effector caspase-
3 mRNA increased additively by a mean factor of 14.723 in response to siRBBP6+camptothecin 
co-treatment as compared to camptothecin- or silencing-only treatments. Caspase-8, which 
remained relatively unchanged in camptothecin treatment and slightly reduced in RBBP6 
silencing, was significantly increased by a mean factor of 10.126. Unlike in silencing- and 
camptothecin-only where Bcl-2 was down-regulated, this mRNA increased by atleast 2-folds 
when the two treatments were combined. GABA treatment in the presence of RBBP6 silencing 
led to no change in bax, bak1, bad, caspase-3 and -8 and a slight decrease in Bcl-2 expression by 
a mean factor of 3. Furthermore, combination with RBBP6 overexpression led to a slight down-
regulation of TP53 and no significant changes in other genes. 
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Figure 27: Relative quantification of gene expression in HeLa cell line was performed using qPCR. 
Whisker box plots with expression ratio on the y-axis and gene type on the x-axis indicate quantification 
of mRNA isolated from cells treated with camptothecin (top left), GABA (top right), siRBBP6 (bottom 
left) and pRBBP6 (bottom right). Gene expression is depicted by the colour coded whisker bars in the 
following manner: RBBP6 (red), TP53 (blue), bax (yellow), bak1 (light green), bad (grey), caspase-3 
(dark green), caspase-8 (cyan) and Bcl-2 (light blue).  
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Figure 28: Relative quantification of gene expression in HeLa cell line was performed using qPCR. 
The cells were treated with siRBBP6+camptothecin (top left), siRBBP6+GABA (top right), 
pRBBP6+camptothecin (bottom left) and pRBBP6+GABA (bottom right).  
 
In SiHa cell line, treatment with camptothecin had no significant impact on the expression of 
RBBP6 and TP53, whereas expression of bax changed over 32-folds (Figure 29). Bak1 increased 
by a factor of 9.849 and caspase-3 by 6.916 and no significant change was observed in the 
expression of caspase-8 and Bcl-2 following treatment with camptothecin. GABA treatment had 
no effect on the expression of RBBP6, TP53, bad and Bcl-2 genes. However; the mitochondria-
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associated bax increased slightly by mean factor of 3.891 and caspase-8 by 31.233, whereas bak1 
was down-regulated by a factor of 0.015. RBBP6 silencing led to a 2-fold increase in the 
expression of TP53 coupled with bax up-regulation by a factor of about 16. Similarly, caspase-3 
expression increased by 4-folds and caspase-8 by ~13-folds following RBBP6 silencing, whereas 
bak1 expression decreased by a factor of less than 0.001. The change in the expression of bad 
and Bcl-2 was however insignificant. RBBP6 over-expressing cells led to a slight decrease in 
TP53 expression (0.63-fold change) and bax (0.125-fold change) whereas bak1 remained 
unchanged. Similarly, RBBP6 overexpression decreased bad by a mean factor of 0.500, caspase-
3 by 0.044 and caspase-8 by 0.500; however Bcl-2 was increased by a mean factor of 1.414. 
 
Combination of silencing with camptothecin led to a decrease in RBBP6 expression by a mean 
factor of 0.095 (Figure 30). TP53, bax, bad and caspase-3 were up-regulated by mean factors 
42.518, 6.727, 2.099 and 7.037; however change in bak1 expression was insignificant. Caspase-
8 and Bcl-2 were down-regulated by mean factors 0.428 and 0.402 in response to co-treatment 
with siRBBP6+camptothecin. Co-treatment with siRBBP6 and GABA decreased the expression 
of RBBP6 by a mean factor of 0.044 coupled with TP53 up-regulation by a mean factor of 
2.828 and no significant effect on the expression of bax, caspase-3 and caspase-8. (Figure 30). 
Bak1, Bad and Bcl-2 were down-regulated by 0.500, 0.250 and 0.435 mean factors, 
respectively, following co-treatment with siRBBP6+GABA. Treatment with camptothecin in 
RBBP6 overexpressing cells had no additive effect on the expression of RBBP6 (Figure 30). 
TP53 and Bax were down-regulated by mean factors 0.250 and 0.105, respectively and Bak1 
expression did not change significantly. Bad and Bcl-2 were down-regulated by mean factors 
0.049 and 0.319; caspase-3 and caspase-8 up-regulated by 2.828 and 2.828, respectively. 
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Combination of pRBBP6 with GABA increased the expression of RBBP6 by 69.071 and down-
regulated TP53 by 0.429. Bax, bak1 and Bcl-2 remained relatively unchanged whereas bad, 
caspase-3 and caspase-8 were down-regulated by 0.098, 0.250 and 0.500, respectively. 
       
 
Figure 29: Relative quantification of gene expression in SiHa cell line was performed using qPCR. 
The cells treated with camptothecin (top left), GABA (top right), siRBBP6 (bottom left) and pRBBP6 
(bottom right).  
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Figure 30: Relative quantification of gene expression in SiHa cell line was performed using qPCR. 
The cells were treated with siRBBP6+camptothecin (top left), siRBBP6+GABA (top right), 
pRBBP6+camptothecin (bottom left) and pRBBP6+GABA (bottom right).  
 
No significant changes were observed in gene expression following treatment with camptothecin 
and GABA in normal lung fibroblasts (Figure 31). RBBP6 silencing (0.518) led to an increase in 
caspase-8 expression by 1.414 and had no significant effect on the expression of other genes. 
Similarly, no significant changes were observed in the expression of all genes in response to 
RBBP6 up-regulation (2.462). siRBBP6+camptothecin reduced RBBP6 expression by a mean 
factor of 0.154, whilst siRBBP6+GABA reduced RBBP6 and bak1 by 0.330 and 0.500, 
respectively. Furthermore, siRBBP6+GABA increased gene expression of bax by 1.414 (Figure 
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32). RBBP6 was up-regulated by a mean factor of 5.856 in response to co-treatment with 
pRBBP6+camptothecin, and no significant effect was observed on the expression of other genes. 
Co-treatment with pRBBP6+GABA increased RBBP6 expression by a mean factor of 3.053 and 
bax by a mean factor of 1.809.  
 
Figure 31: Relative quantification of gene expression in MRC-5 cell line was performed using qPCR. 
The cells were treated with camptothecin (top left), GABA (top right), siRBBP6 (bottom left) and 
pRBBP6 (bottom right).  
P. Moela: PhD Thesis 
100 
 
 
Figure 32: Relative quantification of gene expression in MRC-5 cell line was performed using qPCR. 
The cells were treated with siRBBP6+camptothecin (top left), siRBBP6+GABA (top right), 
pRBBP6+camptothecin (bottom left) and pRBBP6+GABA (bottom right).  
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4.2.8. RBBP6 and TP53 protein expression: analysis of the relationship 
The relationship between RBBP6, MDM2 and TP53 in cancer development continues to be the 
focus for the betterment of cancer drug discovery (Pugh et al., 2006). Having shown at the 
mRNA level that RBBP6 silencing up-regulation was successful, it was necessary to further 
confirm the success at a protein level because in most cases mRNA is later translated by the cell 
machinery into functional protein and to analyze the effect of RBBP6 on MDM2 and TP53. In 
this study, western blotting was employed to analyze protein expression following RBBP6 
silencing and up-regulation in combination with camptothecin and GABA treatments. Briefly, 
cells were transfected for 48 hours with siRBBP6 and pRBBP6 and then treated with either 
camptothecin or GABA for a further 24 hours, followed by whole cell protein extraction and 
analysis.  
 
In HeLa cell line MDM2 expression remained unchanged across all treatments in comparison to 
untreated, and RBBP6 silencing led to the up-regulation of TP53 on its own and in combination 
with camptothecin treatment (Figure 33). No significant change was observed in TP53 expression 
between GABA-only and GABA+siRBBP6, however both treatment up-regulated the protein in 
comparison to untreated. RBBP6 over-expression was especially high in pRBBP6+camptothecin 
and pRBBP6+GABA co-treatments and TP53 expression showed to decrease in these treatments. 
In SiHa cell line, the observation suggests that RBBP6 up-regulation or silencing did not have a 
significant effect on the expression of MDM2, however silencing alone or in combination with 
GABA led to the up-regulation of TP53 especially in siRBBP6+camptothecin co-treatment as 
well as in GABA treatment. RBBP6 overexpression led to a decrease in the expression of TP53, 
on its own or in combination with both GABA and camptothecin.  
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Figure 33: Western blot analysis of HeLa cells treated with pRBBP6, GABA and Camptothecin. 
The electrophoretogram suggests down-regulation of RBBP6 results in upregulation of TP53 while 
MDM2 remains unchanged. 
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4.3. Discussion  
RBBP6 localization is widespread in a number of squamous cell carcinomas including those of 
the lung, colon and esophagus; suggesting that the protein may serve as an important diagnostic 
marker and a promising target for the treatment of cancer. In this manuscript we describe how 
overexpression and silencing of RBBP6 combined with potential anticancer agents like GABA 
and camptothecin sensitize cervical cancer cells to apoptosis. These are the first result that 
attempt to characterize the role of RBBP6 in cancer development and progression. 
  
It is generally known that the main physiological mechanism by which cancer cells can be 
successfully targeted and eradicated is by induction of apoptosis or cell cycle arrest, yet the 
precise mechanisms behind failed apoptosis induction in cancer cells is still unclear (Motadi et 
al., 2007; Bianco et al., 2005; Zhang et al., 2004). In cervical cancer, HPV is said to inactivate 
TP53 through E6 ligase resulting in cancer progression (Ajay et al., 2012). However, it remains 
unclear which other non-viral genes assist to degrade TP53. It is also known that RBBP6 has 
both TP53 and Rb binding domains together with DWNN and RING finger domains, which are 
associated with protein degradative function. In order to clarify the role of RBBP6 in cervical 
cancer, immunolabelling staining was performed on paraffin fixed tissues of which the results 
are shown above (Figure 6). Expression of RBBP6 was observed in all cancers from non-
keratinized to keratinized and from adenocarcinoma to squamous carcinoma. The result further 
showed less expression in RBBP6 in the poorly-differentiated tumours as compared to well-
differentiated tissues suggesting that RBBP6 expression is higher in proliferating cells; which 
further supports our hypothesis that it is a cell proliferating gene (Figure 6). Similar results were 
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reported in our earlier research where we observed overexpression of RBBP6 in lung cancer and 
by Chen et al. (2013) who also reported over expression of RBBP6 in colon cancer. 
 
RBBP6 manipulation was successful in both silencing and up-regulation in which we reported a 
knockdown of up to 75% while up-regulation was increased to 90% (Figure 7). This was further 
confirmed by immunocytochemistry where GFP-expressing cells which are directly proportional 
to RBBP6 overexpression were identified (Figure 8 and Figure 9). The up-regulation of RBBP6 
is the first study to ever be conducted while silencing has been done before in other laboratories 
including ours on MCF-7 breast cancer cell line (Moela et al., 2014.  Silencing RBBP6 halted 
both HeLa and SiHa cell progression as shown by xCelligence (Figure 10 and Figure 11). All 
cancer cells treated with siRBBP6 24 hour post treatment showed reduced cell index, which is an 
indicator of live cells that are attached to the surface of the plate and proliferating. However, the 
same was not true for cells that had RBBP6 up-regulation since they continued to show a steady 
increase in cell index (Figure 12). Interestingly MRC-5 treated with pRBBP6 had a significant 
increase in cell index suggesting that RBBP6 might be causing them to proliferate. The results 
suggest a role for RBBP6 in cancer progression and present a potential biomarker.   
 
We then went on to combine RBBP6 targeting with chemotherapeutic agents, camptothecin and 
GABA. GABA is a major inhibitory neurotransmitter in adult central nervous system and has 
been shown to inhibit tumour cell migration in liver cancer cells through binding to GABAB 
receptors (Chen et al., 2013; Young and Bordey, 2009; Zhang et al., 2004; Nemana et al., 2013). 
Activation of these receptors has been linked to inhibition of an enzyme called adenylate cyclase 
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which plays a role in promoting cell migration via the protein kinase A signaling cascade (Chen 
et al., 2013; Young and Bordey, 2009; Zhang et al., 2004; Nemana et al., 2013). Camptothecin is 
a plant-derived natural compound that shows high potency in inducing apoptosis by interacting 
with DNA strands breaks thus preventing the function of topoisomerase I during replication (Liu, 
2000). Treatment with camptothecin and siRBBP6+camptothecin halted cell proliferation while 
cells treated with GABA continued to proliferate in a similar manner to those treated with 
pRBBP6 and pRBBP6+GABA. These results indicate that siRBBP6 together with camptothecin 
were able to prevent cell proliferation in cancer cells but did not have any impact on MRC-5 cell 
lines. These types of results are similar to those reported earlier in which similar trends were 
observed in mouse cells (Pugh et al., 2006). GABA on the other hand does not seem to play 
much role in cell growth inhibition in cancer cells.  
 
In tumours expressing inactive TP53, inhibition of RBBP6/MDM2 has been proposed as 
biomarker for restoration of p53 activity (Basset-Seguin et al., 2008; Boatright and Salvesen, 
2003). In this study we combine silencing/up-regulation of RBBP6 together with camptothecin 
and GABA to evaluate their potential to sensitize wild-type TP53-expressing cervical cancer cell 
line to apoptosis-induced cell death. Through flow cytometry we observed increased apoptosis 
rather than necrosis in cancer cells treated with siRBBP6 and those treated with siRBBP6+ 
camptothecin (Figure 14). However, GABA alone did not induce a significant amount of cell 
death but in combination with siRBBP6 it showed a slight reduction in apoptosis perhaps playing 
antagonistic role for siRBBP6. Similar results were previously reported in MCF-7 treated with 
camptothecin and siRBBP6. 
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 pRBBP6, in combination or alone, induced minimum amount of apoptosis suggesting that it 
might be promoting cancer progression. Microscopic analysis showed disruption of nucleus and 
shrinkage of cells treated with siRBBP6, siRBBP6+camptothecin, siRBBP6+GABA and GABA 
confirming that the cell death identified in cell index and flow cytometry was as a results of 
apoptosis induction rather than necrosis (Figure 19 and Figure 20). And that the observations by 
xCELLigence assay that suggested little cell growth inhibition by GABA might be because some 
of the cells were caught in between stages especially early apoptosis. Of note is the 0.1 % 
apoptosis induction in MRC-5 cells treated with pRBBP6, which correlates with the observed 
increased cell index in xCELLigence assay thus suggesting and supporting our hypothesis that 
indeed RBBP6 promotes proliferation. The proliferation potential of RBBP6 was also shown in a 
study by Miotto et al. (2014) in which cancer progression was associated with spontaneous 
breakage of CFSs (common fragile sites); which are otherwise stabilized by un-deregulated 
RBBP6. 
 
The caspases are a family of cysteine proteases that are the main effectors of apoptosis or 
programmed cell death (PCD) and their activation leads to characteristic morphological changes 
of the cell such as shrinkage, chromatin condensation, DNA fragmentation and plasma 
membrane blebbing (Choene and Motadi, 2012). All this characteristics were identified using 
microscopy following treatment with siRBBP6, siRBBP6+camptothecin, siRBBP6+GABA and 
to a lesser extend in GABA. Further analysis of caspase activity also confirmed that caspase3/7 
was increased in siRBBP6 and siRBBP6+camptothecin treated cells. However, the same was not 
true in GABA treated or combinational treatment of GABA+siRBBP6 (Figure 21).  Up-
regulation of RBBP6 did not result in any significant increase in caspase activity. These types of 
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results were also reported in a study by Moela et al. (2014) in which camptothecin was reported 
to increase apoptosis in MCF-7 cancer cell line. In general, the overall apoptosis detection 
experiments support the idea that silencing RBBP6 in cancer cells and co-treating with 
camptothecin halt cell proliferation by redirecting them via apoptosis.  
 
A central checkpoint of apoptosis is the activation of Caspase-9 by mitochondrial cytochrome c. 
The pro-survival proteins appear to protect mitochondria, since Bcl-2 prevents the release of 
cytochrome c (Hansen et al., 2015) Mitochondria are also a place for ATP synthesis that is also 
required for induction of apoptosis (Elmore, 2007). Decrease in mitochondrial ATP activity 
might mean that more and more ATP is utilized by cells to induce apoptosis.  These are some of 
the results we observed in siRBBP6 and siRBBP6+camptothecin treated cells after 6 hours of 
treatment where ATP was reduced. This results correlate with all other results that we reported in 
this study that have shown siRBBP6 and siRBBP6+camptothecin being responsible for cell 
death by apoptosis (Figure 23). pRBBP6 alone or in combination with GABA did not show any 
positive impact on cancer cell line except to keep cells proliferating.  All these hallmarks of 
apoptosis were supported by an increase in bax, caspase-3 and caspase-8 gene expression in all 
cancer cells treated with siRBBP6 and siRBBP6+camptothecin whereas the Bcl-2 anti-apoptotic 
gene remained unchanged thus resulting in an increased bax/bcl2 ratio. However, mitochondrial 
activity assay suggested that the apoptotic pathway induced was not entirely dependent on 
mitochondria since bak1 remained unchanged. Bax oligomerises with itself or with bak1 during 
apoptosis activation via mitochondria and allows it to release cytochrome c (Wan et al., 2006). 
On the other hand TP53 was also increased in all siRBBP6 treatments suggesting that it might 
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have played a role in translocating bax to the outer mitochondrial membrane in order to initiate 
intrinsic apoptosis.  
 
Cell cycle control is a fundamental cellular process that governs cellular proliferation. The 
protein product of CDKN1A, p21, is an important regulatory protein within the cell cycle which 
is activated by TP53, and when cells over-express p21, the cell cycle is arrested in the G1 and G2 
phases (Wan et al., 2006). In this study we have looked at the cell cycle induction following all 
treatment and what we observed is that siRBBP6 alone was able to induce cell cycle arrest at 
G0/G1 while in combination with GABA, percentage cell cycle arrest was slightly reduced 
(Figure 25). In camptothecin-only treatment and siRBBP6+camptothecin combination, most 
HeLa cells were arrested at G0/G1, which suggested that the cells did not progress through to the 
cell cycle process but rather redirected to apoptosis. In contrast, SiHa cell populations 
accumulated in the G2/M phase, which suggested that some of the cells might have escaped 
apoptosis following treatment and were instead directed to undergo what looks like mitotic 
apoptosis.  GABA and camptothecin alone did induce cell cycle arrest in all cell lines except in 
MRC-5 but at a lower percentage. pRBBP6 showed an increase in S-phase which further 
suggested that DNA replication was increased and cells were allowed to proliferate. These 
results suggest that cell cycle arrest was not the preferred mechanism of anti-proliferation in this 
experiment but rather apoptosis. And further suggest that GABA, either alone or in combination 
with siRBBP6, has little or no impact on cancer progression whereas camptothecin and siRBBP6 
play a critical role in halting proliferation of cervical cancer cell lines (Figure 26). 
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4.4. Summary 
Taken all together, we discovered that RBBP6 is markedly up-regulated in squamous cervical 
carcinomas, including the less prevalent adenocarcinomas. And further investigations revealed 
that not only does it play a role in promoting cell proliferation, it is also associated with 
apoptosis. The fact that RBBP6-knockdown cells become sensitized to apoptosis induced by 
camptothecin coupled with cell cycle arrest implicates the gene as a potential target in cervical 
cancer management. The additive effect observed between siRBBP6 and camptothecin could be 
attributed to the mechanism of action of each.  That is, it is well known that camptothecin 
damages and prevents DNA replication thus resulting in failed cell division whereas RBBP6 is 
said to work alongside telomerase in promoting cell division and cell proliferation. Based on this, 
combination of siRBBP6 and camptothecin seems to be effective in preventing cell proliferation 
and inducing apoptosis in HeLa and SiHa cell lines.  
 
Accumulation of TP53 following RBBP6 silencing provides early insights into the possible 
interaction between RBBP6 and TP53 and whether or not RBBP6 plays a role in TP53 
degradation and therefore this area of study leaves room for further investigations. The inability 
of GABA to show effectiveness in inducing apoptosis either on its own or in combination with 
RBBP6 targeting could be attributed to the fact that its mechanism of action focuses more on cell 
migration rather than apoptosis induction. Future investigations on the effects of GABA on cell 
migration and chemotaxis in cervical cancer would therefore be interesting.   
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The attached email below serves as proof that the manuscript “The differential RBBP6 
(retinoblastoma binding protein 6) expression predicts TP53-induced apoptosis in human 
breast cancer cell lines” as detailed in the following chapter (5), has been submitted for 
publication and is currently under review. 
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CHAPTER FIVE - The differential RBBP6 (retinoblastoma binding protein 
6) expression predicts TP53-induced apoptosis in human breast cancer cell 
lines  
5.1.  Introduction 
Breast cancer remains a female-related health problem on a global scale, accounting for over a 
million newly estimated cases that are still on the rise (Tao et al., 2015). Uncontrolled cell 
growth and metastasis are considered hallmarks of not only breast tumorigenesis but most other 
cancers as well. These malignant transformations are due to mutations and/or inactivation of 
genes involved in the regulation of cell cycle and apoptosis (Buchegger et al., 2016; Tao et al., 
2015). For example, TP53 is the most important tumour suppressor gene which has been found 
to be mutated in over 50% of most human cancer types (Bai and Zhu, 2006). In breast cancer, the 
frequency of TP53 mutations varies greatly between the heterogeneous subtypes, with basal-like 
breast cancers having the highest frequency whereas the luminal subtypes have been shown to 
generally express wt. p53 (Haupt et al., 2016).  
 
Wild-type p53 is negatively regulated by MDM2, which inhibits its transcriptional activity and 
facilitates its nuclear transport thus triggering degradation via the ubiquitin proteasome pathway 
(UPP). Research has been done in which the TP53-MDM2 interaction has been successfully 
disrupted (Haupt et al., 2016). Another extensively studied ubiquitous protein that has been 
shown to negatively regulate wt. TP53 is called E6 oncoprotein in cervical cancers since it 
possesses an E3 ligase activity, an important function that’s needed during UPP (Yuan et al., 
2016). RBBP6 is yet another suspected de-regulator of wt. p53 due to its E3 ligase activity as 
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well as the presence of both p53 and RING finger-like domains (Pugh et al., 2006). However, 
more research still need to be done in order to identify RBBP6 as a negative regulator of wt. p53.  
 
RBBP6 is a large multi-domain protein whose localization is widespread in a number of 
squamous cell carcinomas including those of the lung, colon, breast and oesophagus, which 
suggests its involvement in tumorigenesis (Li et al., 2007; Motadi et al., 2011; Chen et al., 2013; 
Moela et al., 2014). We have previously shown that silencing RBBP6 in breast cancer cell line 
expressing wt. p53 leads to accumulation of the TP53 gene followed by apoptosis induction 
(Moela et al., 2014). Furthermore, we have shown that camptothecin-induced apoptosis becomes 
sensitized in a RBBP6-deficient status (Moela et al., 2014). These observations prompted us to 
further analyse the effects of RBBP6 silencing in a breast cancer cell line model that does not 
express wt. p53 as this will enable us to identify whether or not there is a relationship between 
RBBP6 and TP53 expression in breast cancer.  
 
The aim of this chapter was therefore to overexpress and silence RBBP6 gene expression in the 
mutant p53-expressing MDA-MB-231 breast cancer cell line and analyse its effects on cell 
proliferation, cell cycle and apoptosis. Furthermore, the effect of camptothecin and GABA 
anticancer agents in combination with RBBP6 targeting was investigated.  
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5.2.  Results 
To achieve our aim, RBBP6 was silenced and overexpressed in MDA-MB-231 cells as well as in 
the wt. p53-expressing MCF-7 cell line for comparative purposes. Fluorescence microscopy, 
FACS analysis, immunoprecipitation/western blotting and qPCR were used to measure 
transfection efficiency of the RBBP6-containing expression vector or the siRBBP6 
oligonucleotide. Furthermore, apoptosis-based assays were performed to check the effect of 
silencing, overexpression and co-treatment with GABA or camptothecin on breast cancer cell 
lines. The assays included Annexin V/PI staining, caspase activity and mitochondrial ATP. To 
monitor cell proliferation and the cell cycle, xCELLigence assay and PI staining were performed 
respectively.  
5.2.1. RBBP6 transfection efficiency 
RBBP6 expression was manipulated in different cell lines (MDA-MB-231, MCF-7 and MRC-5) 
by either overexpression with pCMV6-AC-GFP or by gene silencing. RBBP6-containing 
expression vector (pCMV6-AC-GFP) was used for overexpression and synthetic siRNA 
oligonucleotides specific for RBBP6 were used in gene silencing. During transient transfection, 
the introduced nucleic acid exists in the cell only for a limited period of time (~4 days) because it 
is not integrated into the genome. Therefore, cell lines were transiently transfected for a period of 
48-72 hours before determining transfection efficiency. 
 
RBBP6 overexpression  
The pCMV6-AC-GFP expression vector was used to deliver the open reading frame of RBBP6 
transcript variant 3 (NM_032626.5) into the cells and green fluorescent protein (GFP) tagged on 
the C-terminus of the vector was used to permit positive identification of cells transfected with 
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the plasmid. RBBP6 protein was significantly overexpressed 72 hours after transfection in all 
cell lines (Figure 34, Figure 35 and Figure 36). The expression of RBBP6 was directly 
proportional to significant overexpression of GFP in pCMV6-AC-GFP+ cell lysate in comparison 
to the pCMV6-AC-GFP- lysate which shows 0% GFP expression in almost all cell lines (Figure 
34, Figure 35 and Figure 36). GFP expression was significant (P < 0.05) in MCF-7 and MDA-
MB-231 cell lysates, with band intensities of 92 and 90%, respectively (Figure 34 and Figure 
35). In contrast, MRC-5 cell line showed only 21% overexpression of RBBP6 according to the 
densitometry quantification of band intensity in pCMV6-AC-GFP+ lysate (Figure 36).  
 
FACS analysis indicated RBBP6 up-regulation in MCF-7 and MDA-MB-231 cell lines with 
varying fluorescence signal of 88.9% and 47.1% respectively (Figure 37 and Figure 38). The 
observed positive staining was further confirmed by the strong GFP fluorescence signal which 
shows cytoplasmic localization of RBBP6 in both tumorigenic cell lines (Figure 37 and Figure 
38). MRC-5 cells on the other hand showed a FACS profile of only 14.9% overexpression in 
pCMV6-AC-GFP+ cells (Figure 39) which is significantly low compared to the observed 
overexpression in the tumorigenic cell lines. More so, the normal cell line shows more 
cytoplasmic localisation of RBBP6 in contrast to the MDA-MB-231 tumorigenic cell line, which 
showed stronger signal in both nuclear and cytoplasmic RBBP6 localization (Figure 39). No 
visible GFP fluorescence was observed in pCMV6-AC-GFP- controls across all cell lines. 
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Figure 34: Overexpression of RBBP6 by transient transfection of MCF-7 cells with RBBP6-containing  
expression vector (pCMV6-AC-GFP). Left: IP-WB (immunoprecipitation-western blotting) 
electrophoretogram showing detection of RBBP6 expression which is directly proportional GFP. 
Expression was detected using anti-GFP monoclonal primary antibody and β-actin was chosen as the 
house-keeping gene. pCMV6-AC-GFP (-) indicates non-transfected cell lysates and pCMV6-AC-GFP (+) 
shows GFP expression in cell lysates transfected with the expression vector. Right: Corresponding 
densitometry quantification of band intensity acquired using the ChemiDoc MP software. 
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Figure 35: Overexpression of RBBP6 by transient transfection of MDA-MB-231 cells with RBBP6- 
containing expression vector (pCMV6-AC-GFP). Left: IP-WB electrophoretogram showing detection of 
RBBP6 expression which is directly proportional GFP. Expression was detected using anti-GFP 
monoclonal primary antibody and β-actin was chosen as the house-keeping gene. pCMV6-AC-GFP (-) 
indicates non-transfected cell lysates and pCMV6-AC-GFP (+) shows GFP expression in cell lysates 
transfected with the expression vector. Right: Corresponding densitometry quantification of band intensity 
acquired using the ChemiDoc MP software. 
231 
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Figure 36: Overexpression of RBBP6 by transient transfection of MRC-5 cells with RBBP6-containing 
expression vector (pCMV6-AC-GFP). Left: IP-WB electrophoretogram showing detection of RBBP6 
expression which is directly proportional GFP. Expression was detected using anti-GFP monoclonal 
primary antibody and β-actin was chosen as the house-keeping gene. pCMV6-AC-GFP (-) indicates non-
transfected cell lysates and pCMV6-AC-GFP (+) shows GFP expression in cell lysates transfected with 
the expression vector. Right: Corresponding densitometry quantification of band intensity acquired using 
the ChemiDoc MP software. 
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Figure 37: FACS analysis and immunocytochemistry of MCF-7 cells stained with 0.2 μg/ml mouse 
monoclonal anti-GFP antibody and labelled with Alexa Fluor-488 goat anti-mouse secondary antibody 
48-hours post-transfection. Cells were fixed using 4% formaldehyde and permeabilized using 0.01% 
triton X-100 before immunostaining. Counterstaining was obtained using DAPI. Histograms represent 
FACS profiles of RBBP6 expression, i.e. top left: control cells that were not transfected and bottom left: 
cells transfected with the plasmid (pCMV6-AC-GFP). Fluorescence microscopy images (top and bottom 
right) show cytoplasmic/nuclear localisation of RBBP6. 
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Figure 38: FACS analysis and immunocytochemistry of MDA-MB-231 cells stained with 0.2 μg/ml 
monoclonal anti-GFP antibody and labelled with Alexa Fluor-488 goat anti-mouse secondary antibody 
48-hours post-transfection. Cells were fixed using 4% formaldehyde and permeabilized using 0.01% 
triton X-100 before immunostaining. Counterstaining was obtained using DAPI. Histograms represent 
FACS profiles of RBBP6 expression, i.e. top left: control cells that were not transfected and bottom left: 
cells transfected with the plasmid (pCMV6-AC-GFP). Fluorescence microscopy images (top and bottom 
right) show cytoplasmic/nuclear localisation of RBBP6. 
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Figure 39: FACS analysis and immunocytochemistry of MRC-5 cells stained with 0.2 μg/ml mouse 
monoclonal anti-GFP antibody and labelled with Alexa Fluor-488 goat anti-mouse secondary antibody 
48-hours post-transfection. Cells were fixed using 4% formaldehyde and permeabilized using 0.01% 
triton X-100 before immunostaining. Counterstaining was obtained using DAPI. Histograms represent 
FACS profiles of RBBP6 expression, i.e. top left: control cells that were not transfected and bottom left: 
cells transfected with the plasmid (pCMV6-AC-GFP). Fluorescence microscopy images (top and bottom 
right) show cytoplasmic/nuclear localisation of RBBP6 
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RBBP6 silencing  
Gene silencing by RNAi leads to a highly potent repression of gene expression mainly because it 
employs cellular machinery that effectively allows targeting of specific mRNA transcripts. In 
this study the RNAi technique was employed to down-regulate RBBP6 in breast cancer cells 
(MCF-7 and MDA-MB-231) as well as normal lung fibroblast (MRC-5).  To check whether or 
not gene silencing was successful, qPCR which relies on reverse transcription of total RNA to 
synthesize complimentary DNA that serves as a template during real time PCR amplification of 
the genes of interest was used (Figure 40A). This was further confirmed by detection of RBBP6 
protein expression using western blot analysis (Figure 40B). A statistically significant down-
regulation of RBBP6 mRNA was achieved 48 hours post-transfection across all cell lines, with 
nearly 80% gene silencing in both MCF-7 and MDA-MB-231. Detection of RBBP6 at a protein 
level 72 hours post-transfection confirmed the observed gene knockdown. RBBP6 expression 
was down 70-90 % in cancer cell line (Figure 40A).  In MRC-5 cell line RBBP6 expression was 
lowest as confirmed by the faint bands on the blot (Figure 40A), showing down-regulation of 
nearly 92% in RBBP6 mRNA expression (Figure 40B).  
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Figure 40: Transfection efficiency of RBBP6 gene silencing using siRNA technology in MCF-7,  
MDA-MB-231 and MRC-5 cell lines. A) Western blot detection of RBBP6 expression following 72 hour 
transfection. B) Relative quantification of gene expression was performed 48 hours post-transfection 
using qPCR. No siRNA: indicates negative control cells that were not transfected; siRBBP6: indicates 
cells transfected with oligonucleotides specific for RBBP6 and β-actin was used as a reference gene. 
 
5.2.2. The effect of RBBP6 overexpression and silencing on cell proliferation 
In order to analyse the effect of RBBP6 targeting on cell growth, the real time cell analysis 
(RTCA) assay was used. This voltage-based instrument depends on spreading and adhesion of 
cells to electron charged bottom of each well of a 16-well E-plate which produce electrical 
impedance (Ke et al., 2011). The disturbance in current flow as a result of cell adhesion is 
represented by the logarithm CI which is directly proportional to cell proliferation. Cells were 
seeded simultaneously with transfection agents, siRBBP6 and pRBBP6, in 16-well E-plates and 
growth was monitored for a period of 72 hours using the RTCA machine. 
 
A B 
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Growth of MCF-7, MDA-MB-231 and MRC-5 cell lines was normalized at approximately 24 
hours just before the effects of either gene silencing or overexpression on cell proliferation was 
observed (Figure 41, Figure 42 and Figure 43). In MCF-7 breast cancer cells, a rapid decrease in 
cell proliferation was evident (magenta) 24 hours later into silencing, whilst RBBP6-
overexpressing cells (red) maintain the highest cell index throughout the last ~30 hours of the 
experiment (Figure 41). In contrast, the p53-mutated breast cancer cell line, MDA-MB-231; 
shows no significant difference in growth rate when compared to untransfected or negative 
control cells despite the induced RBBP6 overexpression (Figure 42). More so, RBBP6 silencing 
appears to have minor effect on proliferation of MDA-MB-231 cells since the cell index 
continues to increase although at a slower rate (magenta). In MRC5 there was no significant 
effect on cell proliferation/growth following transfection in both overexpression and silencing 
(Figure 43).  
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Figure 41: Cell growth of MCF-7 cells analyzed using the xCELLigence system 
which relies on the generation of electrical impedance as cell growth by 16-well plates coated with a gold 
microelectron covering at the base of each well. The y-axis shows normalised cell index or cell adhesion 
over a period of about 72 hours (x-axis). The growth patterns highlighted in green show cells that are not 
treated. Those highlighted in coral show control cell populations treated with transfection reagent only 
whereas red and magenta growth curves show cells that are overexpressing RBBP6 (transfected with 
pRBBP6) and cells that were silenced, respectively. 
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Figure 42: Cell growth of MDA-MB-231 cells analyzed using the xCELLigence system 
which relies on the generation of electrical impedance as cell growth by 16-well plates coated with a gold 
microelectron covering at the base of each well. The y-axis shows normalised cell index or cell adhesion 
over a period of about 72 hours (x-axis). The growth patterns highlighted in green show cells that are not 
treated. Those highlighted in coral show control cell populations treated with transfection reagent only 
whereas red and magenta growth curves show cells that are overexpressing RBBP6 (transfected with 
pRBBP6) and cells that were silenced, respectively. 
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Figure 43: Cell growth of MRC-5 cells was analyzed using the xCELLigence system 
which relies on the generation of electrical impedance as cell growth by 16-well plates coated 
with a gold microelectron covering at the base of each well. The y-axis shows normalised cell 
index or cell adhesion over a period of about 72 hours (x-axis). The growth patterns highlighted 
in green show cells that are not treated. Those highlighted in coral show control cell populations 
treated with transfection reagent only whereas red and magenta growth curves show cells that are 
overexpressing RBBP6 (transfected with pRBBP6) and cells that were silenced, respectively. 
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5.2.3. Apoptosis Detection 
Among other characteristics of apoptosis such as cell shrinkage, membrane blebbing, loss of 
adhesion with neighbouring cells, nuclear condensation and fragmentation, externalisation of 
phosphatidyl serine (PS) peptide outside the plasma membrane plays a central role in identifying 
apoptotic cells (Liu et al., 2011; Ouyang et al., 2012; Wen et al., 2012). This is because PS 
externalisation allows dying cell to be recognised by phagocytes for a subsequent removal. 
Synthetic peptides with high affinity for PS have therefore been developed in order to enable 
identification of apoptotic cells, and annexin V is the commonly used peptide in apoptosis assays 
(Andree et al., 1990). In flow cytometry and fluorescence microscopy detection of apoptosis, the 
peptide is usually tagged with a fluorescent dye, FITC, in order to enable positive identification 
of dying cells. And since PS externalisation enables detection of early apoptosis, it is usually 
combined with DNA binding dyes in order to allow for late apoptosis detection. Propidium 
iodide (PI) and DAPI (4',6-diamidino-2-phenylindole) are the commonly used DNA intercalating 
dyes during apoptosis assays. The present study made the use of annexin V/FITC, PI and DAPI 
fluorescent dyes in order to detect both early and late apoptosis using flow cytometer and 
fluorescence microscope, following transfections and co-treatments.  
 
 Flow cytometry detection of apoptosis 
Apoptosis was significantly increased following transfection with siRBBP6 in both tumorigenic 
cell lines, with 57% apoptosis in MCF-7, whereas in MDA-MB-231 cells, there was just 9% of 
cells undergoing apoptosis (p˂0.05) (Figure 44). RBBP6 silencing significantly induced 
apoptosis in camptothecin-treated cells to 75% in MCF7 and 46.6 % in MDA-MB-231, as 
compared to that of GABA where there was no change in apoptosis induction in MCF7 and 
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MDA-MB-231 (Figure 44). Transfection with pRBBP6 induced minimum amount of apoptosis 
across both cell lines, with 12% and 17% apoptosis in MCF-7 and MDA-MB-231, respectively. 
Significant reduction in apoptosis following co-treatment with pRBBP6+camptothecin and 
pRBBP6+GABA was observed in MCF-7 (15% and 13%, respectively) and MDA-MB-231 
(27% and 15%, respectively) (Figure 44). 
 
Apoptosis induction in MRC-5 fibroblast was fairly low following treatment with camptothecin 
or GABA (16% and 12%, respectively) as compared to the one observed in tumorigenic cell 
lines (Figure 45). Only 0.2% apoptosis was observed in untreated MRC-5 cells. Silencing MRC-
5 with siRBBP6 induced 13% apoptosis whereas up-regulation of RBBP6 induced 0.1% 
apoptosis (Figure 45). Combination with camptothecin led to 19% and 13% apoptosis induction 
following silencing and up-regulation, respectively (Figure 45). There was no significant change 
in apoptosis following combination of siRBBP6 and GABA (11%) or pRBBP6 with GABA 
(18%) when compared to GABA treatment only (12%) (Figure 45). Figure 46, Figure 47 and 
Figure 48 illustrate early (upper right quadrant) and late apoptosis (lower right quadrant) 
induction as well as the level of necrosis (upper left quadrant) in comparison to live cells (lower 
left quadrant) in all cell lines.  
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Figure 44: Statistical analysis of flow cytometry-obtained apoptosis (%) in MCF-7 and  
MDA-MB-231. T-test was used to generate p-values in order to compute the difference between treated 
and untreated scores. * indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** indicates p ≤ 0.001 and ns indicates 
p ≥ 0.05. 
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Figure 45: Statistical analysis of flow cytometry-obtained apoptosis (%) in MRC-5 cell line. 
T-test was used to generate p-values in order to compute the difference between treated and untreated 
scores. * indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** indicates p ≤ 0.001 and ns indicates p ≥ 0.05. 
 
. 
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Figure 46: Apoptosis of MCF-7 cells was analyzed using flow cytometer with annexin V/PI staining. 
(a) Untreated. (b)  Camptothecin, (c) GABA, (d) siRBBP6, (e) siRBBP6+camptothecin, (f) 
siRBBP6+GABA, (g) pRBBP6, (h) pRBBP6+camptothecin and (i) pRBBP6+GABA. 
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Figure 47: Apoptosis of MDA-MB-231 cells was analyzed using flow cytometer with annexin V/PI 
(a) Untreated. (b)  Camptothecin, (c) GABA, (d) siRBBP6, (e) siRBBP6+camptothecin, (f) 
siRBBP6+GABA, (g) pRBBP6, (h) pRBBP6+camptothecin and (i) pRBBP6+GABA.  
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Figure 48: Apoptosis of MRC-5 cells was analyzed using flow cytometer with annexin V/PI staining. 
(a) Untreated. (b)  Camptothecin, (c) GABA, (d) siRBBP6, (e) siRBBP6+camptothecin, (f) 
siRBBP6+GABA, (g) pRBBP6, (h) pRBBP6+camptothecin and (i) pRBBP6+GABA. 
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 Microscopic detection of apoptosis 
As mentioned in the previous section, externalization of phosphatidylserine peptide (PS), which 
is a marker of early apoptosis, as well as changes in nuclear morphology, was used to analyse the 
observed apoptosis. These events were imaged using confocal fluorescence microscope in the 
presence of DAPI and annexin V-FITC staining to confirm the event of apoptosis in intact 
attached cells. In MCF-7 cells, green fluorescence signal which is indicative of apoptosis 
induction was observed in both siRBBP6 and camptothecin treatment, whereas combinational 
treatment further indicated increased apoptosis induction (Figure 49). GABA treatment alone 
produced a weaker fluorescence signal; however combination with siRBBP6 led to higher 
fluorescence intensity (Figure 49). pRBBP6, alone or in combination with camptothecin or 
GABA, produced weaker fluorescence signal compared to siRBBP6 combination (Figure 49).  
 
Changes in cell morphology were observed in treated cells compared to untreated cells, where 
nuclei appeared to remain intact and round in shape in untreated cell (blue stain) whereas cells 
undergoing apoptosis had adopted irregular shapes (Figure 49).  RBBP6 silencing led to a subtle 
apoptosis induction in MDA-MB-231 cells as shown by the weak fluorescence signal; however 
combination with camptothecin led to a much higher PS externalization and loss in cell 
morphology (Figure 50). Similarly to GABA treatment alone, combination with siRBBP6 
produced a weak fluorescence signal coupled with loss of cell shape in MDA-MB-231 cells 
(Figure 50). Co-treatment of pRBBP6 with either camptothecin or GABA failed to produce any 
visible green fluorescence signal in MDA-MB-231, however cell shrinkage is especially 
observed in pRBBP6+GABA co-treatment (Figure 50).   
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Figure 49: Microscopic analysis of Annexin V stained in MCF-7 cells. 
The Annexin V positive cells are indicated by the green dye as a representation of apoptotic cells. 
Apoptosis induction was high in siRBBP6+camptothecin (panel E) and siRBBP6+GABA (panel F). 
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Figure 50: Microscopic analysis of Annexin V stained MDA-MB-231 cells. 
The Annexin V positive cells are indicated by the green dye as a representation of apoptotic cells. The 
staining above shows visible apoptosis in camptothecin (panel B) and siRBBP6+camptothecin (panel E) 
at 10X magnification. 
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5.2.4. Analysis of caspase activity and mitochondrial ATP 
Effector caspases 3 and 7 play an important role in executing apoptosis, and therefore their activation 
indicates a point of no return in apoptosis induction. Activation of these caspases depends on the release 
of cytochrome c from the outer mitochondrial membrane (OMM) following permeabilization by bcl-2 
family pro-apoptotic proteins (Wen et al., 2012; Ouyang et al., 2012). In the cytosol, cytochrome c binds 
to apoptosis peptidase activating factor 1 (Apaf-1) and active caspase 9 in order to form an apoptosome 
complex which is responsible for the activation of the effector caspases (Wen et al., 2012; Ouyang et al., 
2012). Active caspase 3 and 7 therefore trigger apoptosis by cleaving DNA in the nucleus. On the other 
hand, permeabilization of OMM leads to a decrease in mitochondrial transmembrane potential 
(ΔΨm) which subsequently leads to ATP depletion (Gergely et al., 2002). Decreasing mitochondrial 
ATP is therefore another indicator of apoptosis induction which is why it was important for the present 
study to monitor ATP levels in response to treatment.    
 
Caspase 3/7 activity was not significantly changed following transfection with either siRBBP6 or 
pRBBP6 in comparison to untreated cells in both MCF-7 and MDA-MB-231 cells (Figure 51). 
However camptothecin treatment increased caspase activity to 6000 RLU and 4000 RLU in 
MCF-7 and MDA-MB-231 cell lines, respectively. Co-treatment with siRBBP6 and 
camptothecin failed to sensitize caspase activity as well in MCF-7 cells (3800 RLU); however a 
significant increase was observed in MDA-MB-231 cells (4100 RLU) (Figure 51). pRBBP6, 
alone or in combination with either camptothecin or GABA led to a non-significant increase in 
caspase 3/7 activity in both MCF-7 and MDA-MB-231 cells (Figure 51). No significant caspase 
activity was observed in normal fibroblasts (MRC-5) except in cells transfected with siRBBP6 
where a statistically significant caspase activity (308 RLU) was induced (Figure 52). 
 
P. Moela: PhD Thesis 
138 
 
 
Figure 51: Caspase 3/7 activity analysis of MCF-7 and MDA-MB-231 cells. 
Caspase activity was increased in co-treatment with Camptothecin and siRBBP6 in MDA-MB-231.  
 
 
Figure 52: Caspase 3/7 activity analysis of MRC-5 cells. 
Mitochondrial ATP depletion is a good indicator of outer membrane permeabilization due to 
activated pro-apoptotic proteins responsible for the activation of the intrinsic pathway. Following 
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transfection with either siRBBP6 or pRBBP6 for 24 hours, mitochondrial ATP depletion was 
measured at two hours intervals post co-treatment with either camptothecin or GABA. In MCF-7 
cells treated with siRBBP6, camptothecin and siRBBP6+camptothecin, ATP depletion continued 
steadily for 8 hours at the value of between 30 RLU before recovering back to 110 RLU 24 hours 
later (Figure 53). ATP continued to decrease throughout the entire experiment in MDA-MB-231 
cell transfected with siRBBP6 whereas it remains constant below 50 RLU in 
siRBBP6+camptothecin treatment (Figure 53). pRBBP6, alone or in combination with 
camptothecin or GABA led to an increase in ATP production in both MCF-7 and MDA-MB-231 
cells. However, in MDA-MB-231 cells, ATP level drops back to ~150 RLU where it remained 
constant throughout the experiment. No ATP depletion was observed in MRC-5 fibroblasts 
except in camptothecin and siRBBP6+GABA treatments where it decreased for 2 hours before 
continuing to increase for the remainder of the experiment (Figure 54).  
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Figure 53: Mitochondrial ATP analysis in MCF-7 and MDA-MB-231 cells at different time intervals. 
The assay was conducted in triplicate and ATP levels were reported as a mean % of relative light units 
(RLU) normalized to control at each time point. 
 
Figure 54: Mitochondrial ATP analysis in MRC-5 cells at different time intervals in hours. 
The assay was conducted in triplicate and ATP levels were reported as mean % of relative light units 
(RLU) normalized to control at each time point. 
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5.2.5. Analysis of cell cycle arrest 
Cell proliferation and division are governed by proper progression of the cell cycle in which cell 
in the quiescence stage (G0) are allowed to enter the first gap phase (G1) before transition into 
the next phase (Besson et al., 2008) . During the G1 phase, all requirements needed for proper 
DNA replication in the S-phase get checked. This is followed by a second checkpoint, G2, in 
which ploidy or the correct number of sets of chromosomes is ensured before transition to 
mitosis (M phase) where the cells undergo division (Khodjakov and Rieder, 2009; Collins et al., 
1997). In response to DNA damage, the cell becomes arrested in G0 where it undergoes DNA 
repair, failure of which triggers apoptosis. However, during carcinogenesis cell divide rapidly 
such that regulatory process become impaired thus leading to progression into either the S-phase 
or the M phase without going through the cell cycle checkpoints (DiPaola, 2002).  The present 
study therefore analyses the effect of transfection and co-treatment on the cell cycle checkpoints 
G0/G1 and G2/M as well as the S-phase.  
 
In breast cancer cell line (MCF-7), populations in G0/G1 arrest were increased following 
treatment with camptothecin at 67.45% and in GABA at 54.9% (Figure 55). Following RBBP6 
silencing cells in G0/G1 arrest increased to 70.3% from initial value of 26.35 % in untreated 
cells; similarly a treatment with siRBBP6+camptothecin and siRBBP6+GABA showed a 
moderate increase of cells to 58.05% and 45.65% respectively (Figure 55). In up-regulated 
RBBP6, there was no change in cell populations in G0/G1 arrest following treatment with 
pRBBP6+camptothecin (37.35%) and pRBBP6+GABA (38.1%). For S-phase analysis, there was 
insignificant change in cell populations following treatment with camptothecin (10.65%), GABA 
(7.2%), siRBBP6 (8.65%), siRBBP6+camptothecin (6.35%) and a significant decrease in 
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siRBBP6+GABA at 4.7%. Transfection with pRBBP6 significantly increased the amount of cells 
in the S-phase to 26.9%; however a moderate decrease was observed in pRBBP6+camptothecin 
at 17.25% as well as in pRBBP6+GABA at 17.6% (Figure 55). Induction of G2/M arrest was 
insignificant at 13.9% in camptothecin and 16.8% in GABA in comparison to untreated at 
25.5%. In treatment cells in G2/M was reduced in siRBBP6 (14.85%), siRBBP6+camptothecin 
(14.05%) and siRBBP6+GABA (9.1%).  A significant increase in populations of G2/M arrest 
was evident in pRBBP6+GABA at 31% (Figure 55).  
 
In MDA-MB-231 cell line induction of G0/G1 arrest increased to 59.7% after treatment with 
camptothecin and to 55.6% in GABA from 31.25% in untreated cell (Figure 55). Treatment with 
siRBBP6 significantly increased cells in G0/G1 arrest to 61.35% while co-treatment with 
camptothecin (58.6%) and GABA (63.35%) did not have a significant change in G0/G1 arrest 
from silencing only. In RBBP6 overexpression and co treatments, there were little differences in 
cell populations in G0/G1 arrest with pRBBP6 (48.65%), pRBBP6+camptothecin (37.25%) and 
pRBBP6+GABA (38.1%). The cells in the S-phase showed a little difference from untreated to 
treated cells with 9.1% in untreated, 5.7% in camptothecin, 7.15% in GABA, 8.45% in siRBBP6, 
7.95% in siRBBP6+camptothecin and 6.45% in siRBBP6+GABA. On the other hand a 
significant increase was observed in pRBBP6 at 15.4% cell population whereas co-treatment 
with pRBBP6+camptothecin and pRBBP6+GABA slightly increased cells in the S-phase to 
17.75% and 17.6%, respectively. Cells in G2/M arrest were fairly high in GABA treatment at 
40.5% and in siRBBP6+GABA at 40.4%. Insignificant changes were observed in cells treated 
with camptothecin at 31.75%, siRBBP6 at 38.15% and siRBBP6+camptothecin at 30.55% 
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relative to untreated at 35.8%. Transfection with pRBBP6 led to 18.75% cell populations in 
G2/M arrest with 13.15% in pRBBP6+camptothecin and 24% in pRBBP6+GABA (Figure 55).  
 
 
 
 
Figure 55: Cell cycle analysis in MCF-7 and MDA-MB-231 cell lines. 
 
In normal lung fibroblasts (MRC5) induction of G0/G1 arrest was observed however there was 
no significant change following different treatments (Figure 56). The cells in G0/G1 arrest were 
recorded as  53.85% in untreated, 59.55% in camptothecin, 50.2% in GABA, 50.55% in 
siRBBP6, 55.35% in siRBBP6+camptothecin, 50.95% in siRBBP6+GABA, 55.5% in pRBBP6, 
57.75% in pRBBP6+camptothecin and 57.6% in pRBBP6+GABA. Slight changes were 
observed in cell populations in the S-phase with camptothecin treatment at 19.55% in 
comparison to untreated at 13.85%. There was a decrease, however, to 10.2% in GABA, 10.55% 
in siRBBP6 and 10.95% in siRBBP6+GABA. The S-phase cell populations were increased to 
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15.4% in pRBBP6, 17.75% in pRBBP6+camptothecin and 16% in pRBBP6+GABA. Cells in 
G2/M arrest remained around 30% across all treatments, with 32.75% in untreated, 33.55% in 
camptothecin, 25.75% in GABA, 37.8% in siRBBP6, 38.75% in siRBBP6+camptothecin, 38.7% 
in siRBBP6+GABA, 38.65% in pRBBP6, 27.25% in pRBBP6+camptothecin and 28.1% in 
pRBBP6+GABA (Figure 56). 
 
 
Figure 56: Cell cycle analysis in MRC-5 cell line. 
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5.2.6. Quantification of genes involved in apoptosis 
Apoptosis is mainly regulated by the Bcl-2 family proteins and therefore understanding their 
expression levels in response to RBBP6 targeting and co-treatment might help determine the 
mode of the observed apoptosis. Quantitative PCR was therefore used to analyse the mRNA 
expression levels of the following pro-apoptotic genes: bax, bak1, bad, caspase-3 and caspase-8, 
the Bcl-2 anti-apoptotic gene as well as the p53 transcription factor. Relative gene expression  
was calculated using REST 2009 software (version 2.0.13) which computes expression ratios 
based on real time PCR efficiency and delta crossing points (∆CP) of unknown samples versus a 
control. 
 
In MCF-7 cell line, treatment with camptothecin led to no change in RBBP6, TP53 and bax gene 
expression (Figure 57). Bak1 and bad were up-regulated by 39.397 and 4.691, respectively, 
whereas caspase-3 and Bcl-2 were down-regulated by 0.600 and 0.398, respectively. No 
significant change was observed in the expression of Caspase-8 following treatment with 
camptothecin. GABA treatment had no effect on RBBP6, TP53, and bax genes; however Bak1 
was down-regulated by a mean factor of 0.123. Bad gene expression was increased by a mean 
factor of 2.014 whilst the expression of Bcl-2 anti-apoptotic gene remained the same following 
GABA treatment. RBBP6 was down-regulated by 0.109 following silencing in MCF-7 and this 
led to TP53 up-regulation by a mean factor of 4.611. No change was observed in bad expression 
following RBBP6 silencing; however, Bcl-2 expression was increased by 3.797 and bax by 11. 
In contrast, silencing of RBBP6 led to a decrease in bak1 (0.247) and caspase-3 (0.700). RBBP6 
up-regulation (5.657) had no effect on TP53, bad and bcl-2 expression; however bax and bak1 
were down-regulated by 0.177 and 0.500, respectively. Furthermore, caspase-3 and caspase-8 
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were down-regulated in response to RBBP6 upregulation by mean factors 0.400 and 0.203, 
respectively.  
 
RBBP6 silencing in combination with camptothecin led to down-regulation of RBBP6 by 0.086 
whereas TP53, bax, bak1, bad and caspase-8 were up-regulated by 30.065, 9.514, 5.796, 2.969 
and 9.350, respectively (Figure 58). In contrast, the anti-apoptotic Bcl-2 was down-regulated by 
a mean factor of 0.273 following siRBBP6+camptothecin treatment. In combination with 
GABA, RBBP6 silencing (0.041) in combination with GABA increased the expression of TP53 
by 5.657 and caspase-8 by 2.828. siRBBP6+camptothecin led to no change in bax, caspase-3 and 
bad expression; however down-regulation was observed in bak1 (0.488) and Bcl-2 (0.540). In 
RBBP6 overexpressing cells treated with camptothecin, RBBP6 overexpression (8.282) was 
coupled with TP53, bax and Bcl-2 down-regulation by 0.203, 0.297 and 0.371, respectively. No 
significant change in expression was observed in bak1 and bad genes; however, caspase-8 was 
up-regulated by a 2-fold change. Combination of RBBP6 overexpression with GABA increased 
expression of RBBP6 and caspase-8 by 34.535 and 2.144, respectively, however no change was 
observed in TP53 and bax expression. Bak1, bad and Bcl-2 genes were down-regulated by 0.392; 
0.196 and 0.215, respectively, following treatment with pRBBP6+GABA.   
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Figure 57: Relative quantification of gene expression in MCF-7 cell line performed using qPCR. 
Whisker box plots with expression ratio on the y-axis and gene type on the x-axis indicate quantification 
of mRNA isolated from cells treated with camptothecin (top left), GABA (top right), siRBBP6 (bottom 
left) and pRBBP6 (bottom right). Gene expression is depicted by the colour coded whisker bars in the 
following manner: RBBP6 (red), TP53 (blue), bax (yellow), bak1 (light green), bad (grey), caspase-3 
(dark green), caspase-8 (cyan) and Bcl-2 (light blue).  
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Figure 58: Relative quantification of gene expression in MCF-7 cell line was performed using qPCR. 
Gene expression in response to treatment with siRBBP6+camptothecin (top left), siRBBP6+GABA (top 
right), pRBBP6+camptothecin (bottom left) and pRBBP6+GABA (bottom right).  
 
In MDA-MB-231 cell line, RBBP6, TP53, bax, bak1 and caspase-8 expression changed slightly 
whereas bad was up-regulated by a mean factor of 3.317. Caspase-3 and Bcl-2 were down-
regulated by a 0.5-fold and 0.281-fold changes, respectively, in camptothecin treatment (Figure 
59).  GABA treatment did not have any effect on the expression of RBBP6, TP53, caspase-3, 
Bcl-2 and caspase-8 as well; however bax and bak1 were down-regulated by mean factors 0.052 
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and 0.087, respectively. Bad was up-regulated by a mean factor of 1.424 in response to GABA 
treatment. RBBP6 silencing (0.077) had no effect on the expression of TP53, bax and bad; 
however bak1 and caspase-3 expression were down-regulated by 0.255. Caspase-8 and Bcl-2 
were up-regulated by 5.521 and 5.370, respectively. Overexpression (5.657) had no significant 
effect on TP53 expression, whereas caspase-3 and Bcl-2. Bax, bak1, bad and caspase-8 were 
down-regulated by 0.125, 0.354, 0.500 and 0.287, respectively.  
 
Combination of RBBP6 silencing with camptothecin led to a decrease in RBBP6 expression by a 
mean factor of 0.171 and had no significant effect on TP53, bax, caspase-3 and Bcl-2 gene 
expression (Figure 60). Bak1, bad and caspase-8 gene expression was increased by 3.215, 3.182 
and 4.675, respectively, in response to siRBBP6+camptothecin co-treatment. Co-treatment with 
siRBBP6+GABA reduced the expression of RBBP6 by a mean factor of 0.041; however the 
change in expression of TP53, bax, caspase-3 and bad was insignificant. Bak1 and caspase-8 
genes were up-regulated by 1.231 and 2.828, respectively, however Bcl-2 was down-regulated 
by 0.419. RBBP6 overexpression combined with camptothecin led to an increase in the 
expression of RBBP6 and caspase-8 by mean factors 3.701 and 1.741, respectively; however the 
change in expression of TP53, bak1 and bad was not significant. A decrease in Bcl-2 (0.320) as 
well as bax and caspase-3 (0.500) were observed following treatment with 
pRBBP6+camptothecin. Co-treatment with pRBBP6+GABA increased RBBP6 expression to 
34.535 and bax expression to 2.378 whereas no significant change was observed in the 
expression of TP53, bak1 and caspase-8. Bad, caspase-3 and Bcl-2 were down-regulated by 
0.049, 0.4972 and 0.137, respectively following co-treatment with pRBBP6+GABA.  
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Figure 59: Relative quantification of gene expression in MDA-MB-231 cell line by qPCR. 
The cells were treated with camptothecin (top left), GABA (top right), siRBBP6 (bottom left) and 
pRBBP6 (bottom right).  
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Figure 60: Relative quantification of gene expression in MDA-MB-231 cell line by qPCR. 
The cells were treated with siRBBP6+camptothecin (top left), siRBBP6+GABA (top right), 
pRBBP6+camptothecin (bottom left) and pRBBP6+GABA (bottom right).  
 
No significant changes were observed in gene expression following treatment with camptothecin 
and GABA in normal lung fibroblasts (Figure 61). RBBP6 silencing (0.518) led to an increase in 
caspase-8 expression by 1.414 and had no significant effect on the expression of other genes. 
Similarly, no significant changes were observed in the expression of all genes in response to 
RBBP6 up-regulation (2.462). siRBBP6+camptothecin reduced RBBP6 expression by a mean 
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factor of 0.154, whilst siRBBP6+GABA reduced RBBP6 and bak1 by 0.330 and 0.500, 
respectively. Furthermore, siRBBP6+GABA increased gene expression of bax by 1.414 (Figure 
62). RBBP6 was up-regulated by a mean factor of 5.856 in response to co-treatment with 
pRBBP6+camptothecin, and no significant effect was observed on the expression of other genes. 
Co-treatment with pRBBP6+GABA increased RBBP6 expression by a mean factor of 3.053 and 
bax by a mean factor of 1.809.  
 
Figure 61: Relative quantification of gene expression in MRC-5 cell line was performed using qPCR. 
The cells were treated with camptothecin (top left), GABA (top right), siRBBP6 (bottom left) and 
pRBBP6 (bottom right).  
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Figure 62: Relative quantification of gene expression in MRC-5 cell line was performed using qPCR. 
The cells were treated with siRBBP6+camptothecin (top left), siRBBP6+GABA (top right), 
pRBBP6+camptothecin (bottom left) and pRBBP6+GABA (bottom right).   
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5.3. Discussion 
The present study demonstrates the effects of RBBP6 silencing and overexpression in 
combination with anticancer agents on breast cancer progression. The study further provides a 
comparative analysis of the two genetically different breast cancer cell lines, MCF-7 and MDA-
MB-231, as far as their response to RBBP6 targeting is concerned.  The two cell lines display 
different p53 expression levels, with MCF-7 being shown to generally express wt. p53 and 
MDA-MB-231 expressing mt. p53 (Gartel et al., 2003). It was therefore interesting to investigate 
the effect of RBBP6 on these cell lines since it (RBBP6) associates with p53 (Pugh et al., 2006). 
 
Silencing in both cell lines was achieved by delivery of siRNA oligonucleotides targeted at 
RBBP6 in which analysis using qPCR and western blotting revealed close to 90% silencing at 
both mRNA and protein levels (Figure 40). This successful silencing is credited to the high 
specificity elicited by the synthetic short interfering RNA molecules in directing homology-
dependent control of gene activity using the cell’s own machinery (Aagaard and Rossi, 2007; 
Meister and Tuschl, 2004). In terms of RBBP6 overexpression, the expression vector system was 
employed to transiently deliver RBBP6 cDNA clone into the cells. The cytomegalovirus (CMV) 
promoter present in the expression construct led to an efficient transcription of the RBBP6 
transcript variant 3 sequence, which was subsequently translated into protein as confirmed by 
expression of the GFP reporter (Figure 34 to Figure 39). 
 
It was interesting to see growth of both cell lines ceasing about 24 hours later into RBBP6 
silencing as shown by the RTCA assay (Figure 41 and Figure 42). More so, the responses were 
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distinct as can be seen by the sharp decrease in MCF-7 cell proliferation as opposed to the 
cytostatic response in MDA-MB-231. This observation highlights early insights into the 
involvement of RBBP6 in cell proliferation, more especially because RBBP6 overexpressing 
MCF-7 cells maintain their growth at higher cellular index (Figure 41). This conforms to the 
high percentages of cell populations in the S-phase of RBBP6-overexpressing cells (Figure 55), 
suggesting that indeed RBBP6 promotes cell proliferation.  It is not clearly known why or how 
RBBP6 affects cell proliferation; however the fact that it stabilizes chromosomal fragile sites 
(CFSs) during DNA replication might account for this (Miotto et al., 2014). It has been reported 
that the instability of these sites on chromosomes perturb proper splitting of the chromatids thus 
leading to improper cell division (Miotto et al., 2014). Based on this, RBBP6 is therefore 
necessary for promoting cell division and proliferation, as suggested by the observed continued 
cellular growth following RBBP6 overexpression.  
 
Another possible explanation could be that RBBP6 negative regulation of wt. p53 inhibits cell 
cycle since functional p53 is needed for proper cell cycle progression (Li et al., 2007). This 
might also help explain the different responses observed in the two cell lines where the mt. p53-
expressing MDA-MB-231 appeared to be less responsive to RBBP6 silencing compared to 
MCF-7. These observations prompted us to quantify the mRNA expression levels of p53 in both 
cell lines. And it was interesting to notice that RBBP6 silencing leads to p53 accumulation (4-
fold increase) in MCF-7 cells and no significant change in MDA-MB-231 cells, whereas 
overexpression did not seem to have a significant effect on p53 in both cell lines. In addition to 
p53, RBBP6 interaction with Rb tumor suppressor is known to release the E2F transcription 
factor which is responsible for promoting the cell cycle as well (Speidel, 2015; Bertheau et al., 
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2014). Therefore this phenomenon could also be used to explain the observed changes in cell 
proliferation as a result of RBBP6 targeting. 
 
To test whether or not the observed decrease in cell viability was as a result of apoptosis, flow 
cytometry and fluorescence microscopy were performed on cells transfected with either 
siRBBP6 or pRBBP6. Highly significant apoptosis induction was observed in MCF-7 cells and 
no significant apoptosis was detected in MDA-MB-231 (Figure 44, Figure 49 and Figure 50) 
following RBBP6 silencing. In terms of RBBP6 overexpression, no cell line elicited significant 
levels of apoptosis induction. These observations might suggest that RBBP6 silencing coupled 
with p53 accumulation in MCF-7 cells were responsible for apoptosis induction since the 
difference between these cell lines is the expression of functional p53. P53-mediated apoptosis 
occurs via the intrinsic pathway where p53 transactivates and promotes translocation of bax to 
the outer mitochondrial membrane, thereby oligomerizing with itself or bak1 in order to porate 
the membrane. Porous mitochondrial membrane allows the release of cytochrome c and other 
factors responsible for inducing apoptosis (Wen et al., 2012; Ouyang et al., 2012; Liu et al., 
2011). Up-regulation of bax in MCF-7 cells might therefore be as a result of p53 activation thus 
confirming the observed apoptosis to be mitochondrial. Even though caspase 3/7 activity was not 
significant in MCF-7, probably due to the fact that the cell line is caspase-3 deficient, ATP 
depletion confirmed that indeed mitochondria were involved in the observed apoptosis induction 
(Gergely et al., 2002; Eguchi et al., 1997; Richter et al., 1996).  
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We then went on to combine RBBP6 targeting with apoptosis inducing anticancer agents, 
camptothecin and GABA to see if the observed apoptosis would be enhanced, especially in 
MDA-MB-231 cells since they failed to elicit significant levels of apoptosis induction. 
Camptothecin is a naturally occurring compound that was extracted from a Chinese medicinal 
plant and has since been shown to have anticancer effect (Chazin et al., 2014). GABA, the 
inhibitory neurotransmitter that’s found in the central nervous system of vertebrates (McCarty, 
2014; Takehara et al., 2007), was chosen as an anticancer agent in this study due to its ability to 
induce apoptosis, cell cycle arrest and blockade of tumour cell migration (McCarty, 2014; 
Caretta and Mucignat-Caretta, 2011). We have shown in our previous studies that camptothecin 
sensitizes MCF-7 cells to apoptosis and therefore similar observations were not surprising in the 
present study (Moela et al., 2014). To our surprise, however; was the sensitization of MDA-MB-
231 cells to camptothecin-induced apoptosis as well following RBBP6 silencing, although the 
effect was not comparable to that observed in MCF-7 cells. Similarly, apoptosis induced by 
GABA was not sensitized in MDA-MB-231 whereas it was in MCF-7 cells.  
 
RBBP6 overexpression on the other hand did not induce nor sensitize cells to significant 
apoptosis levels in both cell lines. Besides the genotypic nature of p53 expression in these two 
cells lines, the mechanisms of action underlying the two anticancer agents might account for the 
differences observed in apoptosis levels. Camptothecin induces apoptosis by inhibiting 
topoisomerase I during the release of supercoils in DNA replication by binding to the single 
strand nicks created by the enzyme thus preventing religation. This leads to damaged DNA 
which then triggers the transactivation of p53 and a subsequent apoptosis induction (Chazin et 
al., 2014; Kümler et al., 2013; Hsiang et al., 1985). Therefore this might account for the 
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synergistic effect observed between camptothecin and RBBP6 silencing in inducing apoptosis 
since both strategies seem to reactivate the function of p53.  
 
No distinctive mechanism of apoptosis induction has been described for GABA yet, however its 
affinity for G-protein coupled receptors has been shown to activate the enzyme adenylyl cyclase. 
This enzyme is responsible for activating the PKA/cAMP (protein kinase A/cyclin AMP) 
signaling pathway; which is responsible for phosphorylating several target proteins including 
those that lead to the induction of apoptosis (McCarty, 2014; Caretta and Mucignat-Caretta, 
2011). This is in agreement with a few studies that have been carried out in other cancers where 
GABA was shown to induce apoptosis (McCarty, 2014; Caretta and Mucignat-Caretta, 2011; 
Khodjakov and Rieder, 2009; Oh and Oh, 2004). In the context of our study, apoptosis induction 
in response to GABA did occur as well; however at minimal levels in both cell lines. The reason 
for this is not known, however we suspect that the anticancer effects of GABA might be highly 
effective against cell migration as opposed to apoptosis. This is because several studies have 
been conducted, especially in liver cancer; where the effect of GABA on regulatory proteins 
associated with cell migration has been shown to be potent (Takehara et al., 2007; Schuller et al., 
2008).   
 
Indeed, MDA-MB-231 and MCF-7 cell lines show differential susceptibilities to apoptosis 
induced by RBBP6 silencing alone or in combination with either camptothecin or GABA. This 
might be as result of the distinct p53 statuses of the two cell line models. The p53 tumour 
suppressor carries missense mutations in most human cancers which are generally more stable 
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and highly expressed than wild-type p53 (Hui et al., 2006).  This is not the case with the other 
two well-studied tumour suppressors Rb and APC as they have been shown to carry deletion and 
truncation mutations (Hui et al., 2006). Missense mutations are often associated with gain-of-
function phenotypes hence mt. p53 in MDA-MB-231 cells have been reported to have the ability 
to interact with certain peptides in order to prevent apoptosis induction. One example of such 
peptides is called phospholipase D (PLD) and has been shown to be highly expressed in MDA-
MB-231 cells where it interacts with mt. p53 (Hui et al., 2004) to generate survival signals that 
suppress DNA damage-induced apoptosis. This interaction might therefore be responsible for the 
restricted apoptosis induction observed in MDA-MB-231 cells in response to silencing and co-
treatment, especially in camptothecin co-treatments since it induces apoptosis by damaging 
DNA.  
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5.4. Summary 
Successful silencing and overexpression of RBBP6 have enabled careful investigation of the 
effects RBBP6 has on growth of breast cancer cell lines. We have reported that both MCF-7 and 
MDA-MB-231 cell lines respond to RBBP6 silencing by ceasing to grow whereas 
overexpression of RBBP6 maintains their continued proliferation. In addition, MDA-MB-231 
cell line seemed to respond at a slower rate to RBBP6 silencing as opposed to MCF-7s. This 
pattern appeared to be repetitive in apoptosis detection since MDA-MB-231 cells showed a weak 
response whereas MCF-7 cells showed significant amount of apoptosis induction. This apoptosis 
was further confirmed by ATP depletion assay as well as expression of pro-apoptotic genes. 
These differential characteristics elicited by the two cell lines were coined on their p53 statuses 
wherein wt. p53 accumulation in MCF-7 was associated with apoptosis induction especially 
because bax pro-apoptotic gene was up-regulated as well. On the other hand, mt. p53 in MDA-
MB-231 is suspected to have had interactions with the pro-survival PLD peptide thus preventing 
apoptosis induction in this cell line.  
 
Taken all together, it is evident that the p53 genotypic status of MCF-7 and MDA-MB-231 
breast cancer cell lines plays a major role in their responsiveness to RBBP6 targeting and co-
treatment with apoptosis-inducing agents. Furthermore, we have demonstrated that the ability of 
these cells to undergo apoptosis in the absence of RBBP6 is partly as a result of p53 reactivation, 
which provides early insights into the possible relationship between RBBP6 and p53 in breast 
cancer. These observations further highlight the significance of understanding the different 
subtypes of breast cancer as far as treatment is concerned because the heterogeneous nature of 
this disease requires patient-specific therapies thus making it difficult to manage breast cancer.  
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CHAPTER SIX - Silencing RBBP6 (Retinoblastoma Binding Protein 6) 
sensitises breast cancer cells MCF7 to staurosporine and camptothecin-
induced cell death  
 
In this chapter, the manuscript “Silencing RBBP6 (Retinoblastoma Binding Protein 6) 
sensitises breast cancer cells MCF7 to staurosporine and camptothecin-induced cell death” 
which was published in 2014, highlights the effects of RBBP6 silencing in combination with 
anticancer agents, staurosporine and camptothecin in breast tumorigenesis.  
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a  b  s  t  r  a  c  t
Retinoblastoma  Binding  Protein  6 (RBBP6)  is a multi-domain  protein  that  uses  its  ring finger  domain  to
interact  with  p53  and  pRb  tumour  suppressor  genes.  The  mechanism  by which  RBBP6  uses  to  degrade
p53  is still  unknown;  nonetheless  it is  well  known  that  RBBP6  promotes  cell proliferation  in several
cancers  by  negatively  regulating  p53  via  its E3 ubiquitin  ligase  activity.  Degradation  of p53  by  RBBP6  may
compromise  p53-mediated  apoptosis  in breast  cancer.  This  study  is  intended  to  investigate,  the  potential
applications  of  RNA  interference  (RNAi)  to  block  RBBP6  expression,  as  well  as  its  subsequent  effect  on
cell  growth  and  apoptosis.  Our  studies  indicate  that  the  knockdown  of  RBBP6  by  siRNA  modulates  p53
gene  expression  involved  in cell  death  pathways  and  apoptosis,  showing  statistically  significant  gene
expression  differences.  RBBP6  siRNA  significantly  reduced  cell  growth  compared  to  the  control  samples
and  inhibition  of  cellular  proliferation  was  observed  between  24 and  48  h,  as  shown  in  the  data  obtained
by  real  time  cell  analysis  using  the  xCELLigence  system.  These  results  were  further  confirmed  by  flow
cytometer  which  showed  some  apoptotic  activity.  About  20.7%  increase  in  apoptosis  was  observed  in
cells  co-treated  with  RBBP6  siRNA  and  camptothecin  when  compared  to camptothecin-only whereas  in
siRBBP6  and  staurosporine  treated  cells  there  was  only  an  8.8%  increase  in apoptosis.  These  findings
suggest  that  silencing  RBBP6  may  be  a novel  strategy  to  promote  camptothecin-induced apoptosis  in
breast  cancer  cells.
© 2014  Elsevier  GmbH.  All  rights  reserved.
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Introduction
Screening tests performed over a decade ago revealed
Retinoblastoma Binding Protein 6 (RBBP6) as a multi-domain pro-
tein that uses its ring-finger domain to interact with the p53 and
pRb tumour suppressor genes (Pugh et al. 2006; Pretorius et al.
2013). Also known as RBQ-1, PACT or P2P-R, the RBBP6 mRNA
occurs in the form of three major transcripts, transcript 6.1, 6.0
and 1.1 kb as a result of alternative splicing, which code for protein
isoforms 1, 2 and 3, respectively (Pugh et al. 2006).
RBBP6 is highly expressed in cancer of the oesophagus as well as
other cancers and this makes it a potential target in the treatment of
cancers with intact p53 (Pugh et al. 2006; Ntwasa 2008). In addition
to several of its biological functions including transcription, trans-
lation and ubiquitination, it is also associated with the execution
of p53 degradation following inhibition of the tumour suppressor
gene by MDM2,  thus facilitating cell proliferation (Ntwasa 2008;
Pretorius et al. 2013). However, little is known about the mecha-
nism with which RBBP6 uses to degrade the p53 tumour suppressor
protein. Taking note of the fact that the most efficient regimens for
http://dx.doi.org/10.1016/j.imbio.2014.03.002
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anticancer activity including multidrug combinations still present
patients with harsh side effects, it is important to continue evalu-
ating any possible safe therapy (Aagaard and Rossi 2007; Arakawa
et al. 2009). In this study, we report on the therapeutic poten-
tial of RBBP6 gene silencing in combination with camptothecin and
staurosporine in human breast cancer cells.
Materials and methods
Materials
MCF-7 human breast cancer cell line was obtained from the
Japan Health Resource Centre. Silencing was achieved by the use
of Ambion’s Silencer® Select Pre-designed siRNAs supplied by Life
TechnologiesTM, which target the RBBP6, MDM2  and p53 genes.
Staurosporine and camptothecin were purchased from Calbiochem®.
Tissue culture and treatments
MCF-7 cell line was cultured in DMEM (Dulbecco’s Mod-
ified Eagle Medium) growth medium supplemented with 1%
pen/strep and 10% FBS (Foetal Bovine Serum) and incubated in
a humidified atmosphere at 37 ◦C and 5%CO2. Once they reached
∼70–80% confluency, cells were trypsinized and resuspended in
an antibiotic-free media. The cell suspension was then mixed with
siRNA/transfection agent (Ambion®) complexes, at 100 nM con-
centrations, targeting RBBP6, MDM2  and p53 genes in a 24-well
plate and incubated at 37 ◦C for 24 and 48 h. Post transfection cells
were exposed to 0.25 M staurosporine and 0.25 M camptothecin
for an additional 24 h. The cells were then harvested for subse-
quent analysis, i.e. RNA and protein were extracted 48 and 72 h
post transfection, respectively.
Real time RT-PCR
RNA was extracted using Nucleospin® RNA II total RNA isola-
tion kit according to the manufacturer’s protocol and quantified
using a nanodrop (NanoDrop Technologies, USA). RNA integrity was
confirmed using ethidium bromide-stained agarose gel to analyse
the 18s and 28s rRNA bands. Following RNA extraction, cDNA was
synthesised using ImProm-IITM Reverse Transcription system from
Promega®. RT-PCR was then performed in a 20 l reaction mixture
containing 2 g/l  cDNA, SYBR Green (SIGMA®), reverse and for-
ward primers (GADPH: Forward – 5′-GAG TCA ACG GAT TTG GTC
GT-3′, Reverse – 5′-TTG ATT TTG GAG GGA TCT CG-3′; RBBP6: For-
ward – 5′-CAG CGA CGA CTA AAA GAA GAG TCT-3′, Reverse – 5′-GGT
AAT TGC GGC TCT TGC CT-3′ and p53: Forward – 5′-GTT CCG AGA
GCT GAA TGA GG-3′, Reverse – 5′-TGA GTC AGG CCC TTC TGT CT-3′)
under the following conditions: 36 cycles of 94 ◦C for 35 s, 59 ◦C for
45 s, and 72 ◦C for 45 s.
Western blot
Whole cell protein was extracted using RIPA buffer (1%
NP-40, 0.5% sodium deoxycholate, 10% sodium dodecylsulfate
(SDS), 3 l/ml aprotinin and 5 g/ml leupeptin in PBS, pH 7.4).
Seventy-two hours post transfection and co-treatment with either
staurosporine or camptothecin, cells were washed twice with cold
PBS then resuspended in 500 l RIPA buffer and collected by
scraping. The total protein was then separated from cell debri by
centrifugation at 14,000 rpm for 15 min  and quantified with Pierce®
BCA Protein Assay Kit. The protein was heated at 95 ◦C for 5 min  and
30 g was loaded per well for electrophoretic separation in 40%
acrylamide gel preparation at 100 V for 1 h. The protein was  trans-
ferred onto a nitrocellulose membrane using wet electro-transfer
method overnight at 30 V followed by incubation with primary
antibody after 1 h of blocking with 5% non-fat milk buffer. The
weak light signal produced by HRP-linked secondary antibody was
detected and enhanced using the Pierce® ECL Western Blotting
Chemiluminescence Substrate and the blots were imaged by the
CCD-based ChemiDocTM MP  system.
xCELLigence system
Before cells were seeded, 16-well E-plates containing antibiotic-
free medium were imposed to current flow on the xCELLigence
instrument placed in a 37 ◦C incubator to record background
readings. In each well of the E-plates, 1 × 105 cells were seeded
simultaneously with 100 nM siRNA targeting RBBP6, MDM2  and
p53 genes in the same antibiotic-free medium. After leaving the
E-plates at room temperature for 30 min  to allow for cell attach-
ment, they were locked in the RTCA xCELLigence instrument and
the experiment was allowed to run for 24 h. Twenty-four hours post
transfection, cells were further treated with 0.25 M apoptosis-
inducing agents (staurosporine and camptothecin). The experiment
was continued for an additional 24 h. Cell Index values were
recorded at 15 min  interval sweeps until the end of the experiment
under the following xCELLigence parameters: [1st step: 1 sweep,
1 min  interval, 00:00:39 total time; 2nd step: 100 sweeps, 15 min
interval, 24:45:39 total time; 3rd step: 100 sweeps, 15 min  interval,
49:30:39 total time].
Flow cytometry
Cultured cells were seeded in 24-well plates and simultaneously
transfected with siRNAs targeting RBBP6, MDM2, and p53 for 24 h
and treated for an additional 24 h with apoptosis-inducing agents
(0.25 M staurosporine and camptothecin).  The treated cells were
then trypsinized, resuspended in growth medium and transferred
to 15 ml  tubes, pelleted for 2 min  at 1500 rpm and resuspended in
100 l 1X binding buffer (annexin V-FITC Apoptosis Detection Kit,
abcam®) at a concentration of 1 × 104 cells/ml. The cell suspen-
sions were then transferred into 1 ml  tubes and 5 l of Annexin V
FITC and 5 l of PI were added. This was  followed by gentle vortex-
ing and incubation for 15 min  at room temperature in the dark. To
each tube, 400 l of 1X binding buffer was  then added and the cell
solutions were analysed by flow cytometry within 1 h.
Statistical analysis
The results of each series of experiments (performed in dupli-
cates) are expressed as the mean values ± standard deviation of
the mean (SD). Levels of the statistical significance were calculated
using the paired Student’s t-test when comparing two groups, or by
analysis of variance (ANOVA). P-values of ≤0.05 were considered
significant.
Results
Gene silencing and mRNA expression analysis
Quantitative PCR analysis was  used to evaluate the transcript
on the silenced RBBP6, p53, MDM2,  Bax and Bcl2 genes as shown
in Fig. 1. As expected, a 37% decrease in RBBP6 expression was
observed following silencing with 100 nM siRBBP6 while in com-
bination with camptothecin the expression was further reduced
by about 49%. In cells that were treated with Staurosporine and
siRBBP6, expression was reduced by only 22%. In siMDM2, we
observed a much higher silencing following co-treatment with
both staurosporine and camptothecin, at 50% and 51%, respectively
(Fig. 1.1A and B). The present study emphasizes the important role
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Fig. 1. (1.1) Relative quantification of gene expression in MCF-7 cells was performed using real time RT-PCR. (A) and (B), gene expression of RBBP6 and MDM2 in cells that
were  not transfected and either not treated, treated with staurosporine or camptothecin, co-treated with either MDM2  or RBBP6 siRNAs and treated with either staurosporine
or  camptothecin. (C) and (D), p53 gene expression after co-treatment of MCF-7 cells with siRNAs targeting RBBP6 and MDM2,  respectively, and the apoptosis-inducing agents
(staurosporine and camptothecin). The experiments were done in duplicates and the data is statistically significant, p-value <0.05.
(1.2) Relative quantification of gene expression in MCF-7 and MRC-5 cells was performed using real time RT-PCR. (A) and (C), gene expression of Bax and BCl-2 in MCF-7 and
MRC-5, respectively, that were not transfected and either not treated, treated with staurosporine or camptothecin, silenced with either RBBP6-, p53- and MDM2-targeting
siRNAs then treated with either staurosporine or camptothecin. (B) and (D), Bax/BCl-2 ratios after co-treatment of MCF-7 and MRC-5 cells, respectively, with siRNAs targeting
RBBP6, p53 and MDM2,  and the apoptosis-inducing agents (staurosporine and camptothecin).
(1.3) Relative quantification of gene expression in MRC-5 cells was performed using real time RT-PCR. The figure shows gene expression of p53 in cells that were not treated,
silenced with either MDM2  or RBBP6 siRNAs and then treated with either staurosporine or camptothecin.
(1.4) Agarose gel electrophoretic analysis of real time RT-PCR products. (A) and (B), bax and bcl-2 RT-PCR products in MCF-7 cell line before and after treatments. (C) and (D),
bax,  bcl-2 and p53 RT-PCR products of MRC-5 cells after co-treatment.
of p53, Bcl-2 and Bax pro-apoptotic genes in activating apopto-
sis and reducing cell proliferation by gene silencing. The effect
of RBBP6 and MDM2  silencing on p53 expression is shown in
Fig. 1.1C and D. As observed, siRBBP6 in combination with camp-
tothecin treatment led to a 13% increase in the expression of p53,
whereas siMDM2 in combination with camptothecin resulted in
31% increased expression of p53 (Fig. 1.1C and D). However, co-
treatment with staurosporine showed little to no-effect in the
expression of p53 after silencing with either RBBP6 or MDM2
(Fig. 1.1C and D). One important factor in apoptosis induction is
the Bax/Bcl2 ratio which determines whether cells survive or die.
We have observed up to double increase in the Bax/Bcl2 ratio fol-
lowing MDM2  silencing (Fig. 1.2B). Bax was significantly increased
following MDM2  and RBBP6 silencing that was followed by treat-
ment with staurosporine (Fig. 1.2C and D). Silencing both RBBP6 and
MDM2  seem to have favoured Bax/Bcl2 ratio that is for apoptosis.
In MRC5 fibroblast cells that we considered normal cells, p53 was
only slightly increased when RBBP6 and MDM2  were silenced even
when treated with both agents (Fig. 1.3).
Protein expression by Western blot analysis
The expression of RBBP6, MDM2  and p53 proteins was sig-
nificantly reduced after silencing with their respective siRNAs in
comparison to protein expression in cells that were treated with
staurosporine or camptothecin alone (Fig. 2). Combination of siRNAs
with either staurosporine or camptothecin almost led to a com-
plete repression of RBBP6 and MDM2  proteins, whereas reduction
in p53 protein expression seemed to be constant in siRNA-only
and siRNA + staurosporine/camptothecin-treated cells (Fig. 2A–C).
Silencing with either RBBP6 or MDM2  led to an up-regulation of p53
protein (Fig. 2A and C) whereas p53 silencing caused MDM2  down-
regulation (Fig. 2B). These findings suggest that there is indeed a
relationship between RBBP6, MDM2  and p53 at both mRNA and
protein level. Silencing both RBBP6 and MDM2  followed by treat-
ment with staurosporine resulted in an increase in bax protein
expression (Fig. 2D) whereas that of Bcl-2 seemed to be reduced
or remained unchanged.
Analysis of cell growth after co-treatment
The anti-proliferative effect of gene silencing was measured
using xCELLigence system. In accordance with the previous results,
we verified the growth inhibitory effect of siRBBP6, siMDM2 and
sip53 (100 nM)  on MCF-7 breast cancer cells by measuring cell
growth in real time using xCELLigence system (Roche) (Fig. 3).
Growth curves were normalised to the CI at the last measured time
point before compound addition for each well. MCF7 growth curve,
596 P. Moela et al. / Immunobiology 219 (2014) 593–601
Fig. 1. (Continued)
which is presented in Fig. 3 showed a significant reduction in cel-
lular growth after silencing siRBBP6 and siMDM2, whereas sip53
reduced cell growth at a slower rate. Combination of siRNAs and
the apoptosis-inducing agents (staurosporine and camptothecin)
further reduced cell growth as shown in Fig. 3B and C. Stau-
rosporine reduced cell growth at a much faster rate as compared
to camptothecin (Fig. 3B and C). These findings suggest that both
co-treatments (siRNAs + staurosporine and siRNAs + camptothecin)
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Fig. 2. Protein expression in MCF-7 cells was  performed using Western blot technique. GAPDH was used to confirm that an equivalent amount of protein was  loaded into
each  well. (A) protein expression of RBBP6 and p53 in cells that were either not treated or co-treated with RBBP6 siRNAs and staurosporine (STS) or camptothecin (CPT). (B) p53
and  MDM2  protein expression after co-treatment of MCF-7 cells with siRNA targeting p53 and the apoptosis-inducing agents (staurosporine and camptothecin). (C) MDM2
and  p53 protein expression after silencing with siRNAs targeting MDM2 and the apoptosis-inducing agents (staurosporine and camptothecin). (D) and (E), protein expression
of  Bax and Bcl-2, respectively, in cells that were either not treated or co-treated with RBBP6-, p53- and MDM2-targeting siRNAs and staurosporine (STS) or camptothecin (CPT).
induce cell death; however, the siRNAs + staurosporine combina-
tion might be more effective on the cells as seen by the rapid fall
in cellular growth (Fig. 3C). When comparing these results to those
observed in MRC5 cells, an almost similar pattern of growth inhibi-
tion was observed but it was at a minimal level (Fig. 3D–F). In this
case, staurosporine and RBBP6 silencing did not have as much effect
as in MCF-7 cells.
Apoptosis detection
Annexin V and PI staining make flow cytometry an effec-
tive technique to distinguish between early and late apoptosis in
cultured cells. Analysis by flow cytometry revealed that the per-
centage of apoptotic cells following treatment with camptothecin
and staurosporine was significantly increased to 53.2% and 55.9%
respectively in MCF-7 cells (p < 0.05) (Table 1). siRBBP6 significantly
increased apoptosis in cells treated with camptothecin (20.7% incre-
ment), however, only 8.8% increase in apoptosis was observed in
cells treated with siRBBP6 and staurosporine (Table 1). siMDM2
significantly induced apoptosis in camptothecin by 26.6% as com-
pared to that of staurosporine and this was insignificant at 0.5%
(Table 1). sip53 reduced camptothecin-induced and staurosporine-
induced apoptosis by 26% and 30.7%, respectively (Table 1) which
was far less than those of MDM2  and RBBP6. In MRC5, silencing
RBBP6 and MDM2  could only induce apoptosis to about 14 and
15% in combination with apoptosis inducing agents (Table 2 and
Figs. 4 and 5).
Discussion
Several E3 enzymes are associated with cancer development and
are therefore highly expressed in a number of tumours (Motadi
et al. 2011). RBBP6 has been identified as an E3 ubiquitin lig-
ase that is markedly up-regulated in tumours of the lung (Motadi
et al. 2011). Because RBBP6 possesses a p53 binding domain, the
p53 tumour suppressor is prone to ubiquitination by the ring fin-
ger domain of RBBP6 thus leading to cancer progression (Vassilev
et al. 2003; Malloy et al. 2012). RBBP6 therefore serves as a hall-
mark target in the development of anticancer therapeutics and
findings in this manuscript reveal how a synergistic effect of two
biological compounds could become a potential treatment against
breast cancer by targeting RBBP6. In this study we demonstrated at
both the mRNA and protein level that it is possible to markedly
silence the expression of RBBP6 in human breast cancer cells
(MCF-7) using RNA interference. We further demonstrated that
combinational therapy of siRBBP6 and either camptothecin or stau-
rosporine further reduces expression of RBBP6 and lead to reduction
in cell proliferation. However, siRBBP6 in combination with stau-
rosporine does not significantly reduce RBBP6 gene expression.
These differences in the effects of these two combinational ther-
apy (RBBP6 siRNA/staurosporine and RBBP6 siRNA/camptothecin)
on RBBP6 expression may  be attributable to the fact that the two
apoptosis-inducing agents possess different mechanisms of apo-
ptosis induction.
Camptothecin acts as a topoisomerase I inhibitor thus causing
DNA strand breaks during the S-phase of the cell cycle which
leads to apoptosis in cancer (Arakawa et al. 2009). The mecha-
nism by which staurosporine uses to induce apoptosis is not well
understood, however it is suspected that it uses its protein kinase
inhibiting function to mediate translocation of bax from the cyto-
sol to the mitochondria where it causes the release of cytochrome
c from the outer mitochondrial membrane (Xue et al. 2003; Motadi
et al. 2007). Silencing of RBBP6 in these cells markedly enhanced
the level of apoptosis induced by camptothecin; however, apoptosis
induced by staurosporine was  not significantly enhanced by RBBP6
silencing. The results also strongly suggest that the enhanced apo-
ptosis is as a result of the synergistic effect between RBBP6 siRNA
and camptothecin as treatment with camptothecin alone (or siRNA
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Fig. 3. Cell growth of MCF-7 (top) and MRC-5 (bottom) cells was analysed using the xCELLigence system which relies on the generation of electrical impedance as cell growth
by  16-well plates coated with a gold microelectrode covering the base of each well. The y-axis shows normalised cell index or cell adhesion over a period of about 48 h
(x-axis).  The growth patterns in (A) and (D) show cells that are not treated (blue), those that were exposed to transfection reagent only (orange) and those transfected with
siRBBP6, siMDM2 and sip53 (pink, green and light blue). (B) and (E) curves of cells co-treated with siRNAs and the camptothecin and (C) and (F) curves of cells co-treated
with  siRNAs and staurosporine.
alone) induces less apoptosis (Fig. 9).p53 induces apoptosis by tran-
scriptionally activating bax and causing its translocation to the
mitochondria where it porates the outer mitochondrial membrane
(Shen and White 2001). p53-silenced cells were not undergoing
as much apoptotic cell death as those that were RBBP6-silenced
and from this it is arguable that some of the observed apopto-
sis might be attributed to some p53-mediated pathway. These
findings suggest that, by blocking the gene expression of both
MDM2  and RBBP6, the activation of other proapoptotic genes is
promoted, leading to the activation and upregulation of differ-
ent intracellular signalling pathways, including BCL-2 gene family,
inflammatory caspases and death receptors (Morissette et al. 2007;
Porichi et al. 2009). These signalling pathways promote p53 medi-
ated cell death.
Table 1
Apoptosis of MCF-7 cells analysed using flow cytometer with annexin V and PI following co-treatment with 100 nM siRNAs (siRBBP6, sip53 and siMDM2) and 0.25 M
staurosporine or 0.25 M camptothecin.
Untreated Staurosporine
(STS)
Camptothecin
(CPT)
siRBBP6 + STS siRBBP6 + CPT sip53 + STS sip53 + CPT siMDM2 + STS siMDM2 + CPT
Live cells (%) 85.5 42.0 46.2 31.7 25.0 74.5 50.3 41.2 19.6
Necrotic cells (%) 13.6 2.1 0.7 3.1 0.2 0.0 0.4 2.5 0.4
Apoptotic cells (%) 0.8 55.9 53.2 65.3 74.7 25.7 49.3 56.3 79.2
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Table  2
Apoptosis of MRC-5 cells analysed using flow cytometer with annexin V and PI following co-treatment with 100 nM siRNAs (siRBBP6, sip53 and siMDM2) and 0.25 M
staurosporine or 0.25 M camptothecin.
Untreated Staurosporine
(STS)
Camptothecin
(CPT)
siRBBP6 + STS siRBBP6 + CPT sip53 + STS sip53 + CPT siMDM2 + STS siMDM2  + CPT
Live cells (%) 94.0 79.5 79.0 85.1 86.5 85.2 84.1 85.9 83.4
Necrotic cells (%) 3.5 5.2 2.4 1.4 1.5 1.5 1.2 1.5 1.2
Apoptotic cells (%) 2.5 14.3 18.7 13.5 12.0 13.3 14.8 12.6 15.4
Under normal physiological conditions, wild type TP53 tumour
suppressor has a short half-life due to its targeted degradation by
MDM2  E3 ubiquitin ligase (Bai and Zhu 2006). This auto-regulatory
feedback loop keeps TP53 under tight regulation to maintain nor-
mal  cell growth and prevent tumorigenesis (Vassilev et al. 2003;
Malloy et al. 2012). In response to stress signals such as DNA dam-
age, activated TP53 stimulates genes such as p21 and Bax which
are responsible for the induction of cell cycle arrest and apoptosis,
respectively (Bai and Zhu 2006). Inhibition of RBBP6 led to over-
expression of the p53 tumour suppressor at both the mRNA and
protein level. This suggests that by silencing RBBP6 we were able
to block the interaction between RBBP6 and p53 and thus prevented
p53 degradation.
During their auto-regulatory feedback loop, p53 activates
MDM2  which in turn has the ability to block the transactivation
activity of p53 by tightly binding the p53 protein (Bai and Zhu
2006). MDM2  is also involved in the nuclear transport of p53
and also serves as an E3 ubiquitin ligase that promotes degrada-
tion of p53 (Vassilev et al. 2003). We  demonstrated in this study
that by tempering with the p53:MDM2 auto-regulatory feedback
loop, i.e. silencing MDM2,  also frees p53 as evidenced by the up-
regulation of both p53 mRNA and p53 protein, and the fact that
p53 silencing leads to MDM2  down-regulation tells us that indeed
the p53:MDM2 interaction does exist and it compromises the
function of p53 during cancer development (Shangary and Wang
2008). These findings suggest that in the absence of RBBP6 and
the p53:MDM2 interaction, p53 degradation by the E3 ubiquitin
ligases is abrogated thus leading to p53-mediated apoptosis. Nor-
mal  skin fibroblasts were less responsive to the co-treatment and
this somehow suggests that silencing RBBP6 is not cytotoxic to
non-cancerous cells.
We showed a good correlation between cellular growth reduc-
tion and apoptosis induction in MCF-7 cells, for example siRBBP6
combined with camptothecin led to a significant cellular growth
rate reduction and an increase in apoptosis induction in compar-
ison to cells that were untreated or treated with camptothecin
only. However combination of siRBBP6 with staurosporine led to a
much faster reduction in growth rate of MCF-7 cells. The observed
difference in the potency of camptothecin and staurosporine on
cell growth may  be attributable to the fact that the two agents
induce apoptosis using different mechanisms. We have shown that
camptothecin induces a much higher apoptosis than staurosporine
when combined with siRBBP6 and this may  be due to the fact that
camptothecin interacts directly with proapoptotic genes in order to
Fig. 4. Statistical analysis of flow cytometry-obtained apoptosis (%) in MCF-7 cell line. t-Test was  used to generate p-values in order to compute the difference between
treated  and untreated scores. A, B and C, statistical analysis between untreated and silenced and between treated and silenced + treated in MCF-7 cells. * p ≤ 0.05, ** p ≤ 0.01,
***p  ≤ 0.001 and nsp ≥ 0.05.
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Fig. 5. Statistical analysis of flow cytometry-obtained apoptosis (%) in MRC-5 cell line. t-Test was  used to generate p-values in order to compute the difference between
treated  and untreated scores. G, H and I, statistical analysis between untreated and silenced and between treated and silenced + treated in MCF-7 cells. *p ≤ 0.05, **p ≤ 0.01,
***p  ≤ 0.001 and nsp ≥ 0.05.
induce apoptosis (Zeng et al. 2012). Wild type p53 has been shown
to enhance camptothecin-induced apoptosis (Zhang et al. 2000; Li
et al. 2000) and this may  also explain the observed enhanced apo-
ptosis in cells co-treated with siRBBP6 + camptothecin.
Interestingly, we also showed that sip53 combined with either
camptothecin or staurosporine leads to a slight increase in cell
growth in comparison to co-treatment with siRBBP6 or siMDM2
and either of the agents. This observation may  suggest that p53
is required in the induction of cell death and to explore this fur-
ther, apoptosis detection was carried out in p53-knockdown MCF-7
cells. We  showed that there is minimal apoptosis induction in p53-
silenced cell population in comparison to cells co-treated with
either siMDM2 or siRBBP6. P53 is involved in the induction of
apoptosis via the intrinsic apoptotic pathway by promoting tran-
scription; translocation and oligomerization of bax on the outer
mitochondrial membrane in order to facilitate cytochrome c release
(Bai and Zhu 2006) and these findings suggest that silencing p53
reduces p53-mediated apoptosis.
Conclusion
p53 could promote the convergence of the extrinsic and intrin-
sic apoptotic pathways, including in MCF-7 breast cancer cells.
The present study provides early insight into the mechanisms
of RBBP6 pathways in mediating p53 in breast cancer cells, as
the mRNA and protein expression data show. Manipulating the
expression of the RBBP6 and MDM2  genes is required for the
induction of apoptosis by different Bcl-2 gene family members.
Therefore, these results provide a promising path to understanding
further the role of RBBP6 in cancer development and treat-
ment.
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CHAPTER SEVEN - General Discussion and Conclusions 
7.1.  Introduction 
According to dictionary.com, a biomarker is defined as a distinct biochemical, genetic, or 
molecular substance that is used as an indicator of a particular biological condition, e.g. a blood 
test can be used to measure protein biomarkers for cancer, which indicate either the extent of 
disease progression or effectiveness of therapy. The question raised in this study is whether or 
not Retinoblastoma binding protein 6 (RBBP6) through its molecular functioning serves as a 
biomarker for breast or cervical cancer. We show through gene silencing, overexpression, 
apoptosis and cell cycle analysis that indeed RBBP6 presents molecular characteristics of a 
cancer biomarker. 
 
RBBP6 is a 250 kDa multi-domain protein whose molecular functions include ubiquitin-protein 
transferase activity, ligase activity, protein binding, zinc ion binding as well as poly(A) RNA 
binding (Pugh et al., 2006; Miotto et al., 2014). RBBP6 localizes in the chromosomes, 
microtubules, nucleolus and cytoplasmic cellular components during utero embryonic 
development where it facilitates progression of the embryo from the formation of a zygote until 
growth into a multicellular organism (Miotto et al., 2014). In terms of its protein binding 
function, recent research has successfully showed that RBBP6 plays a role in the regulation of 
tumour suppressor proteins p53 and pRB via its p53-binding and pRB-binding domains (Pugh et 
al., 2006, Chen et al., 2013; Li et al., 2007). This functioning of RBBP6 in cell biology suggests 
an important role in cancer progression and development.  
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7.1.1. RBBP6 protein expression and localisation in cervical cancer tissue sections 
Conventional prognostic techniques in tumorigenesis are denoted by lymph node status, FIGO 
stage, characteristics of primary tumour which include tumour size, depth of cervical invasion, 
type of histology and uterine diffusion (Gadducci et al., 2013). However, recent identification of 
tissue biomarkers such as EGFR, VEGF, Tap73, p53 and INK4 family proteins has played a 
major role in assessing and predicting a positive response to treatment (Gadducci et al., 2013). 
Previously, RBBP6 has been shown to be highly expressed in several cancer type with the 
expression higher around well-differentiated cells of carcinomas (Li et al., 2007; Mbita et al., 
2012; Motadi et al., 2011; Chen et al., 2013, Moela et al., 2014; Harutyunyan et al., 2016).  This 
findings support the hypothesis that RBBP6 is a cancer causing gene by playing a major role in 
cancer progression.  
 
Through tissue sections collected from cervical cancer patients, we show an increased expression 
of RBBP6 in the stromal and well-differentiated non-keratinizing squamous cell carcinoma 
tissues. These findings are consistent with previous studies (Mbita et al., 2012; Motadi et al., 
2011) and reinforce the role played by RBBP6 in cancer development and progression. In 
keratinized and columnar cells of the glandular element of the less prevalent adenocarcinoma, 
there was aggressive expression of RBBP6. Keratin formation is associated with aggressiveness 
of the cancer and increased cell division (Motadi et al., 2011). This suggests that the presence of 
RBBP6 in such areas might be the driving force of cancer aggression through its perceived role 
in stabilizing chromosomal fragile sites thereby ensuring proper cell division (Motadi et al., 
2011). By implication, this suggests that at the onset of cancer development RBBP6 might be 
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required to make sure that cell division occurs thereby acting as a facilitator for cancer 
development.  
7.1.2. Overexpression and silencing of RBBP6 gene in tumorigenic cell lines 
RBBP6 gene manipulation was highly important in this study so as to understand its role in 
breast and cervical cancer biology. New and exciting findings on the involvement of RBBP6 in 
tumorigenesis continue to emerge, however, this area of study still needs to be thoroughly 
investigated, more so because there are contradictions from one set of findings to the other. For 
example, Gao and Scott (2003) showed that P2P-R overexpression sensitizes MCF-7 cells to 
apoptosis, which is conflicting to the observations made by Motadi et al (2011) where RBBP6 
overexpression plays an inhibitory role by promoting cell proliferation in lung cancer. On the 
other hand, Chen et al. (2013) argues that RBBP6 overexpression together with mutant TP53 is 
deemed predictive of poor prognosis in colon cancer. In terms of silencing, Li et al. (2007) 
showed that RBBP6 silencing was linked to early embryonic lethality coupled with p53 
accumulation and a widespread apoptosis which is in agreement with our previous findings 
(Moela et al., 2014) where RBBP6 silencing led to p53 accumulation and sensitized MCF-7 cells 
to camptothecin-induced apoptosis. Nonetheless, taken all together these observations highlight 
the important role played by RBBP6 in tumorigenesis and puts cancer research a step further in 
exploring the potential of RBBP6 to become a novel biomarker in anticancer therapy. 
  
To gain a better understanding of the possible role of RBBP6 in breast and cervical cancer 
progression, we first overexpressed and silenced the gene in various breast and cervical cancer 
cell lines. RBBP6 overexpression in HeLa, SiHa, MCF-7, MDA-MB-231 cell lines as well as the 
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normal lung fibroblasts was achieved by transient transfection using an expression vector that 
contained transcript variant 3 of RBBP6 tagged with a GFP reporter gene to allow for positive 
identification of RBBP6 overexpression. Transcript variant 3 consists of the DWNN domain 
which plays a central role in the functioning of the full length RBBP6 (Kappo et al., 2012; Pugh 
et al., 2006).  The use of expression vectors to overexpress proteins is a long established method 
which has seen a lot of recombinant proteins being FDA-approved as anticancer drugs (Kinch, 
2015). The aforementioned tumorigenic cell lines were chosen based on their p53 status because 
the tumour suppressor has been shown to be involved in the functioning of RBBP6 (Pugh et al., 
2006, Li et al., 2007).   
 
Overexpression studies of RBBP6 were monitored using GFP tag protein in which 
immunoprecipitation showed expression that was directly proportional to that of RBBP6. 
Furthermore, RBBP6 protein was analysed using 50kDa antibody that was able to detect all 
isoforms of the gene. Gene expression was also evaluated at mRNA levels to confirm the success 
of our expressional studies. From the results as described in chapter 4, overexpressional studies 
were successful in all cervical cancer cell lines, whereas HeLa showing statistically significant 
(P < 0.001) up-regulation of RBBP6. This successful transfection of HeLa cells is similar to a 
study that has shown it to be an easy to transfect cell line and therefore remains the most 
commonly used in transfection studies (Ning and Tang, 2012). The difference in overexpression 
between HeLa and SiHa was insignificant (11%). This was further confirmed by analysis of 
expression in live cells using FACS and confocal microscopy where a strong GFP fluorescence 
signal was detected in both cell lines. Similarly, mRNA quantification showed an average of 12-
fold increase of gene expression in all cell lines further confirming the observed overexpression.   
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RBBP6 overexpression was successful in breast cancer as indicated by Figure 34 and Figure 35. 
To the best of our knowledge this is the first study to successfully overexpress RBBP6 in human 
cancer cell lines using transient transfection. The success of this study is similar in sense to that 
by Gao and Scott (2003) in which they used stable transfection (knockout) of P2P-R in MCF-7.   
The successful overexpression of RBBP6 will enable us to understand and identify its molecular 
mechanism in cell biology. This understanding of its mechanism will be able to present RBBP6 
as a potential target for cancer therapy.  
 
RBBP6 gene silencing was achieved by the use of siRNA technology, a method that is rapidly 
becoming important for studying gene functioning and thus holds promise for the development 
of therapeutic gene silencing (Aagaard and Rossi, 2007; Meister and Tuschl, 2004).  The main 
question that exists in RBBP6 studies is whether it binds to p53 or Rb and leads to their 
degradation thereby leading to cancer development or whether that ubiquitin function results in 
the activation of spindle and speed up cell division. Depending on which theory is true, siRNA 
technology will assist in clarifying the functions of RBBP6 in cell biology.   
 
Silencing studies were successful as indicated in our earlier results where we managed to 
knockdown RBBP6 by over 90% in all cell lines. These results are similar to those conducted by 
other researchers in both breast and cervical cancer (Jung et al., 2015; Shen et al., 2013; Peralta-
Zaragoza et al., 2010; Alvarez-Salas and DiPaola, 2007).  RNAi technology assisted many 
researchers in the identification of cancer biomarkers (Milani et al., 2016; Koivusalo et al., 2006) 
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and we show in this study that it was able to assist in the understanding of RBBP6 function. As 
described through central dogma, protein synthesis is much dependent on mRNA transcription. 
In many cases, degradation or blocking of mRNA results in deficiency of that particular protein. 
The success of RBBP6 gene silencing should thus be evident in translation. It was clear from 
western blot as indicated in Figure 7 and Figure 40 that silencing RBBP6 mRNA resulted in a 
decreased protein expression confirming the success of the transient transfection.  
7.1.3. The effect of RBBP6 gene targeting on cancer cell progression  
Cancer progression and development is characterised by many molecular defects. One such 
defect is the inactivation of the cell cycle arrest machinery which is tasked with redirecting 
damaged cells to a cell repair mechanism. Many researchers have identified several genes 
including p53 and Rb as either being mutated or inactivated during cancer development (Bai and 
Zhu, 2006).  However, to date there is still no clear biomarker derived from our understanding of 
cell cycle. Perhaps the solution lies in unlocking the molecular functions of RBBP6 domains 
responsible for binding p53 and Rb.  
 
Cell proliferation occurs very rapidly in embryonic cells due to increased levels of RBBP6 in 
order to fulfil early development, which is followed by cell differentiation to produce cell types 
that are more specialised and can make up a multicellular organism (Miotto et al., 2014). In 
contrast, the rate of cell proliferation decreases during differentiation and as a result most cells in 
a fully developed organism remain arrested in the interphase (G0) of the cell cycle (Huang et al., 
2013). However, this is not the case with differentiated cancer cells; instead they acquire the 
ability to invade the cell cycle checkpoints so as to continue proliferating uncontrollably at much 
higher rates (Huang et al., 2013).  Through the use of RBBP6 silencing, overexpression and 
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xCELLigence systems, cell proliferation was monitored.  Interesting results were observed in 
RBBP6 silencing and overexpression in normal cell lines.  In these cells when RBBP6 was 
silenced the cell continued at the same growth rate as untreated whereas overexpression of 
RBBP6 in the same cell line resulted in increased cell growth rate. MRC5 is a foetus-derived cell 
line (Friedman and Koropchak, 1978) and increasing RBBP6 will automatically as described in 
the previous sections, speed up cell division. This further places RBBP6 at the centre of cell 
proliferation as an important marker.  For cancer cells, silencing RBBP6 as shown in Figure 7 
and Figure 40 reduced cancer cell progression while overexpression resulted in moderately high 
cell growth rate. The reduced cell growth rate highlights the importance of RBBP6 in cancer 
progression and that if this gene was to be managed it might assist in combating cancer 
progression.  
 
In response to DNA damage in the cell, ATM (ataxia telangiectasia mutated) protein kinase 
becomes active and in turn activates Chk2 kinase, both of which activate p53 by phosphorylation 
at distinct sites (Speidel, 2015; Bertheau et al., 2014). The active p53 therefore up-regulates the 
expression of a cyclin-dependent kinase inhibitor known as p21waf1/Cip1 which functions to 
induce G1 arrest by inhibiting cyclin E/CDK2-mediated phosphorylation of Rb and the release of 
E2F transcription factor; which is responsible for the activation of genes required for entry into 
the S-phase (Speidel, 2015; Bertheau et al., 2014).  Through cell cycle analysis, RBBP6 
silencing was shown to arrest cancer cells in G0/G1 which suggested that following reduction of 
the gene cell biology mechanisms were restored. However, it was not clear whether it was cell 
cycle arrest that was restored or apoptosis activated. But the fact that many of the cells were 
arrested at G0 stage is a suggestion that apoptosis might be induced.  Interestingly, when RBBP6 
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was overexpressed, more cells accumulated in the S-phase which is a stage in cell cycle that 
involves the replication of DNA and thereby cell proliferation. This evidence suggests that 
RBBP6 expression promote DNA replication which by implication, promotes cell proliferation. 
In normal cell, similar results were observed after overexpression of RBBP6 where most cells 
appeared to be accumulating in the S-phase suggesting increased cell proliferation. This was also 
confirmed by the xCELLigence that indeed the cells were growing faster. It is now clear that 
RBBP6 silencing has an inhibitory effect on breast and cervical cancer cell proliferation whereas 
overexpression promotes the cell growth process; however, the mechanism of action responsible 
for this phenotype is not fully understood. 
7.1.4. Implicated apoptosis induction by RBBP6 silencing 
The process of cancer progression involves transformation of normal cells into malignant types 
as a result of genetic alterations that lead to dysregulation of cellular processes especially cell 
cycle and apoptosis (Dashzeveg and Yoshida, 2015). Current therapeutic strategies therefore are 
aimed at targeting these pathways in order to combat cancer (Dashzeveg and Yoshida, 2015). 
Morphologically, apoptosis is characterised by externalisation of phosphatidyl serine (PS) 
peptides on the outer cell membrane coupled with cell shrinkage and pyknosis which eventually 
lead to irregular cell shape (Kerr et al., 1972). Indeed, staining of live cells with the annexin 
V/FITC fluorescent dye that has maximum binding affinity to PS as well as the DNA-
intercalating DAPI enabled visualisation of PS externalisation and DNA fragmentation. 
 
In support of our earlier observations and arguing for apoptosis induction, cancer cells treated 
with the siRNA presented morphological similarities to that of apoptotic cells, namely cell 
P. Moela: PhD Thesis 
170 
 
shrinkage, irregular shape and decrease in size. Whereas those stained with annexin V/PI, stained 
positive for both late and early apoptosis as observed through flow cytometer.  In cells treated 
with overexpression vector, the opposite was true with apoptosis at its lowest levels of about 5% 
which was in line with untreated cells. The two opposing observation provide a clear evidence 
that RBBP6 plays a major role in cancer development that the observed cell cycle arrest at G0 
might be that apoptosis was restored in proliferating cells following gene silencing.  Normal cell 
lines treated with both siRNA and overexpression vector did not induce a significant amount of 
apoptosis. 
7.1.5. Mechanism of cell death as induced by siRBBP6  
Mitochondria are the main source of ATP generation and loss of mitochondrial membrane 
potential due to permeabilization of the outer mitochondrial membrane during intrinsic apoptosis 
induction often leads to ATP depletion (Gergely et al., 2002; Eguchi et al., 1997; Richter et al., 
1996). However, lack of ATP restoration may be indicative of necrotic cell death because 
apoptosis is a highly organised and co-ordinated form of cell death that requires energy (Gergely 
et al., 2002; Eguchi et al., 1997; Richter et al., 1996). It is also worth noting that 
permeabilization of the outer mitochondrial membrane is the final decider of apoptosis induction 
because it releases apoptosis inducing factors such as cytochrome c (Gergely et al., 2002). This 
is followed by the activation of effector caspases 3 and 7 by proteins released from the 
mitochondrial intermembrane space, which ensures execution of apoptosis (Namura et al., 1998; 
Parton et al., 2001). These caspases trigger apoptosis by cleaving the inhibitor of endonucleases, 
ICAD, thus promoting fragmentation of DNA in the nucleus by the activated endonucleases 
(Namura et al., 1998; Parton et al., 2001). 
 
P. Moela: PhD Thesis 
171 
 
In the present study, we measured mitochondrial ATP content and caspase 3/7 activity following 
treatment with both siRBBP6 and cDNA construct at different time points. Treatment with 
siRBBP6 led to ATP depletion for up to 6 hours followed by restoration in both cervical cancer 
cell lines. ATP depletion continued for longer (8 hours) in MCF-7 cells whereas no significant 
restoration was observed in MDA-MB-231. The observed mitochondrial ATP depletion suggests 
that mitochondrial transmembrane potential (ΔΨm) decreased and the outer mitochondrial 
membrane of the cells in question had undergone permeabilization, the point of no return in 
apoptosis induction. Indeed, loss of ΔΨm has been associated with ATP depletion with a 
subsequent necrotic cell death in the absence of ATP restoration (Gergely et al., 2002). Based on 
findings in this study, ATP generation appeared to increase exponentially in RBBP6 
overexpressing cells suggesting that the cells remained intact and functional. These observations 
validate the observed apoptosis induction as discussed in the previous section because for 
apoptosis to occur ATP generation is necessary. 
 
Caspase 3 and 7 activities were enhanced in both breast and cervical cancer cell lines following 
siRBBP6. A significant change in activity was observed in HeLa, SiHa and MDA-MB-231 after 
RBBP6 silencing. Caspase-3 and 7 mediate apoptosis upon activation via proteolytic cleavage by 
upstream caspases, followed by cleavage of protein kinases, cytoskeletal proteins, DNA repair 
proteins, ultimately leading to morphologic manifestation of apoptosis such as DNA 
condensation, fragmentation and membrane blebbing (Namura et al., 1998). This significant 
change in caspase activity is in correlation with the observed apoptosis induction as detected by 
flow cytometry as well as the changes in cell shape detected by fluorescence microscopy. The 
observed statistically insignificant caspase 3/7 activity in MCF-7 cell line is not surprising since 
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MCF-7 cell do not express caspase-3 due to a frame shift mutation within exon 3 of the caspase-
3 gene (Los et al., 1997). This means that the activity observed in this cell line is that of caspase-
7 and not caspase-3, or the apoptosis induction observed in this cell line was caspase-
independent.       
7.1.6. Expression of apoptotic genes in response to RBBP6 gene targeting 
Since the observed caspase activity coupled with ATP depletion seem to confirm the observed 
apoptosis induction in both breast and cervical cancer cell lines, understanding the effect of 
RBBP6 targeting on the expression of key apoptotic genes was necessary. Not only did this help 
understand the mechanism behind the observed apoptosis induction in this study, it also helped 
determine any possible link between RBBP6 and p53 gene expression. We analysed the 
expression levels of wild type p53 and key apoptotic genes bax, bak1, bad, caspase-3, caspase-8 
and the anti-apoptotic Bcl-2 in order to understand their relationship with RBBP6 gene.  
 
Silencing of RBBP6 led to a significant up-regulation of wild-type p53 coupled with an 
increased expression of bax and caspase-3 especially in HeLa and SiHa cells. Similar results 
were observed in MCF-7 with the exception of caspase-3 (Figure 57 and Figure 58). These 
observations suggest that RBBP6 gene silencing might results in the release of p53 from 
inactivation, allowing it to trigger intrinsic apoptotic pathway probably by facilitating the 
translocation of bax to the outer mitochondrial membrane. Bax oligomerises with itself or forms 
a complex with bak1 in order to porate the outer mitochondrial membrane for the release of 
cytochrome c and apoptosis inducing factors and a subsequent activation of effector caspases as 
affirmed by caspase 3/7 activity assay (Ouyang et al., 2012). It is however important to note that 
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bak1 expression did not change in response to RBBP6 silencing meaning the observed ATP 
depletion was as a result of bax dimerization.  
 
Our observations are supported by clinical findings made by Chen et al. (2013) in which RBBP6 
overexpression coupled with mutant TP53 was associated with poor prognosis in colon cancer 
tissues. The study showed that patients with RBBP6 overexpression coupled with mutants TP53 
protein accumulation presented with disease recurrence followed by death. Furthermore, our 
observations that RBBP6 silencing promotes p53-mediated apoptosis are reminiscent of the 
phenotype observed in PACT knockout mice where widespread apoptosis was accompanied by 
wild-type p53 accumulation, and concomitant deletion of p53 rescued the mice (Li et al., 2007). 
Moreover, the insignificant apoptosis induction observed in the wild-type p53-null MDA-MB-
231 cell line further implicates the importance of p53 in apoptosis detected in this study. Overall, 
RBBP6 silencing suggests a biomarker function in intrinsic pathway induction. 
7.1.7. Combinational therapy the new success in cancer treatment 
Targeted therapy is one approach that is directed at inhibiting growth and spread of tumour cells 
by specifically targeting molecular mechanisms responsible for tumour growth and survival 
without detrimental side effects (Vanneman and Dranoff, 2012; Wu et al., 2006). Despite high 
specificity and low cytotoxic effects however; limitations in targeted therapy can still arise (Dy 
and Adjei, 2013). For example, the target may change through mutations or the tumour may find 
a new pathway to achieve continued growth thus leading to drug resistance (Dy and Adjei, 2013; 
Vanneman and Dranoff, 2012; Wu et al., 2006). Targeted therapies therefore work best in 
P. Moela: PhD Thesis 
174 
 
combinations that are aimed at different parts of the cell signalling, an approach well known as 
combinational therapy (Wu et al., 2006).   
 
In recent times, many reports have suggested highly effective and improved side effects in 
combinational therapy (Vanneman and Dranoff, 2012). Molecular targets have been reported to 
improve efficacy of chemotherapy by sensitizing cancer cells to the treatment (Vanneman and 
Dranoff, 2012). We find this approach much useful in this study as we have shown earlier that 
RBBP6 plays a critical role in cancer cell progression. The function of RBBP6 on cell cycle and 
proliferation has been elucidated where silencing seemed to inhibit cancer progression whilst 
overexpression appeared to favour it. On the other hand, the potential of camptothecin and 
GABA in apoptosis induction have been extensively explored (McCarty, 2014; Caretta and 
Mucignat-Caretta, 2011). The present study therefore shows that RBBP6 targeting enhances 
cellular response to these anticancer agents in cancer management.  
 
Combination of RBBP6 silencing with camptothecin seemed to have an additive effect on the 
expression of p53 meaning that both treatments do trigger TP53 restoration in all cell lines 
except MDA-MB-231 which is known to contain mutant p53. RBBP6 silencing most likely 
prevents TP53 inactivation by releasing it from ubiquitination. In this case, the combination 
works in a way that camptothecin leads to DNA damage while RBBP6 frees and activates TP53 
thus leading to either cell cycle arrest or apoptosis induction. The mechanism does not hold in 
GABA-siRBBP6 in which the expression of p53 remained unchanged. However, the caspase-8 
activity might suggest PERP-mediated apoptosis rather than mitochondrial-dependent apoptosis.  
P. Moela: PhD Thesis 
175 
 
Pretorius et al. (2013) on the other hand showed that RBBP6 silencing has an inhibitory effect on 
apoptosis in which bax/bcl-2 ratio was less than one. These findings might appear contradictory 
to the present study. However, it is worth noting that the cell line model (NIH3T3) used in the 
aforementioned study is not tumorigenic and its RBBP6 status has not been thoroughly 
investigated.  Silencing RBBP6 stably, as opposed to transiently as is the case in the present 
study, might account for the observed apoptosis resistance in their study. In fact, their findings 
correlate well with our non-cancerous cell line model of choice, MRC-5, in which RBBP6 
silencing failed to exhibit strong apoptotic characteristics when analysed by flow cytometry, 
even when combined with camptothecin.  
 
From the results observed with combinational treatment of siRBBP6 and the two selected 
compounds, it remained clear that somehow there is a regression of cancer cells. But the question 
remained whether the combinational treatment resulted in apoptosis induction or cell cycle 
arrest. Camptothecin-siRBBP6 somehow sensitized cancer cells to apoptosis by significantly 
increasing cell death through the activation of p53 and bax. On the other hand, GABA-siRBBP6, 
apoptosis levels remained statistically unchanged with other cell lines showing a reduction in 
apoptosis, which suggests an antagonistic mechanism between the two treatments. 
Overexpression on the other hand had little impact on the apoptosis level rather than significantly 
reducing cell death. Cell cycle arrest was not the preferred mechanism of the apoptotic cell 
response to camptothecin and siRBBP6 as was seen by low cell populations in G0 phase. On the 
other hand overexpression and camptothecin showed increased number of cells in the S-phase of 
cell cycle which is a representation of dividing cells through DNA replication phase. GABA 
combination did not show any significant changes to perhaps allow us to come to a conclusive 
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argument of its involvement in cell cycle. From all these results we are able to suggest that 
siRBBP6 in combination with camptothecin successfully induced cell death through intrinsic 
pathway by restoring functional TP53. 
 
Treatment with GABA had no significant effect on the overall expression of apoptotic genes 
except TP53 which appeared to be up-regulated. The observed mRNA changes in 
GABA+siRBBP6 co-treatment could mainly be the effect of silencing rather than GABA since 
low levels of apoptosis induction were detected in GABA-only treatments. MCF-7 cells are an 
exception though because a synergistic apoptosis induction was observed in GABA+siRBBP6 
co-treatment when detected by microscopy. Such strong apoptotic characteristics could be 
accounted for by the observed caspase-8 up-regulation in this treatment, implying that apoptosis 
induction by GABA might have been due to p53-mediated PERP activation which has been 
associated with overexpression of caspase 8 (Davies et al., 2009).  
7.1.8. Summary 
Taken all together, we have discovered that RBBP6 is markedly up-regulated in squamous 
cervical carcinoma tissues, including the less prevalent adenocarcinomas. And further 
investigations revealed that not only does it play a role in promoting cell proliferation, it is also 
associated with apoptosis. The fact that RBBP6-knockdown cells become sensitized to apoptosis 
induced by camptothecin coupled with cell cycle arrest implicates the gene as a potential target 
in breast and cervical cancer management. The additive effect observed between siRBBP6 and 
camptothecin could be attributed to their almost-convergent mechanisms of action.  That is 
camptothecin damages and prevents DNA replication thus resulting in failed cell division 
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whereas RBBP6 is said to work alongside telomerase by stabilizing chromosomal fragile sites 
thus promoting cell division and cell proliferation. Based on this, combination of siRBBP6 and 
camptothecin seems to be effective in preventing cell proliferation and inducing apoptosis in 
breast and cervical cancer. Accumulation of TP53 at mRNA level following RBBP6 silencing 
provides early insights into the possible interaction between RBBP6 and TP53; however, 
whether or not RBBP6 plays a role in TP53 degradation leaves room for further investigation in 
this area of study. Nonetheless, the accumulation of TP53 seems to be playing a central role in 
the induction of apoptosis observed in the present study. The inability of GABA to show 
effectiveness in inducing apoptosis either on its own or in combination with RBBP6 targeting 
could be attributed to the fact that its mechanism of action focuses more on cell migration rather 
than apoptosis induction.  
 
The cell cycle was therefore analysed in this study in order to gain insights into the possible 
mechanism used by RBBP6 to affect cell proliferation. RBBP6 silencing led to increased cell 
populations in G0/G1 phase of all tumorigenic cell lines whereas overexpression induced slightly 
lower G0/G1 arrest compared to those in silencing. In contrast, RBBP6 overexpression resulted 
in cell cycle arrested of slightly higher (60%) percentage in normal lung fibroblasts at G0/G1 
phase as compared to RBBP6 knockdown (52%).   Interestingly, RBBP6 targeting led to an 
increase in normal cell populations of up to 40% in G2/M phase whereas all tumorigenic cells 
remained at around 20% in this phase.  Similar studies were performed to test whether RBBP6 
plays a role in the cell cycle. For example, one study in mouse embryonic fibroblasts that were 
stably transfected with siRBBP6 oligonucleotides showed increased cell populations in G1 phase 
(Pretorius et al., 2013). Accumulation of MCF-7 cell populations in the sub-2N phase that 
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precedes the G1 interphase was observed following stable overexpression of P2P-R (Gao and 
Scott, 2003). In HEK293T cells it was suggested that the isoform 3 of RBBP6 is needed for G2 
arrest since knockdown led to depletion of cell populations in G2/M checkpoint whereas 
knockdown of the full length isoform 1 did not have any effect in G2/M (Mbita et al., 2012). 
  
These observations demonstrate RBBP6 to be an important regulator of the cell cycle and 
therefore cell proliferation. Increasing cell populations in G0/G1 phase as a result of RBBP6 
knockdown as well as in the S-phase in response to RBBP6 overexpression suggest that RBBP6 
plays a significant role in prompting cell cycle arrest. Ever since RBBP6 was proven to be 
involved in protein degradation where they showed that the RING finger-like domain is able to 
ubiquitinate YB-1, resulting in its proteasomal degradation (Chibi et al., 2008), more 
investigations emerged in which it was suspected that RBBP6 plays a role in p53 degradation as 
well (Motadi et al., 2011). Therefore the fact that RBBP6 overexpression shifted cell populations 
towards the S-phase might suggest p53 deregulation.  To summarise, it is evident that RBBP6 
silencing inhibits cell proliferation by arresting cells in the G0/G1 phase and overexpression 
facilitates growth by increasing cell populations in the S-phase.    
 
RBBP6 overexpression in cervical cancer might be reminiscent of viral E6 oncoprotein since 
both proteins possess E3 ligase activity and have been shown to promote proteasomal 
degradation of TP53 protein thereof (Fernandes et al., 2013; Denny, 2010; Bosch et al., 2002). 
The E6 oncoprotein has been shown to be involved in the development of cervical 
carcinogenesis in which it is responsible for the transfer of ubiquitin molecules from E2 ligase to 
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TP53 target protein, which is subsequently recognized by the proteasome for degradation 
(Fernandes et al., 2013). Besides TP53 degradation, both proteins have been shown to interact 
with yet another tumour suppressor, Rb, thereby releasing E2F transcription factor which is 
responsible for activation of the cell cycle, thus promoting tumour cell proliferation (Denny, 
2010; Bosch et al., 2002). Therefore it is highly likely that overexpression of RBBP6 in cervical 
cancer acquaints with an additive effect to the functioning of E6, thus leading to aggressive 
cervical tumours. This therefore makes RBBP6 an important target in the management of 
cervical cancer. The status of RBBP6 expression alone is however not sufficient to identify it as 
a prognostic marker, and therefore its involvement in cellular proliferation, apoptosis and cell 
cycle had to be extensively explored in this study. 
7.1.9. Conclusions and future prospects 
This study extensively characterized the role of RBBP6 in cell proliferation and apoptosis. The 
experimental approach provided novel exploration of the RBBP6 gene towards breast and 
cervical cancer and the study remains significant because both malignancies are still a common 
cause of female-related deaths in Africa. RBBP6 overexpression is indicative of poor prognosis 
in breast and cervical cancer atleast in vitro as seen by the continued cell proliferation and 
minimal apoptosis induction in RBBP6-overexpressing cells. The absence of RBBP6 sensitizes 
cells to what seems like p53-mediated apoptosis as demonstrated by TP53 accumulation, cell 
cycle arrest, up-regulation of pro-apoptotic genes, ATP depletion and activation of effector 
caspases. Furthermore, combined treatment with camptothecin showed an overall additive effect 
on apoptosis induction, which is very important in anticancer therapy because the goal is to 
improve drug efficacy while minimizing resistance. Even though GABA managed to induce cell 
death to a certain extent, its anticancer effects are not entirely governed by the apoptotic avenues. 
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In conclusion, these observations suggest that RBBP6 might be a potential biomarker for both 
breast and cervical cancer, and it provides an even more promising management assay when in 
combination with the chemotherapeutic agent, camptothecin. 
 
Future investigations on the effects of GABA on cell migration and chemotaxis in breast and 
cervical cancer would be interesting. Quantification of GABA receptors in order to understand 
which ones (GABAA/C or GABAB) are being stimulated by GABA treatment might be necessary 
in clearly understanding the mechanism of action of GABA in breast and cervical cancer. 
Thorough understanding of the suspected interaction between RBBP6 and p53 can be 
accomplished in part by performing protein-protein interaction experiments such as co-
immunoprecipitation and western blotting. Furthermore, testing this promising anticancer 
management assay in mouse models of breast and cervical cancer would help to better 
understand the function of RBBP6 in vivo.  
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Statistical Analysis (Mitochondrial Activity) 
HeLa Time (Hour) p-value, t-test 
 2 4 6 8 24 
CPT 0.002975 0.002975 0.048124 0.039301 0.000553 
GABA 0.018208 0.018208 0.058594 0.047711 0.055623 
siRBBP6 0.012141 0.012141 0.17117 0.027422 0.049165 
siRBBP6+CPT 0.032 0.031 0.432 0.16 0.003 
siRBBP6+GABA 0.432 0.16 0.003 0.0021 0.0023 
pRBBP6 0.012141 0.012141 0.205327 0.023623 0.041377 
pRBBP6+CPT 0.046873 0.046873 0.08773 0.045402 0.067357 
pRBBP6+GABA 0.002975 0.002975 0.026579 0.001517 0.006782 
 
SiHa Time (Hour) p-value, t-test  
 2 4 6 8 24 
CPT 0.05375 0.05215 0.01324 0.039301 0.00523 
GABA 0.01208 0.01208 0.04594 0.047711 0.05623 
siRBBP6 0.03841 0.04141 0.17117 0.05322 0.03165 
siRBBP6+CPT 0.04232 0.0031 0.04724 0.03516 0.05403 
siRBBP6+GABA 0.01432 0.0161 0.01032 0.0021 0.03023 
pRBBP6 0.02141 0.01276 0.05327 0.02643 0.01367 
pRBBP6+CPT 0.01883 0.04833 0.08773 0.04402 0.35765 
pRBBP6+GABA 0.00275 0.00279 0.02579 0.01517 0.00682 
 
MCF-7 Time (Hour) p-value, t-test  
 2 4 6 8 24 
CPT 0.017430522 0.099775366 0.156338512 0.000521904 0.000152258 
GABA 0.027754288 0.029047709 0.92998554 0.017504419 9.09658E-07 
siRBBP6 0.033835546 0.084388542 0.139875936 0.000606661 0.070566457 
siRBBP6+CPT 0.003820205 0.430733753 0.468394605 2.4312E-05 0.004397034 
siRBBP6+GABA 0.008193212 0.008496109 0.467327572 0.06663708 0.000454948 
pRBBP6 0.005831468 0.189158778 0.008772099 0.000356224 0.03250804 
pRBBP6+CPT 0.001110167 0.020998515 0.135790788 0.066051391 0.20764419 
pRBBP6+GABA 0.000518484 0.000848091 0.093573565 0.003116928 0.000751035 
 
MDA-MB-231 Time (Hour) p-value, t-test  
 2 4 6 8 24 
CPT 0.022304786 0.624983114 0.507205489 2.08683E-05 0.000118704 
GABA 0.016263 0.022627 0.012021 0.015556 0.005657 
siRBBP6 0.02687 0.022627 0.020506 0.005657 0.014849 
siRBBP6+CPT 0.016803 0.016147 0.022727 0.044418 0.016803 
siRBBP6+GABA 0.015556 0.019799 0.032527 0.03182 0.04799 
pRBBP6 0.077979 0.056035 0.077318 0.134155 0.054829 
pRBBP6+CPT 0.175962 0.026729 0.099584 0.209909 0.005115 
pRBBP6+GABA 0.077979 0.056035 0.077318 0.134155 0.054829 
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MRC-5 Time (Hour) p-value, t-test  
 2 4 6 8 24 
CPT 0.026729 0.099584 0.209909 0.005115 0.028799 
GABA 0.028858 0.227302 0.169609 0.04057 0.034126 
siRBBP6 0.043041 0.118726 0.055998 0.128971 0.024437 
siRBBP6+CPT 0.061739 0.118058 0.109818 0.025767 0.263889 
siRBBP6+GABA 0.201486 0.047865 0.275889 0.026771 0.005623 
pRBBP6 0.022727 0.099584           0.041572 0.03841 0.01432 
pRBBP6+CPT 0.032527 0.077318         0.00209 0.04232 0.02141 
pRBBP6+GABA 0.077318 0.08773        0.04402 0.35765 0.01883 
 
 
 
